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ABSTRACT
An increasing number of studies suggest that the complex microbial community of the
human gut may have an important role in human health and disease conditions such as obesity and
diabetes. However, the causal relationship among gut microbiota, obesity, weight loss, and the
influence of bariatric surgery remains largely unknown. This study investigated the correlation
between human gut microbiota and obesity via determining how gut microbiota is associated with
obesity improvement induced by bariatric surgeries (BRS) and low-calorie diet (LCD) treatment.
Specifically, we investigated the effects of various bariatric surgery (BRS) procedures and a lowcalorie diet (LCD) treatment on the diversity, composition, and metabolism of the gut microbiota
of obese patients using a combination of robust, high-throughput metagenomic technologies,
(Illumina sequencing and HuMiChip microarray), quantitative polymerase chain reaction (qPCR),
and gas chromatography.
We discovered that following BRS procedures or LCD treatment the gut microbial
community structure significantly altered, along with efficient, persistent obesity improvement
after bariatric surgeries and, to a lesser degree, LCD treatment. First, microbial richness and
diversity were significantly increased after both treatments. Second, the distribution and
composition of microbial community were switched toward a healthier profile. For instance,
phylum Actinobacteria was significantly reduced, while phylum Verrucomicrobia was
significantly increased at week 52 after BRS. Phylum Firmicutes was significantly reduced, while
phylum Bacteroidetes was significantly increased after LCD treatment. Microbial community
structure at different taxonomic levels and their connectivity were significantly correlated with
obesity-related physiological variables, and high-molecular-weight adiponectin (ADPHMW)
seemed to be an important factor that links to the correlation. Third, microbial functional gene
profile was significantly altered at week 7 post treatments, with the BRS group showing
significantly higher gene richness and diversity than the LCD group. Over half of the gene
categories showed significant correlations with obesity-related physiological variables, and the
entire gene community significantly correlated with obesity-related hormones (adiponectin [ADP],
APHMW and active Ghrelin [GHRA]), with the gene richness and diversity significantly
negatively correlated with the active hunger hormone GHRA. In addition, we found that genus
Akkermansia was significantly correlated with better health condition. It significantly increased
after BRS treatment, and its change showed a significantly negative correlation with a change of
obesity conditions following the treatments. Moreover, the concentrations of gut microbial
metabolites (short-chain fatty acids [SCFAs]) were significantly altered. Total SCFAs and acetate
were significantly reduced after both treatments. Following BRS, the proportion of acetate was
significantly reduced, while proportions of propionate and butyrate were significantly increased.
Correspondingly, the relative abundance of most butyrate-producing genera was significantly
increased after BRS, and the gene communities relevant to the metabolism of SCFAs significantly
correlated with obesity-related hormones (ADP, ADPHW, peptide tyrosine tyrosine [PYY] and
GHRA).
Using a combination of multiple approaches, this research revealed that both taxonomical
and functional gut microbial communities significantly correlate with obesity-related variables.
The study indicates that weight-loss treatments might induce the alteration of gut microbial
community structure toward a healthier profile, which then further fosters the weight loss and
better health condition and thus form a positive loop. Obesity-related hormones, including
ADPHMW, ADP, glucagon-like peptide-1 (GLP-1), PYY, GHR, and GHRA, in particular,
vii

ADPHMW, might play important roles in linking gut microbiota and obesity. A pathway of gut
microbiota-ADPHMW-obesity could be one of the important mechanisms that underlie the
substantial and persistent weight loss following bariatric surgeries.
The study suggests several potential therapeutic methods that could be developed for
treatment and/or prevention of obesity and obesity-related health conditions, including (1)
supplying obese people with prebiotics (materials that boost beneficial microbes) and/or probiotics
(beneficial microbes, such as Akkermansia and butyrate-producing bacteria) that can improve the
healthiness of gut microbial community structure, (2) supplying human subjects with beneficial
gut microbial products, such as butyrate and propionate that can increase the level of GLP-1 and
PYY which have been proven to signal satiety, and (3) direct use of hormones such as ADPHMW,
GLP-1, and PYY with caution of other possible health effects.

viii

CHAPTER ONE: INTRODUCTION
1.1 Obesity
Obesity and type 2 diabetes are a growing epidemic worldwide. Among the adults in the
world’s population in 2008, around 35% were overweight and 12% were obese, nearly doubled
when compared to the obesity rate of 6.5% in 1980 (WHO). In the United States, the prevalence
of obesity among adults has increased from 15% to 33% during 1980-2004 and currently more
than one in three US adults are obese and the prevalence remains stable (Ogden et al., 2007, Ogden
et al., 2014).
Obesity has been shown to be associated with multiple comorbidities, including diabetes
mellitus type 2 (Eckel et al., 2011), metabolic abnormalities (Chang et al., 2012), cardiovascular
diseases (Nakamura et al., 2014), carcinomas in colon, renal, gallbladder, pancreas, esophageal
glands, endometria, bone marrow, and breast, malignant melanoma (Dobbins et al., 2013), hepatic
adipose infiltration (Fabbrini et al., 2010), fertility (Pasquali et al., 2007), and psychological wellbeing (Jorm et al., 2003). Type 2 diabetes accounts for 90-95% of all cases of diabetes. With an
estimated over 300 million affected individuals by 2025, the lifetime risk of developing type 2
diabetes will approximate 20% (King et al., 1998). The rapidly growing prevalence of obesity and
type 2 diabetes impairs the patients’ life quality greatly and places a severe burden on our society’s
economy. A better understanding of the forming mechanism of obesity is critical to developing
efficient preventive and therapeutic approaches.
Obesity is a medical status that surplus body fat has accrued to the degree that it may have
negative effects on health, causing increased health problems and/or reduced longevity (Haslam
and James, 2005). The degree of obesity is often measured by body mass index (BMI), the weight
divided by the height (kg/m2), due to low cost and simplicity, although BMI cannot tell the body
fat percentage. The World Health Organization (WHO) has characterized overweight as having a
BMI ≥25.0 kg/m2 and obesity as having a BMI ≥30.0 kg/m2.
Obesity is well-known as an outcome of energy expenditure and intake imbalance; an
increased intake of energy-dense foods, especially when combined with reduced physical activity,
surely predisposes obesity. However, the existence of complex systems that regulate energy
balance requires that this paradigm is considered in a more comprehensive context (Morton et al.,
2006). Other involved factors may include personal genetics (Vaisse et al., 1998, Clement et al.,
1998) and health status. Moreover, increasing studies have evidenced the links between gut
microbiota and adiposity (Backhed et al., 2004, Ley et al., 2005, Turnbaugh et al., 2006, DiBaise
et al., 2008, Zhang et al., 2009, de La Serre et al., 2010, Caesar et al., 2010, Sanz et al., 2010,
Musso et al., 2011, Tremaroli and Backhed, 2012, Nicholson et al., 2012).
1.1.1 History of Obesity
The term ‘obesity’ was coined during the 1610s. Its origin is the Latin word ‘obesus’, the
past participle of ‘obdere’, where ‘ob’ means ‘over’ and ‘edere’ means ‘eat’.1 Today obesity is
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defined as a medical condition associated with a variety of adverse health effects and reduced
longevity due to the accumulation of excessive amounts of surplus body fat (Haslam and James,
2005). The degree of obesity is often measured by the body mass index (BMI), the weight divided
by the square of the height (kg/m2) of the individual. Measuring the BMI is simple and inexpensive.
However, the BMI does not reveal the percentage of body fat. The World Health Organization
(WHO) has associated the condition of being overweight with a BMI of 25–30 and obese with a
BMI of 30–35.
Before the Neolithic revolution, which began in the Middle East about 12,000 years ago,
people obtained food mainly by hunting and gathering. The Neolithic revolution resulted in a
transition in the methods of obtaining food to farming (agriculture of crops and domestication of
animals). During that period, however, food production was a limiting factor to the human
population, as was the primitive state of medicine and poor living conditions. As a result, being
corpulent was difficult and was seen as a sign of health and good fortune. After the Industrial
Revolution, Medical Revolution, and Green Revolution in the 19th and 20th centuries, the
availability of food increased greatly, and living conditions improved dramatically. One the
consequence of these revolutions was the increases in the chances for people to lead a sedentary
lifestyle and to live a long life. The result was a dramatic increase in the incidence of obesity in
the human population.
Obesity has recently become a growing epidemic worldwide. The incidence of being
overweight or obese increased markedly worldwide between 1980 and 2013. Among adults in the
world’s population in 2008, around 35% were overweight, and 12% were obese. The latter
percentage was nearly double the corresponding figure of 6.5% in 1980. In the United States, the
prevalence of obesity among adults increased from 15% to 33% from 1980 to 2004. Currently,
about 35% of US adults are obese, and another 6% are extremely obese (BMI > 40) (Ogden et al.,
2007, Ogden et al., 2014). Since 2005, those percentages have been stable.
1.1.2 Causes of Obesity
The storing of adipose tissue (i.e., body fat) in the human body is a result of evolution.
During prehistoric times, when people survived by hunting and gathering food in a harsh
environment, the food was scarce, and the supply was irregular. Natural selection favored a
phenotype that was able to store large amounts of fat from a small supply of food and to release it
as frugally as possible over the long run. Thus, those individuals who could store fat easily had an
evolutionary advantage. However, with the advancement of science and technology, and in
particular with the significant changes in the methods of obtaining food as a result of the Neolithic
Revolution and Green Revolution, food became much less of a limiting resource, and those thrifty
genes and the function of storing fat made people liable to become obese. Body fat was defined as
an organ that contained its own genetics, cellular biology, hormones, and receptors, instead of a
place that could only passively store energy (Kershaw and Flier, 2004).
Advances in the understanding of the thermodynamics of food utilization and of the
nutritional aspects of the metabolism of food have refined the understanding of obesity. After the
introduction of chemical analytical methods at the end of the 18th century, the thermodynamics of
the nutrition of the human body was elucidated based on the pioneering studies of respiration, the
acquisition of nitrogen required for tissue synthesis, and the association of muscular mechanical
work with the generation of heat, concomitant with milestone discoveries related to the physiology
of digestion. These advances in understanding began with the studies of William Beaumount on
2

gastric physiology (Beaumont, 1977, Eknoyan, 2006) and the early studies of hunger, beginning
with Walter Cannon’s studies of hunger sensation (Cannon and Washburn, 1993, Eknoyan, 2006).
This research was followed by studies of gastrointestinal absorption, feelings of satiety, disorders
related to nutritional deficiencies, and in particular the effects of vitamin and trace mineral
deficiencies (Wilmshurst and Crawley, 1980, Krotkiewski, 1984, Wisen and Hellstrom, 1995,
Bottiglieri, 1996, Jovanovic-Peterson and Peterson, 1996, Suchner et al., 1996, Eknoyan, 2006).
Currently, obesity is understood to be the result of an imbalance between energy
expenditure and caloric intake. An excessive intake of energy-dense foods (e.g., high-fat and highsugar foods), especially when combined with a lack of physical activity (e.g., much time spent
sitting), predisposes a person to obesity. However, the pathogenesis of obesity is not as simple as
that. The existence of complex systems that regulate energy balance requires that this paradigm is
considered in a more comprehensive context (Fabricatore and Wadden, 2003). Other relevant
factors include the following.
1. Genetic susceptibility (Clement et al., 1998). For example, Prader-Willi syndrome caused
by several deleted or unexpressed genes on paternal chromosome 15 (Kishimoto et al.,
2015), miR-26b mutation (Xu et al., 2015), or whole genome epigenetic changes (Franks
and Ling, 2010);
2. Maternal pre-pregnancy obesity (Daraki et al., 2015);
3. Other diseases, for example, tumor-induced hypothalamic damage (Steele et al., 2013),
decreased integration of brain regions for awareness of body and emotional states leading
to less successful self-regulation (Paolini et al., 2015), and mental disorders (Fezeu et al.,
2015);
4. Short sleep duration was identified as an independent risk factor for overweight and obesity
(Beccuti and Pannain, 2011, Knutson, 2012) for children and adults (Rutters et al., 2010,
Liu et al., 2012). Short sleep duration may trigger increased food intake to meet the energy
needs during the elongated awake time (Hasler et al., 2004), impact hormones regulating
appetite, and lead to an increase of the appetite for carbohydrate-rich food (Spiegel et al.,
2004). Short sleep duration is also related to reduced glucose tolerance, another risk factor
for overweight and obesity (Van Cauter and Knutson, 2008). In addition, habitual sleep
variability but not habitual sleep duration was found significantly correlated with
abdominal obesity, which may result from elevated caloric intake, especially carbohydrates
(He et al., 2005).
5. Medical practices such as the use of steroids (Merritt et al., 1986).
6. Environmental stress. For instance, chemical exposure to di-(2-ethylhexyl) phthalate
(DEHP) increases the risk of obesity (Lee et al., 2016).
1.1.2.1 The Microbiota in Human Gut May Have an Important Role in the Regulation of
Energy Balance and Weight
Obesity arises as a consequence of alterations in energy balance, i.e., how the body
regulates energy intake, expenditure, and storage. An increased intake of energy-dense foods,
especially when combined with reduced physical activity, surely contributes to the high prevalence
of obesity, however, the existence of complex systems that regulate energy balance requires that
this paradigm is considered in a larger context (Morton et al., 2006). There are 10 trillion to 100
trillion microorganisms normally residing within the human gastrointestinal tract, collectively
referred to as the gut microbiota. Recent studies suggest that obesity may affect the diversity of
the gut microbiota (Ley et al., 2005), which in turn may play a role in the pathogenesis of obesity
3

by increasing the host’s energy-harvesting efficiency (Ley et al., 2005, Ley et al., 2006). A review
article by DiBaise and colleagues (DiBaise et al., 2008) examined the evidence supporting these
claims; much of it obtained recently using tools such as sequencing of 16S rRNA gene clone
libraries, metagenomics, DNA microarrays, microbiota transplant, and gnotobiotic knockout mice.
It concluded that the gut microbiota has a role in the regulation of energy balance and weight. The
evidence further suggests a role for a gut-derived factor, such as lipopolysaccharide (LPS), in the
pathogenesis of obesity-related type 2 diabetes (DiBaise et al., 2008). A study observed a large
bacterial population shift in the post-RYGB individuals, with the decreased level of interspecies
H2 transfer between bacterial and archaeal species that is possibly an important mechanism for
increasing energy uptake by the human large intestine in the obese patient; it provides another
perspective about the link between the gut microbiota and host energy balance (Zhang et al., 2009).
Despite these very implicative findings, studies are needed to better understand the causal
relationship among gut microbiota, obesity, weight loss, and the influence of various bariatric
surgery procedures.
1.1.3 Harmful Effects of Obesity
Attitudes to obesity began to be negative in the 18th century, mainly for esthetic reasons.
Since the 18th century, the negative impacts of obesity on a person’s quality of life have started to
be documented. In the middle of the 18th century, obesity was recognized as a cause of
compromised health. Morbidity and mortality related to obesity have been reported from the
beginning of the 20th century.
Obesity has been shown to be associated with multiple co-morbidities, including the
following:
 diabetes mellitus type 2 (Kahn et al., 2006);
 insulin resistance (Kahn and Flier, 2000);
 metabolic syndrome (MetS)2;
 immune dysregulation (Rizzo and Sen, 2015);
 chronic kidney disease (CKD) (e.g. glomerular hyperfiltration) (associated with nondiabetic obesity) (Srivastava, 2006, Hsu et al., 2006, Gore et al., 2006, Ogna et al., 2016);
 cardiovascular diseases (CVD) (e.g. Myocardial dysfunction) (Nakamura et al., 2014);
 atherosclerosis (Kim et al., 2015, Gustafson and Smith, 2015);
 non-alcohol fatty liver disease (NAFLD) (Fabbrini et al., 2010);
 malignant melanoma (Morpurgo et al., 2012);
 cancers such carcinomas in the colon (Chen and Huang, 2015), kidneys (Wilson and Cho,
2016), bladder (Sun et al., 2015), pancreas (Wang et al., 2015), esophageal glands (Chen
et al., 2012), endometria (Kaaks et al., 2002), and postclimacteric breast tissue (Dobbins et
al., 2013) and prostate (Joshu et al., 2011);
 hepatic adipose infiltration (Fabbrini et al., 2010);
 increased fracture risk (Gonnelli et al., 2014);
 gout (Lee et al., 2015);
2
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osteoarthritis (OA) (Messier, 2009);
obstructive sleep apnea (Schwartz et al., 2008);
asthma (Delgado et al., 2008);
chronic systemic inflammation (Gogebakan et al., 2015, Todendi et al., 2016);
increased reproductive disorder such as incipient secondary hypogonadism in middle-aged
men (Pasquali et al., 2007) and polycystic ovarian syndrome in women (Sam, 2007);
malaise (Fabricatore and Wadden, 2003);
infertility (Pasquali et al., 2007);
poor pregnancy outcomes, including gestational diabetes, fetal macrosomia, stillbirth, postterm pregnancy, and cesarean delivery (Mission et al., 2015);
reduced telomere length and accelerated aging (Kim et al., 2009);
lower back pain (Shiri et al., 2010);
decreased postural control and aiming performance (Boucher et al., 2015). Aiming tasks
of pointing to two different sizes of targets were given to obese and normal-weight children
in standing and sitting conditions. The measured hand movement time and mean speed of
the pressure center switch were used for evaluating their postural stability during the
movement, and obese children showed significantly higher values for both two
measurements, which may be caused by longer slowdown period during the aiming
performance. It indicated that obesity should have added a postural curb to obese children
and lead them to spend longer time to correct their movements owing to their body’s higher
postural instability during the aiming performance test.
increased risk of neurodegenerative disorders (e.g. Alzheimer disease (AD)) (Petrov et al.,
2016);
psychiatry disorders (e.g. mood and anxiety disorders) (Vieira et al., 2015);
and social stigmatization.

Thus, the quality of life of an obese person may be greatly impaired. The numerous
monetary costs associated with obesity and its rapidly growing prevalence have led to very
significant public health costs. Development of efficient preventive approaches and therapeutic
treatments for obesity would, therefore, be highly desirable. However, such developments will
require a better understanding of the causes of obesity.
1.1.4 Treatment of Obesity
Limiting calorie intake and increasing energy expenditure are well-known methods of
treating obesity. As more components involved in the pathogenesis of obesity are identified, more
methods for preventing or treating obesity may become available. For example, identification of
the relative deficiencies of various nutrients can provide a basis for medical therapy of obesity
with drugs. Now a variety of medicines and dietary supplements are available to help people lose
weight. Dietary supplements, for example, include vitamins, trace minerals, fiber, probiotics
(beneficial microorganisms), and/or prebiotics (substances that can support the growth of the
probiotics). Because the severity of obesity in some groups of people has begun to seriously impact
morbidity and mortality, treatments are urgently needed, and surgical intervention has been
introduced to help people lose weight because it is more efficacious than other traditional methods
such as calorie restriction, exercise, and prescription medication, all of which are limited with
respect to their impact on weight. The evolution of methods for treating obesity is reflected in the
5

changes of the name of the society for obesity management. The National Obesity Society was
first established in the 1950s; it was then renamed the National Glandular Society, then the
American College of Endocrinology and Nutrition, and finally the American Society of Bariatrics3
in 1961. The Society subsequently divided into the American Association of Bariatrics Surgery4
and the American Society of Bariatrics Physicians (Eknoyan, 2006).
1.2 Gut Microbiota
1.2.1 Microbiota
‘Microbiota’ was coined by American molecular biologist Joshua Lederberg in 2001, by
combining ‘micro(be)’, which means microorganisms, and ‘biota’, which means life of a region,
and was defined as ‘the ecological community of commensal, symbiotic and pathogenic
microorganisms that literally share our body space’ (Lederberg and McCray, 2001). Lederberg
also coined the term ‘microbiome’ and was defined as ‘the totality of microorganisms and their
collective genetic material present in or on the human body or in another environment’, by
combining ‘micro(be)’, which means microorganisms, and ‘biome’ which means a complex biotic
community characterized by distinctive species and maintained under the environmental
conditions of a region. The terms were coined to emphasize the importance of the microbial
inhabitants of human in human health and disease. The difference between these two terms are
that the microbiome includes the genetic material of the microbes, but they have been used as
synonymous concepts in most cases.
1.2.2 Human Microbiota
There is indigenous microbiota in skin, eyes, respiratory system, oral cavity, the
gastrointestinal tract, the urinary system, and the reproductive system in human (Wilson, 2005).
There are a variety of environmental determinants at differential locations of the skin and the main
determinants that influence the survival and growth of the microbial inhabitants of the skin are
temperature, moisture content, pH, oxygen, and carbon dioxide concentration, light, nutrient
availability, interactions with other microbes and host defense systems. Different environmental
conditions of the different skin locations (e.g. forehead, ear, hands, arm, leg, foot sole, etc) make
their community composition different. There are some diseases caused by members of the skin
microbiota, such as acne, wound infection, and erythrasma.
Each location site has its specific anatomy and physiology of the respiratory tract and its
specific antimicrobial defense mechanisms, environmental determinants at different regions of that
location; Indigenous microbiota of the location (1. key members of that location; 2. ways to the
acquisition of the respiratory microbiota, 3. community composition at different sites within the
location, 4. Interactions among members, 5. Dissemination of organisms, 6. Effects of antibiotics
and other interventions on the location); diseases caused by members of the microbiota.
1.2.3 Human Intestinal Microbiota
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Bariatrics reflects the evolution of the methods for treating obesity via appetite control, calorie restriction, and
exercise.
4
Bariatric surgery is the use of surgical intervention to treat obesity.
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Human intestinal microbiota is an aggregation of microbes dwelling in human
Gastrointestinal (GI) tract, including the mouth, esophagus, stomach, small intestine (duodenum,
jejunum and ileum), large intestine (caecum, ascending colon, transverse colon, descending colon
and sigmoid colon), rectum and anal canal. Gut microbiota is composed of around 300-1000
species and can be bacteria, archaea, yeast, fungi and protozoa, while 99% of them are made up of
30-40 species, and 1/3 of their components is common among the population. The net weight of
the microbial components of human being are around 1.25 kg (1-2 kg; 60% of dry feces.), and
their cell numbers are around 1014, which is 10 times of the human being’s cell number, and 100
times as many genes as the human genome, most of which confer physiological function.
In the human gastrointestinal (GI) tract there are normally about 100 trillion
microorganisms, collectively referred to as the gut microbiota (Dore et al., 2013). The gut flora
can be derived via early colonization from the mother during delivery, diet, the environment in
which the person lives, and medical practices such as vaccination, administration of antibiotics,
and poor hygiene (Guarner and Malagelada, 2003). The gut community is typically dominated by
30–40 bacterial species but is composed of 300–1000 species spanning the kingdoms of bacteria,
archaea, yeast, fungi, and protozoa (Sears, 2005, Guarner and Malagelada, 2003). Gut microbes
exist in human GI systems as symbionts and may exert either beneficial or harmful effect on human
health under different scenarios (Sekirov et al., 2010). On the one hand, some gut species (1) help
the host process certain components of the host’s diet that would otherwise be indigestible for the
host by converting the organic compounds into usable forms (Cummings and Macfarlane, 1997),
(2) synthesize vitamins in the B and K groups (Hill, 1997, LeBlanc et al., 2011), (3) metabolize
primary bile acids into secondary bile acids (Sayin et al., 2013), (4) inhibit the growth of
pathogenic microbes (Kamada et al., 2013), and (5) maintain the homeostasis of the immune
system (Arrieta and Finlay, 2012). On the other hand, some species may interfere with the
excretion of xenobiotics by causing them to enter an enterohepatic cycle (Bjorkholm et al., 2009),
induce inflammatory bowel disease (IBD) (Frank et al., 2007), and even influence brain functions
and behavior via neural, endocrine, and immune pathways (Cryan and Dinan, 2012).
1.2.4 The Microbiota in Human Gut May Play an Important Role in Regulating Adiposity
In addition, increasing research results support the functions of gut microbiota in energy
balance and fat storage regulation. Some human gut microbes take part in the metabolism of bile
acids whose main activity is to facilitate the metabolism of dietary fat, affecting signaling pathways
complicated in the metabolism of energy and lipid, and leading to changes in lipid peroxidation,
hepatic fatty acid production, and triglyceride deposition (Nicholson et al., 2012). Also, it has been
found that gut microbiota in mice increase the process of dietary polysaccharides by microbial
glycosylhydrolases, promote increased monosaccharides uptake from the gut to the liver by
doubling of the density of capillaries that underlie the small intestinal villus epithelium, increase
transactivation of lipogenic enzymes by transcription factors such as ChREBP leading to the
enhancement of the hepatic triglyceride production, and suppress Fiaf, a circulating LPL inhibitor
gene of intestinal villus epithelial cells promoting LPL-directed incorporation of these extra
triglycerides into adipocytes of peripheral tissues (Backhed et al., 2004). Besides, it has been
discovered that gut microbiota from obese mice helped the host harvest more energy from the diet
compared with the counterpart from lean ones and transplantation of germ-free mice with ‘obese
microbiota’ leaded to a significant boost in total body fat than transplantation with ‘lean
microbiota’, indicating gut microbiota could be a factor contributing to obesity by enhancing the
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host’s energy-harvesting efficiency (Turnbaugh et al., 2006). Furthermore, gut microbiota changes
induced by prebiotics in genetic obese mice significantly reduced fat/lean ratio, lowered plasma
triglycerides and muscle lipid content, reduced food intake, reduced fasting glycemia, and
advanced glucose tolerance; the mechanisms may involve the increased muscle lipoprotein lipase
level (Amandine 2011). Gut microbiota changes induced by the administration of prebiotics such
as oligofructose markedly reduced body weight and fat, and improved glucose homeostasis in dietinduced obese, although food intake was not significantly changed; the involved mechanisms may
relate to the significantly increased portal plasma glucagon-like peptide-1 (GLP-1) levels and
colon proglucagon, as well as the improved sensitivities of leptin in its anorectic, weight-loss, and
lipogenesis-reducing effects (Everard et al., 2011). Additionally, a large bacteria population shift
was observed in the post-RYGB individuals, with the decreased level of interspecies H2 transfer
between bacterial and archaeal species that is possibly an important mechanism for increasing
energy uptake by the human large intestine in the obese patient (Zhang et al., 2009).
1.3 Bariatric Surgeries (BRS)
1.3.1 Bariatric Surgical Treatments Show Extremely Promising Results in Severe Obesity
Although lifestyle intervention programs with or without pharmacotherapy induce weight
loss and attenuate insulin resistance, these interventions have limited success, especially in
severely obese people. Gastric bypass surgery is currently the most effective treatment for
advanced obesity (BMI > 40), and lesser obesity (BMI > 35) if associated with type 2 diabetes,
cardiopulmonary insufficiency, sleep apnea, or other comorbidities. Last year alone, there were
about 200,000 procedures carried out in the US (Mechanick et al., 2008). A meta-analysis of
135,246 patients from 621 studies over 16 years concluded that after bariatric surgery, overall
weight loss was 38.5 kg (55.9% of excess weight lost) and that diabetes was improved or resolved
in 86.6% of the patients (Buchwald et al., 2009). The growing pool of patients undergoing bariatric
surgery is increasingly recruited to study possible mechanisms underlying the large and sustained
weight loss and has led to several useful hypotheses (Korner et al., 2006).
1.3.2 A Comparison between Gastric Bypass, Sleeve Gastrectomy, and Gastric Banding
Although gastric bypass as an open surgical procedure has been practiced since the 1980’s,
a laparoscopic approach to the procedure was not developed until the mid-1990’s (Lonroth et al.,
1996). Roux-en-Y gastric bypass (RYGB) is an irreversible procedure which alters the intestine
anatomy and has the greatest operative risk when compared to the other two procedures. Also, it
requires supplements after the operation. Of all the bariatric procedures, it produces the most
effectiveness in terms of safe and sustained weight loss and relieves diabetes effectively, and needs
lesser requirement for compliance. A review showed excess weight loss achieved via the
laparoscopic gastric bypass was 26% greater than laparoscopic gastric banding one year after
treatment (Tice et al., 2008). The laparoscopic gastric bypass is recognized as the standard of care
for obesity surgery in the United States and is the predominant surgical procedure that has been
carried out currently. Gastric bypass is also recognized as being the superior procedure for
reversing type 2 diabetes mellitus. Pories et al. reported that 121 of 146 subjects (83%) with type
2 diabetes and 150 of 152 subjects (99%) with impaired fasting glucose maintained normal levels
of glucose, glycosylated hemoglobin, and insulin following the surgery (Pories et al., 1995).
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Figure 1.3.2.1 A comparison among gastric bypass, sleeve gastrectomy, and gastric banding.

Sleeve gastrectomy (SGx) is an irreversible procedure which alters the intestinal anatomy
and has less operative risk than RYGB and higher operative risk than Gastric banding. It produces
slower and less weight loss when compared to RYGB, but faster and more weight loss than the
gastric band. It needs lesser requirements for compliance than gastric banding. No supplements
are required after its operation. A case series with many sleeve gastrectomy cases reported a 59%
excess weight loss after one year and a 62% excess weight loss after two years. A study compared
35 diabetic subjects who had a sleeve gastrectomy procedure with 50 subjects who had a gastric
bypass procedure and showed that 4-month after surgery, both groups achieved similar weight
losses and comparable improvement of their diabetic condition. Within U.S. academic medical
centers, the use of laparoscopic sleeve gastrectomy is significantly increased and has surpassed the
adoption of laparoscopic gastric bypass since 2013. Laparoscopic sleeve gastrectomy is now the
most commonly performed bariatric surgery nationally in academic centers (Esteban Varela and
Nguyen, 2015).
Bands placed by an open approach have been utilized since the 1980’s, but the adjustable
laparoscopic gastric band was not introduced until 1994 (Belachew et al., 1994). The laparoscopic
approach reduced the complication rate of the surgery from 18.5% to 9.5% and has become the
procedure of choice for gastric banding (Fried and Peskova, 1995). Gastric banding (GBa) is a
reversible procedure which does not alter the intestinal anatomy and has the least operative risk
when compared to the other two procedures. It has the slowest and least total weight loss and needs
greater compliance after its operation. No supplements are required after its operation. It causes
weight loss by restriction of caloric intake but the amount of weight loss is less spectacular and
the weight of individuals are more likely to relapse when they do not follow the compliance.
Furthermore, in a small study, sleeve gastrectomy was shown to increase PYY levels, a gut
hormone associated with satiety, to a similar extent as gastric bypass but reduced ghrelin to a

9

greater extent than gastric bypass. Sleeve gastrectomy gave a statistically significant greater
reduction in excess body weight (70% vs. 60%) at one year.
Some studies showed that although gastric bypass produces greater weight loss within a
year, the adjustable gastric band produces slower weight loss over a longer period so that over the
long term, its weight loss effect becomes comparable to that of the gastric bypass. Biagini and
Karam reported a one-year post surgery of 66.7% excess weight loss increased to 76% after 2 years
and 82% after 4 years, and was maintained after 10 years (Biagini and Karam, 2008). A review
reported a 56% excess weight loss at five years with the GBa treatment compared to a 59% excess
weight loss with the RYGB treatment (O'Brien and Dixon, 2003).
Also, the adjustable laparoscopically-placed gastric band has been shown to reverse type 2
diabetes two years postoperatively in 73% in individuals with type 2 diabetes for two years or less
prior to the procedure (Dixon et al., 2008). The adjustable gastric band treatment has also been
compared to intensive medical weight loss treatment (a very low-calorie dieting, pharmacologic
therapy, and a lifestyle change program). After two years, the laparoscopic adjustable band group
lost 22% of body weight and 87% of excess body weight, which is much higher than the intensive
medical group (5.5% of initial body weight loss and 22% of excess body weight loss), and reversal
of the metabolic syndrome and improvement of the life quality was also greater in the laparoscopic
adjustable gastric band group (O'Brien et al., 2006).
1.3.3 Bariatric Surgeries Help Weight Loss
The mechanisms behind the weight-loss effect by bariatric surgery may include restrictive
and/or malabsorptive methods (Rubino, 2006). Malabsorptive method bypasses a portion of the
small intestine and results in malabsorption by reducing the functional size of the absorptive
surface (Tadross and le Roux, 2009). Gastric bypass and sleeve gastrectomy operations involve
both restrictive and malabsorptive procedures; they reduce the effective stomach size and/or
rearrange small intestine causing incoming food bypassing most parts of the stomach, the entire
duodenum, and a section of the jejunum (Tadross and le Roux, 2009), leading to the reduced the
amount food that the individual can take and decreased absorption of the food they can consume,
and therefore achieve the substantial weight loss. The gastric band operation causes weight loss
by the restrictive method; it reduces energy intake mainly by gastric restriction, and the other
mechanism underlying these bariatric surgeries may include decreases appetite (Tadross and le
Roux, 2009), decreases leptin level (Abbott et al., 2005), and increases fasting and postprandial
satiety (Dixon et al., 2005).
In addition, sleeve gastrectomy can cause ghrelin, a hormone secreted from the stomach to
stimulate food intake, to drop by two-thirds and this reduction was maintained over the six-month
study. It might be caused by the exclusion of the gastric fundus, resulting in the reduced contact
between the mucosal cells which secretes ghrelin, and nutrients. Ghrelin is predominantly secreted
in stomach and pancreas, and its secretion is stimulated by the empty stomach. Ghrelin stimulates
appetite, increase hunger, increase gastric emptying and gastrointestinal motility for preparing for
eating, induce the release of growth hormone, and hinders the glucose-stimulated insulin
production. Sleeve gastrectomy can also cause increased levels of postprandial glucagonlike peptide-1 (GLP-1) and peptide tyrosine tyrosine (PYY), both of which are beneficial to obesity
improvement by increasing the host’s feeling of satiety (Dimitriadis et al., 2013). GLP-1 is secreted
in L cells in distal ileum and colon and its secretion is stimulated by the nutrients in the gut lumen.
It stimulates the production of incretin hormone, promotes the production and release of insulin in
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the pancreas, reduces gastric emptying and intestinal motility, and promotes the feeling of satiety.
PYY is secreted in L cells in distal small intestine and colon and its secretion is stimulated by
nutrients in the gut lumen. It promotes a feeling of satiety, reduces gastric emptying and intestinal
motility. That postprandial PYY in obese people was lower than the healthy people and PYY
infusion reduced calorie intake have resulted in the hypothesis that obesity is a status of PYY
deficiency (Meek et al., 2016).
Both RYGB and sleeve gastrectomy groups showed increased postprandial
Cholecystokinin (CCK) levels after treatment when compared to the pre-operative levels, and the
sleeve gastrectomy showed a greater increased level of CCK than the RYGB group. CCK is
secreted in I cells in duodenal mucosa and its secretion can be induced by fatty acids or amino
acids in the duodenum (Meek et al., 2016). It contracts the gallbladder for releasing bile. It induces
the secretion of pancreatic enzymes, insulins, glucagon and pancreatic polypeptide (PP). It also
slows gastric emptying and promotes the feeling of satiety (Meek et al., 2016).
Patients after gastric bypass are less hungry and prefer healthier food options (le Roux et
al., 2006, Miras and le Roux, 2013, Sweeney and Morton, 2014, Behary and Miras, 2015). It may
be achieved by the below mechanisms. 1) Increased/more intense taste acuity (Bueter et al., 2011).
2) The appeal of sweet fatty food reduces by a corresponding decrease in activation of the brain
reward to high-energy food cues (functional MRI studies). 3) Patients experiencing post-ingestive
symptoms with sweet and fatty food develop conditioned aversive behaviors towards the triggers.
4) Elevation of gut hormones and their effect on the appetite centers of the brain: The enhanced
nutrient sensing by the L cells of the distal ileum promote the exaggerated release of the gut
hormones glucagon-like peptide-1 (GLP-1), peptide tyrosine tyrosine (PYY), and oxyntomodulin
in response to a meal, which has been shown to reduce hunger and promote satiety and reduce
food intake; they are likely mediators of the beneficial effects of RYGB on appetite, taste functions
and food preferences (le Roux et al., 2006, Borg et al., 2006). Also, the reduced postprandial level
of gastrin after RYGB was observed after two weeks (Stoeckli et al., 2004) and a year (Dirksen et
al., 2013).
Gastrin is produced in enteroendocrine G cells mainly in gastric antrum and duodenum and
its secretion is stimulated by gastric distension & food in the stomach. It increases productions of
hydrochloric acid, pepsinogen, intrinsic factor, pancreatic secretions and bile, and promotes the
feeling of satiety. The fall after RYGB might be caused by that RYGB excluded gastric antrum
and duodenum, and so reduced the contact between nutrients and the cells in the gastric antrum
and duodenum. The production of hydrochloric acid in the remaining stomach stimulates the
secretion of secretin and somatostatin, which further hinder the production of gastrin. Reduced
ghrelin level was also observed after RYGB treatment. It might be caused by the exclusion of the
gastric fundus, resulting in the reduced contact between the mucosal cells which secretes ghrelin,
and nutrients (Meek et al., 2016). Oxyntomodulin showed a significant increase after RYGB
treatment. Oxyntomodulin is secreted in L cells in ileum and its secretion is stimulated by nutrients
in the gut lumen. It promotes the feeling of satiety, competes for the receptors of GLP-1 and
glucagon, and increase energy expenditure. An increase in insulin sensitivity (Falken et al., 2011,
Umeda et al., 2011, Jacobsen et al., 2012) and improved beta cell function (Umeda et al., 2011,
Jorgensen et al., 2012) after RYGB was observed. A significant decrease in fasting glucose, insulin,
and improvements of beta-cells sensitivity was observed one week after RYGB treatment
(Jorgensen et al., 2012) and the effects may result from the benefits of GLP-1 (Jorgensen et al.,
2013). Improved condition of type-2 diabetes was observed in all these three types of bariatric
surgeries (Brethauer et al., 2013). The gastric band operation causes weight loss by the restrictive
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method; it reduces energy intake by gastric restriction, decreases appetite (Tadross and le Roux,
2009), decreases leptin level (Dixon et al., 2005), and increases fasting and postprandial satiety
(Dixon et al., 2005). However, it is reported that ghrelin was not reduced, but increased after GBa
treatment (Fruhbeck et al., 2004).
There could be some other gut hormones and/or mechanisms contributing to the weight
loss effect of bariatric surgeries. More studies need to be done to disclose them. Recently,
increasing data has supported that gut microbiota composition is altered after bariatric surgeries
and the changed gut microbiota might also contribute to the weight loss effect of bariatric surgeries.
1.4 Low-Calorie Diet Treatment (LCD)
During the 1970s it was noted that starvation was the fastest way to lose weight, but had
the disadvantage of negative nitrogen balance. Attempts were made to replace the protein lost and
to substitute some of that protein with carbohydrate to optimize weight loss while minimizing
nitrogen loss. In the mid-1970s, the success of the diets of consuming around 400 kcal per day was
reported and people lost an average of 1.5 kg or 1.5% of body weight per week on these regimens
(Vertes et al., 1977). Not long after this report, a diet containing a poor quality of protein made
from collagen was related with sudden death, and the pathology of the heart are alike the hearts of
patients dying of starvation (Sours et al., 1981). Pringle demonstrated that electrocardiographic
voltage started to decrease seven weeks after starting starvation, and in the following weeks, a
prolonged QT interval (a measure of the time between the beginning of the Q wave and the end of
the T wave in the heart’s electrical cycle), which is a harbinger of malignant ventricular
arrhythmias, was observed (Pringle et al., 1983). Subsequently, it was discovered that not only
high-quality protein but also at least 600 kcal per day was necessary to keep the
electrocardiographic voltage from falling (Greenway et al., 1994). Diets of between 400 and 800
kcal per day were shown to make the same effect on weight loss and appetite suppression (Foster
et al., 1992). Therefore, low-calorie diets are now classified as those that are 800 kcal per day or
more, and diets containing less than this or containing poor quality protein are not recommended.
As with all rapid weight loss of 1.5 kg or more per week, gallstone is easier to formed (Weinsier
and Ullmann, 1993). Ten grams of fat given with one meal per day can induce maximal contraction
of the gall bladder and counteracts stasis as a cause of gallstone formation (Stone et al., 1992).
Thus, the rate of weight loss seen with obesity surgery could be reproduced safely with a lowcalorie diet of 800 kcal per day containing 70 grams of high-quality protein along with 10 grams
of fat at one meal per day.
Finally, low-calorie diets (LCD) are still prescribed to those who do not qualify for bariatric
surgery with mixed success and poorer weight outcomes at the longer term. An alternative dietary
approach is the use of resistant starch, a carbohydrate that is not digested in the lower intestine but
is fermented in the colon. This shift in the substrate for the large intestine alters the microbiota
profile to one that produces more butyrate and other short-chain fatty acids (Keenan et al., 2006),
and increases the production PYY and GLP-1 in rodents (Zhou et al., 2008b) and humans
(Greenway et al., 2007). PYY and GLP-1 have both been shown to decrease food intake and reduce
body weight while GLP-1 has been shown to increase insulin sensitivity in rodents and human in
addition to increasing metabolic rate in rodents (Zhou et al., 2008b).
The low-calorie diet program in this research used the standard of 800 kcal per day by
using the meal plan including 5 servings of Health one meal replacement shake with added a
tablespoon of canola oil for protection of the gallbladder, following by weight maintenance by
prescription of a balanced diet containing 500 kcal/day less than required for body weight
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maintenance (measured energy expenditure at week 7–500 kcal/day). The participants needed to
have weekly clinic visits with a dietician for the first 7 weeks and monthly thereafter.
1.5 The ‘BARIA’ Project
The project “Effect of Bariatric Surgery and Weight Loss on Energy Metabolism and
Insulin Sensitivity” (BARIA) is funded by Endo-Surgery, Inc., and compares the four weight loss
treatments (RYGB, SGx, GBa, and LCD) on energy expenditure, body composition, insulin
sensitivity, and the response of gastrointestinal peptides to a standard meal. This $2.4 million
project performs the most comprehensive and in-depth study so far regarding the bariatric
procedures and energy metabolism and insulin sensitivity. However, there exists a main scientific
knowledge gap in how human gut microbiota is impacted by various bariatric procedures and what
the role of the gut microbiota in obesity and the weight loss process after the surgeries is.
The mechanistic observations on the relation of gut microbiota profile change by resistant
starch and their effect on the increased release of GLP-1 and PYY, and the association of RYGB
with increased GLP-1 and PYY, along with the evidence that suggests the correlation between gut
microbiota and host energy balance, bring about our central hypothesis that successful weight loss
following gastric bypass surgery may be partially credited to the alteration of gut microbiota after
the surgical procedure.
Twenty-four participants seeking bariatric surgery for weight loss in the Baton Rouge area
enrolled to the “BARIA” project is included in this study. Four groups will be studied before, and
7 and 52 weeks after bariatric surgery (RYGB, SGx, and GBa) or low-calorie diet program (LCD):
1) 5 patients eligible for Roux-en-Y gastric bypass (RYGB)
2) 9 patients eligible for sleeve gastrectomy (SGx)
3) 2 patients eligible for gastric banding (GBa)
4) 8 patients medically eligible for surgery but put on a low-calorie diet program (LCD)
The inclusion criteria include men and women between the ages of 18–65 years, body mass
index (BMI) > 40 kg/m2 or BMI > 35 kg/m2 with obesity-associated diseases that should improve
with weight loss (diabetes, hypertension, dyslipidemia and sleep apnea), medically qualified for
obesity surgery by our collaborator group of surgeons Drs LeBlanc or Hausmann (groups 1, 2 and
3 only), and meeting the NIH criteria for bariatric surgery (group 4 only). The exclusion criteria
include chronic gastrointestinal disease and chronic medications that have the potential for altering
the human gut microbiota.
Our research takes advantages of the “BARIA” project at two levels: (a) obtaining stool
samples before, 7 weeks and 52 weeks after the four weight loss treatments from the 48 participants
seeking weight loss treatments in the Baton Rouge area that complete the “BARIA” project, and
(b) correlating the microbial data with the physiological data obtained from the physiologic tests
done on these participants by the “BARIA”. We examine and compare the composition, diversity,
and metabolism of the human gut microbial community for difference across the four groups
(RYGB, SGx, GBa, and LCD) before, and 7 weeks and 52 weeks after the treatments.
1.6 Hypotheses and Experimental Design
Hypothesis 1: Gut microbial community structure is altered after BRS and LCD treatments
a. Gut microbial diversity is increased.
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b. Gut microbial distribution and composition is altered, with increased relative abundance of
beneficial microbial groups and reduced harmful microbial groups.
c. The functional gene community involved in metabolic processes of gut microbiota was
altered, with increased relative abundance of beneficial microbial genes.
Hypothesis 2: Genus Akkermansia is increased after BRS treatment and correlates with
obesity improvement.
Hypothesis 3: The amount and constitution of short-chain fatty acids (SCFAs) are altered
after treatments, with reduced acetate and increased propionate and butyrate.
Overall experimental design: Stool sample collection for the proposed human gut
microbiota study will be carried out in parallel to the “BARIA” project. The overall experimental
design of the “BARIA” project is shown in Figure 1. Briefly, following the screening, the study
includes both outpatient and inpatient/overnight visits. The major testing periods are conducted at
Baseline, at weeks 7 and 52 post-surgery/LCD as described:
1) Baseline (conducted 1–6 weeks prior to surgery or LCD)
2) Week 7 (conducted 6–8 weeks after surgery or LCD)
3) Week 52 (48-56 weeks after surgery or LCD)
Study Groups
Roux-en-Y-Gastric Bypass (RYGB)

BASELINE

Major Testing
Outpatient visits
SCREEN

-6 to -1

Gastric Banding (GBa)
Low calorie diet induced weight loss (LCD)
Surgery

SCREENING

Sleeve Gastrectomy (SGx)

x

x

x

x

x

x

0

4

8

12

16

20

24

Wk 7
x

x

x

x

x

x

28
32
36
40
44
48
Weeks
* LCD subjects will have weekly outpatient visits from the beginning of the LCD diet until the inpatient assessment at week 7

Wk 52
x
52

Figure 1.6.1 Experimental design of the BARIA project.
Each testing period includes four outpatient visits and one overnight stay. During each
testing period, energy expenditure (24-hour metabolic chamber stay for oxygen consumption and
fat oxidation, doubly labeled water study for free-living energy expenditure and accelerometry for
activity energy expenditure), body composition (echo magnetic resonance imaging for body fat
and lean tissue, multi-slice computerized tomography for visceral fat quantitation, and magnetic
resonance spectroscopy for intra-hepatic and intra-myocellular lipid), insulin sensitivity (2-stage
euglycemic hyperinsulinemic clamp for insulin sensitivity and hepatic glucose output), and the
response of gastrointestinal peptides to a standard meal (glucose, insulin, ghrelin, GLP-1, and PYY)
will be measured in all four groups. Changes will be compared across the four groups and between
baseline, and 7 and 52 weeks post-operatively. These physiologic data generated by the “BARIA”
project will be made available to interpret gut microbial data obtained on these patients in the
human gut microbiota research.
After obtaining informed consent, stool samples will be collected in the four groups
(RYGB, SGx, GBa, and LCD) at baseline (prior to surgery or LCD) and 7 weeks (after surgery or
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LCD) when the “BARIA” project is in its first two major testing periods. Based on previous studies,
the people would lose about 11-12% of their body weight (about 12-15kg) over the 7 weeks after
surgery or LCD (Greenway et al., 1994, Andrew et al., 2006, Laferrere et al., 2007). This would
be sufficient to get the changes in gut microbiota in response to the weight loss as we previously
observed in our study of mice fed resistant starch (Bae et al., 2009). A longer duration (week 52,
the third testing period of the “BARIA” project) would assess longer term compliance of subjects
to the weight loss treatments and the sustainability of changes in gut microbiota.
The DNA extracted from the stool samples collected from the 24 participants at baseline
and 7 and 52 weeks after the surgery or LCD, will be used for the following microbial analyses:
1) Community structure change (e.g. diversity) of gut microbiota and the microbial
populations changed by the 4 weight loss treatments using Illumina sequencing
targeting on the hypervariable V4 regions of the 16S rRNA gene.
2) Change of functional genes involved in the metabolic processes of gut microbiota using
HuMiChip.
3) Abundance of microbial groups of interest, which have been previously indicated to
associate with obese people and/or to be involved in energy metabolism and the groups
that are identified to respond to the 4 weight loss procedures in this research), e.g.
Firmicute, and Bacteroidetes, Archaea, the archaeal subgroups, using real-time PCR.
4) Short-chain fatty acids (SCFA) including butyrate, lactate, and acetate, using gas
chromatography.
Data integration. Integrated analysis of Illumina sequencing, HuMiChip, and physiologic
data (including those generated by the “BARIA” project) represents an immense challenge. We
used various statistical approaches to identify relationships within the complexity. First, we used
multivariate analyses, such as principal component analysis (PCA), for data reduction. Also,
Mantel test was used for variation partition analysis to determine the relative influence of the
physiologic variables. These analyses help us to identify any possible overall significant
relationships among microbial community structure, physiologic activities, and various metabolic
functional processes. In addition, we will examine the relationships between those key
genes/populations with gut environmental conditions and host health conditions using the Mantel
test, Pearson and/or Spearman correlation analysis and various other statistical approaches.
Expected results. We expect to identify the microbial populations that are responsive
(stimulated or inhibited) to the weight loss procedure (surgery or LCD) by comparing changes
between baseline and 7 and 52 weeks after the procedures. We also expect the four weight loss
procedures (RYGB, SGx, GBa, and LCD) that cure obesity/ diabetes with varying effectiveness
to have different effects on the gut microbial community structure and metabolism, and the altered
gut microbiota, in turn, to be responsible in part for the greater efficacy in weight loss and
improvement in diabetes with gastric bypass and sleeve gastrectomy compared to laparoscopic
banding and low-calorie dieting. We anticipate that this research will help better understand
metabolic pathways uncovered by bariatric surgery and weight loss in a larger context; it will
provide a first step towards intentionally manipulating gut microbial community structure to
regulate energy balance in obese/diabetic individuals in future studies.
Overall summary of the research. The synergism of working as a multidisciplinary team
(encompassing the areas of microbial ecology, clinical research, gut nutrition and physiology,
molecular biology, and molecular analytic techniques) will result in a comprehensive
understanding of the role of human gut microbiota in obesity and diabetes. This research may
ultimately close the loop in understanding the varying effectiveness of different bariatric surgery
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and weight loss procedures and lay the groundwork for the analytic methodologies used in the
future human gut microbiome and diseases studies.
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CHAPTER TWO: MATERIALS AND METHODS
2.1 Stool Sample Collection
Stool samples were used for studying gut microbiota in this research. The subjects were
given stool collection “pilgrim hats” that fit inside the toilet to collect stools. All stools were
collected at baseline (bl), week 7 (w7), and week 52 (w52) post treatment. The stools were placed
directly into Ziplock® plastic bags and frozen at –80C immediately after being collected.
In total, 38 prepared samples from the fecal samples of 16 participants obtained before and
after bariatric surgeries (Band, Sleeve, and Bypass) and 20 samples from the fecal samples of 8
participants collected before and post low-calorie diet program treatment were processed for
Illumina sequencing. Samples from every individual include baseline, and week 7 or week 52 or
both week 7 and week 52 post treatments. The participants included 3 males and 21 females, aged
from 22 to 62 years old. Two participants had diabetes mellitus (DM); two had pre-DM/insulin
resistance; seven had dyslipidemia; 14 suffered from hypertension. None of the patients had a
metabolic syndrome.
2.2 DNA Extraction
Genomic DNA was isolated from the stool samples with a fecal DNA extraction kit
(MoBio) following the manufacturer’s instructions. The extracted DNA was stored at –80C until
the molecular analyses were conducted.
2.3 Illumina Sequencing
16S ribosomal RNA (16S rRNA) is the component of the 30S small submit of a prokaryotic
ribosome. 16S rRNA gene is the gene coding for 16S rRNA and its sequence has been widely used
for building phylogenetic trees, owing to 1) it is highly conserved in all most all bacteria and
archaea species; 2) its slow evolution rate (its function has not changed over time, suggesting that
random changes of sequences are a more accurate measurement of time or evolution; and 3) the
1500 bp of its gene sequence is long enough for informatics analysis. (Janda and Abbott, 2007).
Now it has been widely accepted that 16s rRNA gene sequence is sufficient to classify microbes,
and has greatly saved researcher’s s workload when compared to the traditional methods such as
culture and microscopy.
Sequencing technology has been greatly advanced since its invention. The first generation
of sequencing method (e.g. Sanger sequencing) enabled sequencing of clonal DNA populations.
The second generation of sequencing methods is high-throughput by enabling the process of
multiple reactions simultaneously (e.g. Illumina sequencing). The third generation of sequencing
method is capable of sequencing single DNA molecules (Heather and Chain, 2016).
Previous metagenomic studies of human gut microbiota have mainly relied on the
generation of clone libraries of the 16S rRNA genes. First, genomic DNA will be extracted by
DNA extraction kit. Then Taq polymerase and universal primers will be used for amplifying a
fragment of the microbial 16S rRNA gene sequence of PCR reactions. Then the amplified
sequences will often be cloned by using a cloning kit, which contains linearized vector, DNA
ligase, DNA ligase buffer, PCR buffer, dNTPs, control DNA template, control PCR primers, sterile
water as well as competent cells and corresponding reagents. Since Taq polymerase can add single
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deoxyadenosine (A) to the 3’ ends of amplified PCR products independent of a template, and the
kit-supplied linearized vector has single 3’deoxythymidine (T) residues. This allows the PCRamplified 16S rRNA gene sequence fragment to ligate with the vector. First, the PCR products are
ligated into the supplied linear vector in a commercial clone kit and then transformed into
competent E. coli cells. Next step is to select colonies and isolate plasmid DNA. After that, analyze
plasmid DNA for the presence and orientation of the PCR product by either restriction digestion
or sequencing method. Individual recombinant plasmids are required to be analyzed for the
confirmation of the right direction because the PCR-amplified 16S rRNA gene sequence can be
ligated into the vector in either orientation. The correct recombinant plasmid is then purified for
further subcloning for characterization. After that, the traditional sequencing method, Sanger
sequencing will be used. Sanger sequencing is developed by Frederick Sanger and his colleagues
in 1977, and it is based on the selective incorporation of chain-terminating dideoxynucleotides by
DNA polymerase in the process of in vitro DNA replication.
This traditional method can only produce a limited number of bacterial sequences. To our
knowledge, none of these human gut microbial diversity surveys that used this methodology has
generated more than 20,000 bacterial sequences (Eckburg et al., 2005, Ley et al., 2006, Frank et
al., 2007). According to nonparametric estimations and extrapolations from rarefaction curves,
however, obtaining a much higher number of sequences may reveal as many as 500-15,000 species
(Eckburg et al., 2005, Frank et al., 2007), which include relatively rare members of the microbial
community that collectively could have a profound impact on gut health and disease, including
obesity (Zhang et al., 2009).
Around a decade ago, several new high-throughput sequencing approaches have been
developed. One of the most promising high-throughput 2nd generation sequencing technologies is
Illumina sequencing, which is based on the sequence by synthesis approach. It is a highly parallel
non-cloning Illumina sequencing system capable of sequencing up to 100 million bases in one
four-hour run on a Miseq system. Illumina sequencing has the potential to revolutionize
sequencing studies, including characterizing microbial community diversity with a sample tagging
approach. Currently, this sequencing method has been successfully used to study the microbial
community in animals, humans, soils and oceans.
A recent study analyzing the human gut microbiota with the traditional Sanger and the
Illumina pyrosequencing methods revealed that in general, the two methods were in good
agreement for the more abundant taxa while the Illumina sequencing could capture the rare taxa
missed by Sanger sequencing. Although Illumina sequencing produces relatively short sequences
(~250 bp for the Miseq system), recent studies have shown that those short sequences are sufficient
to statistically determine significant differences among microbial genomes that reflect the most
likely biology occurring in each environment. In addition, multiplexed high-throughput Illumina
sequencing of individual genes (e.g., 16S rRNA gene) by tagging or barcoding with short
nucleotides has been developed to process many samples simultaneously. Zhou’s lab also used a
tagged Illumina sequencing approach to characterize several microbial communities.
Many published studies have demonstrated that the Miseq platform (Illumina) may
generate tremendous sequencing information and is a powerful tool for studying microbial
diversity. Therefore, this study chose Illumina sequencing for studying the effect of bariatric
surgery and weight loss on the structure of the human gut microbial community.
Next sequencing techniques will determine the sequences. Then the sequences will be
compared with reference sequences in databases and denoted as the same reference sequence if
their similarity is greater than 98%. Type strains of 16S rRNA gene sequences of most bacteria
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and archaea are available in public databases (e.g. NCBI). However, the quality of the sequences
found in these databases is not often validated. Thus, secondary databases that collect only
16SrRNA gene sequences are used widely, and Ribosomal Database Project (RDP) is one of the
popular ones.
The problem still exists because, for example, studies on fecal samples found that lots of
detected sequences (around 3/4 of the sequences) do not show 98% similarity with any sequences
in the reference databases. Their sequences will be deposited into the public database and their
classification and identification might be uncovered by the future research.
The
PCR
primers
F515
(GTGCCAGCMGCCGCGGTAA)
and
806R
(GGACTACHVGGGTWTCTAAT) were selected to target the V4 hypervariable regions of the
bacterial 16S rRNA genes. To pool multiple samples for one run of Illumina sequencing, a sample
tagging approach was used (Binladen et al., 2007, Hamady et al., 2008). Each tag (12 mer) was
added to the 5'-end of both forward and reverse primers, synthesized by Invitrogen (Carlsbad, CA,
USA), and then used for the generation of PCR amplicons. PCR amplifications were conducted
with Accuprime high-fidelity Taq polymerase. The amplification mix contained 0.1 µl AccuTag
polymerase, 2.5 µl reaction buffer II, 1 µl of each primer, and a 2.5–5.0 ng template in a volume
of 25 µl. Cycling conditions were an initial denaturation at 94C for 1 min, 30 cycles of 94C for
20 s, 53C for 25 s, 68C for 45 s, and a final 10-min extension at 68C. All the amplified PCR
products from each tagged primer were pooled and purified by 1% agarose gel electrophoresis,
followed by quantification by PicoGreen (Ahn et al., 1996). Finally, amplicons of all samples were
pooled in an equimolar concentration for Illumina sequencing. All sequencing reads were initially
processed using the Galaxy sequencing pipeline (http://zhoulab5.rccc.ou.edu/). Raw sequences
were sorted and distinguished by unique sample tags. All sequences for each sample were aligned
by RDP Infernal aligner, a fast secondary-structure aware aligner (Ribosomal Database Project,
Michigan State University, East Lansing, MI, USA) (Nawrocki and Eddy, 2007), and then Uclust
was used to define operational taxonomic units (OTUs) within a 0.03 difference. A 97% identify
was used as the cutoff, and singleton sequence reads were removed. Each OTU contained more
than two sequence reads from at least two samples. The sequence reads within an OTU were
partitioned into individual samples based on the original sample-tagging information. A total of
3,422,989 V4 regions of 16S rRNA raw sequence reads were generated from the 55 microcosm
samples. After removing the undetermined nucleotides and trimming the sequences, a total of
3,413,843 sequences were derived and were clustered into 11,314 unique OTUs without singlet
based on 97% sequence similarity. Considering that the sequence numbers of the individual OTUs
varied significantly among different samples and the sequence abundance of the sample with the
lowest sequence abundance is 13,780, a resampled dataset with a final total of 13,780 sequence
abundance of each sample for subsequent analysis (Zhou et al., 2011), was employed to reduce the
sampling bias. After resampling, all samples in the baseline, week 7 and week 52 post-treatment
samples have a sequence abundance of 13,780. Then assign taxonomy to the representative
sequences with the RDP classier (Wang et al., 2007) with a confidence cutoff of 0.5. The lineage
of each OTU was summarized with all phylogenetic information.
2.4 HumiChip Analysis
Although the microbial diversity can provide information both on which organisms are
present and what metabolic processes are possible in the community, they have limits in giving a
full picture of microbial activities and dynamics, especially on a large scale and in a parallel and
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high throughput fashion. To overcome such obstacles for studying microbial communities in
natural settings, Zhou and He have been dedicated to developing a microarray-based, highthroughput technology, functional gene arrays (FGAs). Over the last decade, many technical
difficulties relating to applications of microarray technologies to environmental studies with regard
to oligonucleotide probe design, development of computer program, specificity, sensitivity,
quantitative capability, and amplification of the target DNA and RNA at the nano-scale were
solved (Wu et al., 2001, Rhee et al., 2004, Tiquia et al., 2004, Wu et al., 2004, Zhou et al., 2004,
He et al., 2005, Wu et al., 2006, Liebich et al., 2006, Gao et al., 2007, Deng, 2008). With a newly
developed computer program, several generations of functional gene arrays or GeoChip have been
designed. Comparing with 16S rRNA gene-based microarrays (e.g., PhyloChip), the GeoChip is
particularly useful in linking microbial community structure to community function in
environmental studies. So far, the GeoChip has been used in a variety of studies such as
characterizing marine sediment community structure, characterizing grassland microbial
community structure under elevated CO2, examining the effects of contaminants on microbial
communities, assessing spatial scaling of microbial community diversity in a forest soil (Zhou et
al., 2008a), and assessing microbial fuel cells (MFC) for hydrogen production. The results from
various studies demonstrate that GeoChip works very well with the natural environmental samples,
such as soils, marine sediments, and groundwater, and is a powerful tool for profiling microbial
community differences in general, and for linking community structure to functions. To our
knowledge, this was the first and most comprehensive array currently available for studying
various biogeochemical, ecological and environmental processes. With the urgent need for such
technique in studying the metabolism of the human gut microbial community, a GeoChip-like
technique, HuMiChip has been developed.
Although human gut microbial studies based on 16S rRNA clone libraries or high-throughput next generation sequencing (e.g. Illumina sequencing) technique are very powerful, but they
have limited usefulness in determining the metabolic function of the human gut microbiota.
Metagenomic analysis among different healthy individuals microbial composition is highly varied
but their metabolic pathways and gene content are relatively stable, based on the Human
Microbiome Project (Consortium, 2012) and some other related studies (Turnbaugh et al., 2009,
Caporaso et al., 2011, Gevers et al., 2012). Using functional gene array-based technologies to
characterize human microbiota is a novel and promising tool for human microbiome studies. It is
our expectation that the HuMiChip would be a new platform that overcomes the major limitations
of many traditional methods (e.g. PCR-based functional gene analysis) currently available for
human microbiome studies, and is expected to provide insights into physiologic and ecological
mechanisms of human microbiota at the community level. Thus, we applied HuMiChip to
determine the effect of bariatric surgery and weight loss on the metabolism of the human gut
microbial community.
The current version of HuMiChip (HuMichip2) contains two different types of probes,
functional gene probes for identifying functional profiling of human microbiota and strain/speciesspecific probes for identifying strain or species (Tu et al., 2016). The evaluations of the microarray
have been done both computationally and experimentally by using single strains/species and mock
communities, as well as pure culture DNA and mock community DNA (Tu et al., 2014, Tu et al.,
2016). In total, 2063 sequenced microbial genomes and around 2.5 gigabytes (GB) assembled
shotgun metagenome sequences from 14 different human body sites were retrieved from the
Human Microbiome Project Data Analysis and Coordination Center (http://hmpdacc.org). The
sequenced microbial genomes were employed for designing probes for detection of both microbial
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functional gene families and specific strains. The metagenome data were employed for designing
probes targeting microbial functional gene families. Another 3327 sequenced microbial genomes
and human genome sequences were downloaded from the National Center for Biotechnology
Information (NCBI) ftp site, were further employed for specificity check to ensure the specificity
of strain-specific probes against non-human microbes and the human genome. For detection of the
microbial functional gene profile, it included 94,387 sequence-specific probes, 39,537 groupspecific probes, and covers 276,240 coding sequences (CDS) of 157 gene families, which are
involved in 11 microbial functional processes that they play important roles in human (Table 2.1).

Table 2.1 Summary of the microbial functional process and the numbers of gene families,
sequence-specific probes, group-specific probes, and covered coding sequence on the current
version of HuMiChip (HuMiChip2). Gene families targeting human microbiomes are selected
from KEGG pathway database, and may participate in multiple pathways (In other words, the
overlap of functional genes may occur among different functional processes.). The total number
of probes and covered coding sequences is based on non-redundant genes included in all pathways.

Microbial functional process
Antibiotic
Amino acid metabolism
Carbohydrate metabolism
Energy metabolism
Glycan metabolism and biosynthesis
Lipid metabolism
Non-essential amino acids metabolism
Cofactors and vitamins metabolism
Terpenoids and polyketides metabolism
Nucleotide metabolism
Translation
Sum

No. of
gene
families
18
36
27
5
10
5
20
16
5
13
2
157

No. of
sequencespecific probes
0
24,314
15,322
7,115
6,010
3,262
14,420
9,700
3,644
8,523
2,077
94,387

No. of groupspecific
probes
13,567
5,723
4,442
1,878
2,560
1,173
4,040
2,605
861
2,061
627
39,537

No. of
targeted
CDS
32,168
59,392
40,173
16,799
20,277
8,984
37,656
25,854
8,398
20,485
6,054
276,240

Target preparation, microarray hybridization, and image processing were carried out as
previously described (He et al., 2007). Briefly, about 100 ng of purified DNA from each sample
were amplified using whole-community genome amplification (WCGA), labeled with Cy3, and
then hybridized with the HuMiChip. Microarray hybridizations were carried out under the
stringent condition of 50˚C plus 50% formamide using TECAN Hybridization Station ProHS4800
(TECAN US). After hybridization, microarray image and data processing were carried out as
described previously (Rhee et al., 2004, Wu et al., 2006). Briefly, poor or irregular spots were first
automatically removed using the software ImaGene® (Biodiscovery, Inc). Second, hybridization
spots with a signal-noise ratio (SNR) < 2 (He and Zhou, 2008) were removed from further analysis.
In addition, the outlying spots were removed after normalization (Wu et al., 2006). Generally,
absolute hybridization signal intensity data are used for statistical analysis.
In total, 27 prepared samples from 10 participants’ fecal samples obtained before and post
Bariatric surgeries (Band, Sleeve, and Bypass), and 21 samples from 8 participants’ fecal samples
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collected before and post low-calorie diet program treatment were processed for HumiChip
analysis. Samples from every individual include baseline, week 7 or week 52 or both week 7 and
week 52 post treatments, except one without a baseline.
2.5 Quantitative Polymerase Chain Reaction (qPCR)
Quantitative PCR is carried out in a thermal cycler with the capacity to illuminate each
sample with a beam of light of at least one specified wavelength and detect the fluorescence
emitted by the excited fluorophore. The thermal cycler is also able to rapidly heat and chill samples,
thereby taking advantage of the physicochemical properties of the nucleic acids and DNA
polymerase.
We used non-specific fluorescent reporter detection of PCR products: a double-stranded
DNA (dsDNA)-binding dye is used as a reporter. The dye can bind to all dsDNA in the PCR
reaction, causing fluorescence of the dye after being excited by a laser. Thus, an increase in DNA
product during PCR will produce an increase in measured signal intensity of fluorescence at each
cycle. However, dsDNA dyes (e.g. SYBR Green) can bind to all dsDNAs, including non-specific
PCR products and/or primer dimers, preventing from obtaining an accurate result of the amount
of the anticipated PCR products. For running the real-time PCR experiment using this method, the
reaction mix is prepared as that for regular PCR, with the supplement of fluorescent dsDNA dye.
Next, the reaction is run in a real-time PCR instrument, and the signal intensity of fluorescence,
which is produced when dye binds to the dsDNA, is measured by a detector in real time.
For our experiment, qPCR was performed in a CFX Connect Optics Module real-time PCR
detection system from Bio-Rad. A total volume of 600 µl of reaction mixture was made by mixing
thoroughly 95 µl of nuclease-free water (NFW), 5 µl each of 100 µM forward and reverse
primers, and 500 µl of 2 × concentrated, ready-to-use SsoAdvanced™ Universal SYBR® Green
Supermix, which contains antibody-mediated hot start Sso7d-fusion polymerase, dNTPs, MgCl2,
SYBR Green I dye, enhancers, stabilizers, and a blend of passive reference dyes, to a final 1 ×
concentration of SYBR® Green Supermix and 500 µM concentration of primers. Each 6-µl aliquot
was dispensed into a well of a 96-well PCR plate, followed by 4 µl of DNA templates (around
0.05 ng/µl) to each well, making each well incorporating 10 µl reaction mixture composed of 5 µl
of 2 × SYBR® Green Supermix, 0.05 µl of each primer (100 µM), 4 µl of DNA template, and 0.95
µl of NFW to bring the total volume to 10 µl. Wells with 4 µl of NFW was served as no template
controls (NTC). Three replicates of each sample were applied. The thermal cycling conditions
were as follows: 3 min at 98 ˚C for enzyme activation/initial DNA denaturation, followed by 40
cycles of 15 s for denaturation at 95 ˚C and 30 s annealing at 60 ˚C for annealing and final melt
curve analysis from 65 ˚C to 95 ˚C in 0.5 ˚C increments for 5 ˚C per step. 338f (5'-ACTCCTACG
GGAGGCAGCAG-3') and 518r (5 '-ATTACCGCGGCTGCTGG-3') were used as the forward
and reverse primers for total bacteria detection (Ovreas et al., 1997, Buckeridge et al., 2013). 5'ACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGCGAAAGCCTGATG
CAGCGACGCCGCGTGAGCGAAGAAGTATTTCGGTATGTAAAGCTCTATCAGCAGGG
AAGATAATGACGGTACCTGACTAAGAAGCACCGGCTAAATACGTGCCAGCAG
CCGCGGTAAT-3', was the DNA sequence used for standard curve construction to quantify total
bacteria abundance and the complete, and this sequence fragment was selected by combining the
sequence information of the complete genome of Eubacterium rectale ATCC 33656
(http://www.ncbi.nlm.nih.gov/nuccore/238922432?report=fasta) with those of forward and
reverse primers we applied in this research by the online software Sequence Extractor at
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http://www.bioinformatics.org/seqext/ (Guo et al., 2008). The beginning nanograms and copy
numbers of the loaded Eubacterium rectale standard DNA in each cell are 2 × 10–3, 2 × 10–4, 2 ×
10–5, 2 × 10–6, 2 × 10–7, and 2 × 10–8 (2.02 × 107, 2.02 × 106, 2.02 × 105, 2.02 × 104, 2.02 × 103,
and 2.02 × 102). For designing the primers of detection of the genus Akkermansia, first the
fragment of Akkermansia muciniphila strain ATCC BAA-835 16S ribosomal RNA gene, complete
sequence
(NR_042817.1,
http://www.ncbi.nlm.nih.gov/nuccore/343202494?report=fasta)
corresponding to these 42 detected Akkermansia sequences were identified, then this fragment
sequence was used as reference sequence for aligning all of the 42 16SrRNA sequences of the
genus Akkermansia detected in our samples by Illumina sequencing and the known Akkermansia
sequences which have been deposited in the NCBI reference sequence database were aligned and
viewed by multiple sequence alignment with the one of the Clustal series of programs (Mview)
run on the web server at the EBI (European Bioinformatics Institute)
(http://www.ebi.ac.uk/Tools/msa/mview/) (Chenna et al., 2003). Based on this alignment, a 16S
rRNA oligonucleotide fragment of the reference sequence which starts from the first segment to
the last segment, both of which contains consecutive nucleotides (18 -22 bp) (S. Patricia, 2009)
and covers the most highly variable among these sequences, was extracted and used as the
reference gene for making the standard curve. The two sequence fragments at the beginning and
the end of the sequence were used for designing the primer sequences for real-time PCR
amplification to amplify as many of these sequences as possible. Three sets of primers were
designed from these two sequence fragments and synthesized by Integrated DNA technologies
(IDT), and they are the forward primer for the 1st set of primer (5’AATCACTGGGCGTAAAGCGT-3’), the reverse primer for the 1nd set of primer (5’TCTCGCAGTATCATGTGCCG-3’), the forward primer for the 2nd set of primer
(GAATCACTGGGCGTAAAGCG), the reverse primer for the 2nd set of primer
(TTCCGGTTCCCCCTCCATTA), the forward primer for the 3rd set of primers
(TCGGAATCACTGGGCGTAAA), the reverse primer for the 3rd set of primers
(CGGTTCCCCCTCCATTACTC). The forward primer 5’-AATCACTGGGCGTAAAGCGT-3’
and the reverse primer 5’-TCTCGCAGTATCATGTGCCG-3’ were used for the detection of
species Akkermansia Muciniphila. The specificity of the primers was checked by using the
National Center for Biotechnology Information (NCBI) online software primer-baselineAST at
http://www.ncbi.nlm.nih.gov/tools/primer-blast/ (Ye et al., 2012) for making sure that the primers
would only bind with Akkermansia, but not other organisms. The primer-baselineAST result only
showed Akkermansia muciniphila and several uncultured bacterium clones, the top hit of all of
which were Akkermansia muciniphila reference sequence (with sequence similarity of equaling to
or greater than 98%) after blasting them using standard nucleotide baselineAST against the 16S
ribosomal
RNA
sequences
(Bacteria
and
Archaea)
database.
5'TTCGGAATCACTGGGCGTAAAGCGTGCGTAGGCTGTTTCGTAAGTCGTGTGTGAAAG
GCGCGGGCTCAACCCGCGGACGGCACATGATACTGCGAGACTAGAGTAATGGAGGG
GGAACCGGAATTC-3', was the DNA sequence used for standard curve construction to quantify
Akkermansia muciniphila abundance, and this sequence fragment was selected by combining the
sequence information of the complete 16S ribosomal RNA (rRNA) gene of Akkermansia
muciniphila ATCC BAA-835 (http://www.ncbi.nlm.nih.gov/nuccore/343202494?report=fasta)
with those of forward and reverse primers we applied in this research by the online software
Sequence Extractor at http://www.bioinformatics.org/seqext/. The DNA sequences used for
standard curve constructions in the real-time PCR assays were double-stranded linear
gBlocks® gene fragments synthesized by Integrated DNA technologies (IDT). The beginning
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nanograms and copy numbers of the loaded Akkermansia muciniphila standard DNA in each cell
are 2 × 10–3, 2 × 10–4, 2 × 10–5, 2 × 10–6, 2 × 10–7, and 2 × 10–8 (1.17 × 108, 1.17 × 107, 1.17 × 106,
1.17 × 105, 1.17 × 104, and 1.17 × 103).
In addition, the forward primer 5'-TCTCGGTGTAGCAGTGAAATG-3' and the reverse
primer 5'-GTGCCTCAGCGTCAGTTAAT-3', the produced top-ranked primers pairs designed by
using the sequence fragments of Akkermansia muciniphila ATCC BAA-835 that fall within the
amplification region of the our Illumina sequencing result, and the IDT online software
PrimerQuest at https://www.idtdna.com/Primerquest/Home/Index following by the same abovementioned procedure for specificity double-check, were also used for double-check the result. The
DNA sequence used for standard curve construction was identified by the above-mentioned
method
and
its
sequence
is
5'TCGTGTGTGAAAGGCGCGGGCTCAACCCGCGGACGGCACATGATACTGCGAGACTA
GAGTAATGGAGGGGGAACCGGAATTCTCGGTGTAGCAGTGAAATGCGTAGATATCG
AGAGGAACACTCGTGGCGAAGGCGGGTTCCTGGACATTAACTGACGCTGAGGCAC3'. The beginning nanograms and copy numbers of the loaded Akkermansia muciniphila standard
DNA in each cell are 2 × 10–3, 2 × 10–4, 2 × 10–5, 2 × 10–6, 2 × 10–7, and 2 × 10–8 (1.17 × 108, 1.17
× 107, 1.17 × 106, 1.17 × 105, 1.17 × 104, and 1.17 × 103). The result obtained by using this pair of
primers showed the similar pattern as that obtained by using the first set of primer described above.
The specificity of the primers for running qPCR was further confirmed by sequencing the qPCR
products by the Sanger sequencing, and the sequence results showed that they shared 100%
similarity with Akkermansia muciniphila ATCC BAA-835.
2.6 Gas Chromatography
Chromatography is a technique used for separating compounds in mixtures. The phase that
the sample mixture is dissolved in is called the mobile phase, and the other phase that holds the
sample is called the stationary phase. The substances in the mixture are separated owing to that
different substances have different solubility in these two different phases, or in other words, each
constituent has a different partition coefficient (the ratio of a compound’s concentrations in two
phases at equilibrium; It measures the difference in solubility of a compound in these two phases).
Different components in a mixture have different physical structure’s characteristics, making them
having different solubility in mobile and stationary phase, so these components move along the
mobile phase with different rates and separate from each other gradually.
There are many different types of chromatography technologies existing, based on different
methods and techniques. For example, based on the physical states of the mobile phase and
stationary phase, it can be classified as homogeneous (e.g. liquid-liquid chromatography) or
heterogeneous (e.g. liquid-gas chromatography). Based on the shape of stationary phase, it can be
classified as column chromatography (the shape of stationary phase is a column) (e.g. gas
chromatography) and planar chromatography (the shape of stationary phases is planar).
Gas chromatography (GC) is a common type of chromatography used in analytical
chemistry for the separation and analysis of substances that can be vaporized without
decomposition. It has been wildly used to evaluate volatile compounds such as fatty acid, essential
oils, etc. Its mobile phase is gas (usually an unreactive gas (e.g. nitrogen) or inert gas (e.g.) helium),
and its stationary phase is a microscopic layer of liquid or polymer on an inert solid support, inside
a piece of the column which is made of glass or metal. The gaseous sample constituents interact
with the walls of the column, which is coated with a stationary phase, causing each constituent to
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elute at a different time, which is called the retention time for that constituent. Retention times can
be used to calibrate the concentrations of the components in samples by several different methods.
For quantitative analysis by GC, 1) the GC system performance should be stable and consistent.
2), a calibration curve for each analyte of interest is needed because, for most GC detectors, they
have a different response to different analytes given their different molecular composition and/or
size. 3) The range of the concentration of the standard analyte of the calibration curve should
include the expected range of the analyte concentration in the samples being measured. The
quantitative results for sample analyses that fall outside the calibration range are not trustable,
especially when the calibration curve is not linear.
The gas chromatograph is the name of the instrument used to perform gas chromatography.
The basic instrument components of gas chromatograph contain the mobile phase gas in a cylinder,
the sample injection system, column of gas chromatography, the detector, the computer for
recording data, and the thermal chamber for controlling temperature. We used the microFAST™
GC for our experiments. It is a small, fast GC designed to promote analytical efficiency in the
laboratory and in the field. It can precisely and efficiently separate different types of compounds
in a sample by using real-time microprocessor control of temperatures and pressures. Low thermal
mass conduction heater technology is employed by the column heater for precise and fast
temperature programming and cool-down of dual, high-resolution separation columns. A trapbased injection system is also used for concentrating and then desorbing the compounds in samples
for injection onto the narrow bore capillary columns.
There are several approaches for calibrating the unknown concentrations of an analyte
using the calibration curve. The choice depends on many aspects such as the type of the sample
and the protocol for sample preparation, the configuration of the instrumentation system, etc.
These approaches are 1) external calibration which uses the function of the signal intensity of the
detector response versus (vs) analyte’s concentration. The external calibration is the most
straightforward method and is used most often. 2) internal standard calibration which uses a
relative signal intensity of the detector response function of the analyte of interest to another
reference substance (it has similar chemical characteristics of the analyte of interest) that is added
to the sample prior to any sample preparation and /or analysis. The internal standard calibration
method is designed to compensate for the potential sources of errors that may result from sample
preparation and inherent variability of the GC system as well as the analysis method. 3) standard
addition, which uses the function of the signal intensity of the detector response vs the amount of
the concentration of known incremental amounts of the analyte of interest that are added to a
sample to calculate the original concentration of the analyte, which has a concentration value of 0
for the added amount of the standard. The standard addition method is like the internal standard
calibration method, but it adds different standard concentrations of the analyte of interest to the
samples, instead of the reference substance which has similar chemical characteristics as the
analyte of interest. This method is developed to overcome inaccurate quantification caused by the
baseline noise (The signal intensity may not be inaccurate if the unknown concentration is close
to the limit of the detection because that region has great noise) and/or attenuated or magnified
response resulting from sample matrix (sample matrix inhibits linear activity).
Calibration curves can be a linear, non-linear, or mixed (e.g. linear in the low concentration
region, while curved in the higher concentration). A linear function can be expressed using the
form ‘y = ax+b’, where ‘y’ is the signal intensity of the response of the detector, ‘x’ is the
concentration of the analyte, ‘a’ is the slope of the linear line and ‘b’ is the intercept of the linear
line on y-axis given x equals to 0. The calibration curve can be made based on the retention time
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and concentrations of a series known different concentrations of the solution for each component.
The concentration of the compounds in each sample can be calculated based on the corresponding
standard curve.
In most cases, the relationship between the signal intensity and analyte concentration is
linear. Then, the values of a and b can be derived by using several pairs of the known
concentrations of the standard compounds for each analyte of interest and their corresponding
signal intensity under the same running condition as that for running the real samples which
contain analytes of interest with unknown concentrations waiting to be determined. Although two
sets of data are enough to draw a line, researchers cannot see whether the relationship is curved or
not. Thus, at least three sets of standard concentrations are needed to develop a usable calibration
curve; one standard concentration should be close to the limit of determination, one should be the
high limit of the concentration estimated for the samples, and others is supposed to be spread
evenly across the calibration range. More numbers of standard concentrations, more accurate
standard curve can be derived. Sometimes, the detected signal intensity for the analyte of interest
falls outside of the range of the signal intensity derived from the standard concentrations. Then
another standard concentration or several other standard concentrations may need to be added to
let the detected signal intensity for the analytes with unknown concentrations fall within the range
of the calibration curve.
2.6.1 Instrumentation
A model microFAST™ GC from Analytical Specialists, Inc was used in all experiments
and equipped with dual flame ionization detectors (FID). The separation columns were 2 meters
in length by 100 µ ID fused silica capillaries coated with 0.4 µ of DB-5 and DB-1701 liquid phases.
Sample volumes of 1 µl were injected with a 10-µl glass syringe. The injected analytes were
trapped on a Tenax GR absorbent microtrap maintained at 40°C and desorbed at ~240°C.
2.6.2 GC condition
The ready and desorb temperature for concentrator were set at 40 °C and 240 °C and the
pre-heat, cleanout and prepurge time were set as 18 s, 50 s, and 10 s. The initial and final column
temperatures were set at 35°C and 200°C, and the temperature program heated the capillary
columns at a rate 3°C per second, with initial and final hold time for 3 s and 5 s, giving a total run
time of 60 s. The initial pressure, final pressure, and pressure programming rate were set at 15 psi,
33 psi, and 0.4 psi per second; with initial and final hold time for 30 s, and 10 s. The Liquid/SPME
mode was used for injection with an inject time of 1500 ms and the injector temperature was
maintained at 150°C. The detector temperature, fuel pressure, and data acquisition were set at
150°C, 35 psi, and 60s.
2.6.3 Reagents
Acetonitrile (99.8+%, 250 ml), propionic acid (99% 500 ml) and butyric acid (99%+, 100
ml) were obtained from Alfa Aesar, acetic acid (ACS grade, 500 ml) from Amresco, valeric acid
(99%, 100 ml) from ACROS ORGANICS MS, and diethyl ether (ACS Grade, 1L) were obtained
from BDH SOLVENTS - B&J.
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2.6.4 Sample Preparation
After thawing and homogenization of the fecal samples, 0.5 gram of each sample was
measured and put into a 2-ml plastic vial. Then 1 ml of DNAase-free water was added to each vial
containing the measured biological samples, followed by 2-minute inversion mix for reaching a
homogenous state. Next, the vials were centrifuged at 2500 x g at 10 °C for 5 minutes. Then the
top layer was transferred to a 1.5-dram (16 x 50 mm) VWR®, borosilicate glass vials with phenolic
screw cap from VWR International, using a 100-µl micropipette and stored in the -20 °C freezer
till the next step. 1 ml of diethyl ether was added to each vial, followed by 30-second vortex and
2-minute centrifuge at 2000 x g. The upper organic layer was then transferred to a new glass vial
with caution for avoiding any lower aqueous material. The procedure was repeated for another
four times for elevating the extraction efficiency. The vials containing organic extracts were placed
in a chemical hood overnight for allowing the ether to evaporate, followed by storage in the 4 °C
refrigerator.
2.6.5 Standard Solution Preparation
2 ml VWR® 9-425 screw thread glass vials with borosilicate glass and a maximum fill
volume of 1.8 ml and 9-425 polypropylene cap with ivory PTFE/red rubber septa from VWR
International, were used to contain standard solutions. The stock solution of 4000 mg/l of shortchain fatty acids acetic acid, propionic acid, and butyric acid were all prepared in acetonitrile.
Standards with lower concentrations 0.25, 0.5, 1, 5, 10, 25, 50, 100, 150, 200, 500, 1000, 1500,
2000, 2500, 3000, and 3500 ppm for experiments were obtained by series dilution starting from
the 4000 mg/l stock. All standard solutions were stored at -20 °C.
2.7 Obesity-related Physiological Variables
Measured obesity-related physiological variables contain 1) obesity indicators including
weight, fat mass, lean mass, fat%, 24-hour energy expenditure (24HourEE), body mass index
(BMI), and subcutaneous fat size (SubcutMeanSize); 2) insulin resistance indicators, fasting
glucose (GLU), fasting insulin (INS), and glucose disposal rate (GDR1/Weight and
GDR2/Weight); 3) lipid profile, including triglyceride (TRIG), low-density lipoprotein (LDL),
high-density lipoprotein (HDL), and cholesterol (CHOL); 4) hormones, including adiponectin
(ADP), high-molecular-weight adiponectin (ADPHMW), ghrelin (GHR), active ghrelin (GHRA),
glucagon-like peptide 1 (GLP-1), peptide tyrosine tyrosine (PYY), and leptin (LEP); and 5)
inflammation indicator, high-sensitivity C-reactive protein (hsCRP).
Height was measured with a wall-mounted stadiometer and metabolic weight with a digital
scale. Body mass index was equated to weight in kilograms divided by height in meters. Excess
weight losses (% EWL) were estimated as follows:
WBL  WWk7
EWL Wk7 
 100%
WBL  IBWBL
EWL Wk52 

WBL  WWk52
 100%
WBL  IBWBL
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where EWLWk7 and EWLWk52 are the excess weight losses at week 7 and week 52, respectively,
and IBWbaseline is the ideal body weight at the baseline. Whole-body percent body fat was measured
by Dual Energy X-ray absorptiometry (DXA) (Hologics QDR 4500A; Hologics, Bedford, MA).
The mass of fat tissue and lean tissue (kg) were obtained by QuickScan. Twenty-four-hour energy
expenditure (24HourEE) (kcal/d) was measured with a metabolic chamber. Plasma glucose (mg/dl)
was analyzed with a Yellow Springs Instruments 2300 STAT Glucose Analyzer (Yellow Springs
Instruments Inc., Yellow Springs, OH). Plasma insulin (U/dl) was measured by
chemiluminescent immunoassays on an Immulite 2000 Analyzer (Diagnostic Products). Total
fasting cholesterol (CHOL) (mg/dl) and fasting high-density lipoprotein (HDL) (mg/dl)
concentrations were measured with a Beckman Coulter Synchron DXC 600 Pro. Fasting lowdensity lipoprotein (LDL) (mg/dl) was determined with a Friedewald calculation. Fasting
triglyceride concentrations (TRIG) (mg/dl) were measured by computed tomography and magnetic
resonance spectroscopy. Fasting high-sensitivity C-reactive protein (hsCRP) (mg/dl) was
determined by a chemiluminescent immunoassay (Immulite 2000 TM, Siemens Healthcare
Diagnostics, Deerfield, IL, USA). In vivo insulin sensitivity was measured with a two-step
hyperinsulinemic-euglycemic clamp (low insulin, 20 mU/m2/min for 180 min; high insulin, 80
mU/m2/min for 120 min), and the glucose disposal rate (GDR) (mg/kg/min) was calculated. The
units for adiponectin (ADP) and high molecular weight ADP (ADPHMW) are mg/dl, and the units
for Ghrelin (GHR), active Ghrelin (GHRA), glucagon-like peptide-1 (GLP-1), and peptide
tyrosine tyrosine (PYY) are mg/l. The unit for subcutaneous adipocyte size is l and the unit for
leptin is ng/ml. IDXA weight, IDXA fat mass, and IDXA lean mass were measured directly or
calculated indirectly from dual-energy X-ray absorptiometry methods. Values and descriptions of
physiological variables and patient information were provided in the supplemental data.
2.8 Statistical Methods
Multivariate analyses, including Detrended correspondence analysis (DCA) and canonical
correlation analysis (CCA), were used to determine the differences in overall microbial community
structure among different groups. Mantel test was based on Euclidean dissimilarity and was also
performed by R version 3.3.2 for examining the correlation between microbial community and
environmental factors. BioEnv was used to identify the most significant environmental factors
important to microbial community structure. Alpha diversity as measured by Shannon index and
inversed Simpson index was calculated by the Mothur package. Beta diversity was
calculated based on Jaccard's incidence-based dissimilarity matrices and Bray-Curtis's abundancebased dissimilarity matrices and were compared with three complementary dissimilarity
tests, including permutational multivariate analysis of variance (Adonis), multiresponse
permutation procedure (MRPP) and analysis of similarity (ANOSIM), and performed by the
Vegan package in R 3.3.2 (http://www.r-project.org/). Shapiro-Wilk test performed in R was used
for the normality test of the data distribution. Non-parametric Wilcoxon rank sum test and
parametric unpaired student's t-test were used for analysis of variance between unpaired
groups, and non-parametric Wilcoxon signed rank test and parametric paired student's t-test were
carried out in R version 3.3.2 for analysis of variance between paired groups. Non-parametric
Spearman rank correlation test, spearman rank partial correlation test, parametric Pearson
correlation test and Pearson partial correlation test were carried out in R version 3.3.2 to determine
the correlation between variables. Statistical significance was set as α = 0.1.
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CHAPTER THREE: STATISTICAL METHODS IN ECOLOGY STUDIES
3.1 Analysis of Variance
3.1.1 Abstract
When investigating whether there is a difference between two groups of data, it is important
to employ statistical tests to check whether the result is statistically meaningful. Various statistical
methods, for example, analysis of variance (ANOVA), have been used in microbiological research
to determine whether the mean of one group is significantly different from another one. However,
data do not always satisfy the assumptions that underlie these tests. In other words, these tests may
not always be appropriate for the targeted datasets. Specific tests need to be chosen with sufficient
caution, and the results of the analysis need to be explained reasonably for validating the
explanation of the data pattern. However, it has been observed that many published studies used
inappropriate ANOVA tests for their data sets and explained their test result with limited
description. In this writing, we compared the premises for different types of paired or unpaired and
parametric or non-parametric tests for determining whether two populations were significantly
different and compared their analysis results. The result showed that there are some differences
which were detected by all tests, but each test detected the differences that other test did not, based
on its specialized underlying theory. We concluded that employing different statistical methods
can disclose more facts of the actual data and discover more meaningful differences from distinct
angles of viewpoints. We suggest that researchers should take caution in choosing which specific
ANOVA test they are going to use and give a more detailed explanation of the corresponding
results related to the specific test.
3.1.2 Introduction
The variance of X, V ( X ) , is technically defined to be the expected value of the difference

V ( X )  E (( X  E ( X ))2 ) , where X is a group of observations and E is the expectation value. The
expectation value is supposed to be obtained by the following steps: 1) repeat the experiment
infinite number of times, 2) calculate the expression every time, and then 3) take the average of

S2 

( X  X )

2

N 1
that. The expression
calculates an estimate of the variance of X. It represents the
average of the squared deviations of a group of observations from their respective mean. The
division by N – 1 rather than N corrects for the bias created by using the average of X rather than
E(X) in the expression. It measures how much a set of data deviate from their mean. Analysis of
variance (ANOVA) is a group of statistical methods used to analyze the differences between group
means and their associated procedures.
3.1.2.1 Parametric versus Non-parametric ANOVA Tests
1) Parametric statistical tests assume that the measured parameters of the population are
normally distributed, while non-parametric tests do not. However, parametric tests can perform
well with continuous data that are not normally distributed if the sample size satisfies the
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guidelines (Frost, 2015). For example, a one-sample t-test needs a sample size greater than 20, and
a two-sample t-test needs each group to have a sample size greater than 15.
2) Parametric statistical tests assume that the variance of the measurement is homogeneous,
while non-parametric tests do not.
3) Parametric tests are typically used to test continuous (ratio or interval) data. However,
non-parametric statistical tests are designed for analysis of ordinal, ranked, or nominal data. The
existence of outliers can greatly affect the results of parametric tests, but not in the case of nonparametric tests.
4) The best measure of the central tendency of data is not always the mathematical mean.
The center of a skewed distribution can be better represented by the median. Half of the data are
below the median, and half of the data are above the median. If several extremely large or small
data points are added to a sample, the mathematical mean would be impacted strongly, even though
most of the typical data do not change, whereas such additions have relatively little effect on the
median, which is a metric of the center of the distribution. Thus, in this case, even if parametric
tests result in a significant difference between the two groups and non-parametric test do not, the
non-parametric test would be more suitable to choose to analyze and explain the difference
between these two groups.
Decisions on choosing parametric or non-parametric tests are often made based on whether
the mean or median more accurately represents the center of the data distribution. 1) If the mean
can more accurately represent the center of the distribution and the sample size is large enough,
then a parametric test should be valid and preferred because parametric tests are more powerful.
2) If the median can represent the center of the distribution, no matter whether the sample size is
large or small, the non-parametric test should be considered. 3) If the sample size is very small,
then a non-parametric test should be considered. Considering that when sample size is small, the
distribution of the data is difficult to ascertain because the distribution test does not have sufficient
power to give meaningful results (Frost, 2015), and non-parametric test tend to make a test weak,
the chance of detecting a significant difference when these two conditions coexist would be very
low. This explains why collecting as many data as possible is important and can make a big
difference to the result of the analysis, considering that 15 or 20 samples are the threshold for
validating the parametric tests, and only a few more samples need to be collected to satisfy this
requirement if the sample number is below 15 or 20.

Table 3.1 Comparisons between parametric and non-parametric ANOVA tests.

Assumed data distribution
Assumed variance
Data type
Dataset relationships
Measure of central tendency
Advantages

Parametric
Normal
Homogeneous
Continuous
Independent
Mean
More conclusions; more
statistical powerful
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Non-parametric
Any
Any
Ordinal or ranked or nominal
Any
Median
Simple conclusions; less statistical
powerful; Less impacted by outliers

The foregoing points are general differences between parametric and non-parametric
analysis of variance statistical tests. However, different analysis of variance statistical tests have
specific assumptions, and they need to be checked before using the corresponding test.
3.1.2.2 Wilcoxon Signed Rank Test
It is a paired non-parametric test. It is usually used for comparing observations that can be
grouped in pairs.
Assumptions: 1) Data are paired and come from the same continuous population. 2) Each
pair is independent. 3) The values of xi and yi are logically paired, so the comparisons (greater
than, less than or equal to) are meaningful.
Hypotheses: Designate x and y to be the paired observations and (xi, yi) to be a random
pair. Null hypothesis (H0) states that difference between the pairs follows a symmetric distribution
around 0. This distribution has an expected mean value of 0 and a variance of n(n  1)(2n  1) .
6

The alternative hypothesis (H1) states that the difference between the pairs does not follow a
symmetric distribution around 0.
Method: The method involves calculating the difference between the paired datasets (xi, yi)
and ordering them based on their absolute value from the smallest to the largest value. Pairs with
no difference are removed. Then rank the pairs, with the starting number being 1. For ties, when
the absolute values of the differences are equal, the ranks equal the average of the ranks (e.g., if
they rank as 5th and 6th, then they will get the rank of (5+6)/2 = 5.5 for each). Then calculate the
test statistic W, which is the sum of the sign of the difference multiplied by the rank. The calculated
W will be compared with the critical values in a reference table. If |W| is greater than or equal to
the critical value, and then H0 would be rejected (the two-sided test) (Wilcoxon, 1946).
3.1.2.3 Wilcoxon Rank Sum Test
This is an unpaired non-parametric test and is also called a Mann-Whitney U test.
Assumptions: 1) All the observations from both groups are independent of each other. 2)
Data can be ordinal.
Hypotheses: The null hypothesis H0 states that the probability of an observation from the
population group x being greater than an observation from the second population group y equals
the probability of an observation from the group y being greater than an observation from the x
group (Fay and Proschan, 2010).
In the two-sided test, the alternative hypothesis (H1) states that the probability of an
observation from the population group x being greater than an observation from the second
population group y is different from the probability of an observation from the group y being
greater than an observation from the group x. In the left-tail or right-tail one-sided test, the H1
states that the probability of an observation from the population group x being greater than an
observation from the second population group y is greater (or less) than the probability of an
observation from the group y being greater than an observation from the group x (Mann and
Whitney, 1947).
Method 1: For each measurement in one group, count the number of times the first value
is greater than any measurements in the other group and count 0.5 for any ties. Then the sum of
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the counts is the statistic U for the first dataset. Its converse is the U for the second data set. If the
calculated U is greater than the value of U in the reference table, then the H0 is rejected.
Method 2: Rank all observations in the two groups with the starting number 1 for the
smallest value. Ties will be ranked with the average of the ranks they span. Then calculate the sum
of the ranks for the observations in group 1 and designate it as R1. Then U1 = R1 – n1(n1 + 1)/2 (Zar,
1998). If U1 is greater than the U-value in the reference table, then the H0 is rejected.
3.1.2.4 Sign Test
This test is a type of paired non-parametric test. It is usually used for testing for consistent
differences between pairs of observations, for example, the abundance of a genus before and after
bariatric surgeries. The consistent difference means one group is consistently greater or smaller
than the other group.
Hypotheses: Designate x and y to be the paired observations and (xi, yi) to be a random
pair. Null hypothesis (H0) states that the probability for xi being greater than yi equals 0.5 (p =
Pr(X > Y) = 0.5). 1) For the left tail one-sided test, the alternative hypothesis (H1) states that the x
measurements tend to be higher than y measurements (p < 0.5). 2) For the right-tailed one-sided
test, H1 states that the x measurements tend to be lower than y measurements (p > 0.5). 3) For a
two-sided test, the H1 states that there is a difference between x measurements and y measurements.
It means x measurements may be either greater than or less than y measurements. The p-value is
twice as the smaller tail value.
Assumptions: 1) the differences wi (wi = yi – xi) are supposed to be independent. 2) Each
wi is from the same continuous population. 3) The values of xi and yi are paired logically, so the
comparisons (greater than, less than or equal to) are meaningful.
Method: The differences of the paired datasets (xi, yi) are calculated and labeled as positive
‘+’ or negative ‘–’ sign. Pairs with no difference are removed. Assuming H0 is true, then w follows
a binomial distribution. Suppose there are 10 (n) pairs of x and y. The probability of the conditions
n k

that there are k (0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10) numbers of x greater than y is Pr = ( k ) p (1  p) .
If the difference w is binomially distributed, p is 0.5. The probability of 9 or more cases of one
variable being greater than the other variable is Pr(0)+Pr(1)+Pr(9)+Pr(10) = 0.0215. In this case,
the result shows that the difference is significant (Whitley and Ball, 2002).
n

k

3.1.2.5 Independent (Unpaired) Two-sample T Test
Hypotheses: The null hypothesis (H0) states that the means of the two populations are equal.
The alternative (H1) states that the means of the two populations are unequal.
Assumptions: 1) Each of the two sets of data should follow a normal distribution. 2) If
using the original definition of the Student’s t-test, the two populations being compared should
have the same variance, no matter the two sample sizes are equal or not. If the variances are
unequal, the original Student’s t-test is robust enough in case the sample sizes are equal. If the
variances are unequal, no matter the sample sizes are unequal or not, Welch’s t-test is a better
alternative. 3) The data from the two populations should be sampled independently.
Methods: For equal and unequal variance conditions, no matter whether the sample sizes
are equal or unequal, the value of the test statistic t will be calculated by the below two different
formulas. Then the calculated t value will be compared with the critical value for Student’s tdistribution, which can be calculated by the software, such as MATLAB, automatically or be found
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in a traditional reference table. If the calculated t value is not as large as the critical t value, then
H0 is not rejected. Otherwise, H0 is rejected (Student, 1908).
a) Equal variance
t

X1  X 2
where S X1 X 2 
1 1
S X1 X 2 

n1 n2

(n1  1) S X 12  (n2  1) S X 2 2
n1  n2  2

n1 - 1 and n2 - 1 are the numbers of the degrees of freedom for these two groups and n1 + n2 – 2 is
the total number of degrees of freedom.
b) Unequal variance
t

X1  X2
SX 1 X 2

df 

where S X

1 X 2



s X 12 s X 2 2

n1
n2

( s12 / n1  s2 2 / n2 )2
( s12 / n1 ) 2 / ( n1  1)  ( s2 2 / n2 ) 2 / ( n2  1)

3.1.2.6 Dependent (Paired) T-test for Paired Samples
Hypotheses: H0: the mean of the differences between the paired populations is equal to a

specific value 0 . H1: the mean of the differences between the paired populations is unequal to a
specific value 0 (Student, 1908).
Assumptions: 1) Each of the two data populations should follow a normal distribution. 2)
The data from the two populations should be sampled independently.
Method: The differences between pairs of the datasets are calculated. Then the test statistic
t will be calculated by the formula below. Then the calculated t value will be compared with the
critical value for Student’s t-distribution. If the calculated t value is not as large as the critical t
value, then H0 is not rejected. Otherwise, H0 is rejected.

t

X D  0
where X D is the average of the differences,
SD
n

0 is a constant that the user wants to

check whether the average of the differences is significantly different from, and
deviation of those differences.

S D is the standard

3.1.2.7 Randomization Test on Two Dependent Samples (Paired)
Hypotheses: H0: there is no difference between treatments for any subject. H1: there is a
difference between treatments for at least one subject.
Assumptions: This test makes no assumptions because we have not randomly sampled
from any population. With respect to this point, this test is very different from standard parametric
tests (e.g. Student’s t test), for which it is assumed that the data are randomly sampled from
populations. With no random sampling, there is no basis for making inferences about the
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corresponding parameters, so the test only answers the question whether there is an effect of the
treatment, instead of whether the means of the two populations are different.
Method: Pick a test statistic (e.g., the difference of sample averages) and calculate the
observed value. Then create all possible rearrangements of the data between the two groups,
keeping the pairs of observations together. Then calculate the test statistic for each rearrangement
and construct the distribution using all these test statistics. Then compare the observed test statistic
to the distribution just created by assuming H0 is true (The assignments are randomly distributed,
in which case the probability distribution function is the histogram of all the values from all
possible ways that the observations could have been randomly assigned to groups, keeping pairs
of observations together.). The p-value will be the proportion of test statistics in the randomization
distribution that are as much or more extreme than the observed test statistic. If the p-value is
smaller than the threshold α value (e.g. 0.05), then the H0 is rejected (Dwass, 1957, Verbyla and
Litvaitis, 1989, Nichols and Holmes, 2002).
3.1.2.8 Randomization Test on Two Independent Samples (Unpaired)
Hypotheses: H0: there is no difference between treatments for any subject. H1: there is a
difference between treatments for at least one subject. H1 can be true in several different ways. A)
One treatment results in a fixed additive change in response for all subjects; B) one treatment
results in a greater mean of the responses across subjects; C) one treatment results in a greater
variance in response across subjects and D) one treatment results in more skewness in response
across subjects.
Assumptions: There are no assumptions because we have not randomly sampled from any
population. With respect to this point, the assumption is very different from standard parametric
tests (e.g. Student’s t test), for which it is assumed that the data are randomly sampled from
populations. With no random sampling, there is no basis for making inferences about the
corresponding parameters, so the test only answers the question whether there is an effect of the
treatment, instead of whether the means of the two populations are different.
Method: Pick a test statistic (e.g., the difference in sample averages) and calculate the
observed value. Then compare the observed test statistic to the randomization distribution of the
test statistic obtained by assuming H0 is true (The probability distribution function is the histogram
of all the values from all possible ways that the observations could have been randomly assigned
to groups.). The p-value will be the proportion of test statistics in the randomization distribution
that are as extreme as or more extreme than the observed test statistic. If the p-value is smaller than
the threshold α value (e.g. 0.05), then the H0 is rejected (Dwass, 1957, Verbyla and Litvaitis, 1989,
Nichols and Holmes, 2002).
3.1.3 Materials and Methods
The abundance of genera (a taxonomic level in microbiology) detected by Illumina
sequencing (Illumina Miseq platform) from the genomic DNA samples extracted from fecal
samples obtained at baseline before bariatric surgeries and fecal samples obtained at week 52 post
bariatric surgeries were used. There were 11 bariatric surgery participants included, and 11 pairs
of relative abundance data for each genus. In total, 247 genera were detected.
Non-parametric tests including Wilcoxon signed rank test, Wilcoxon rank sum test and
sign test, as well as parametric tests including paired t-test, unpaired t-test, randomization test, and
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unpaired randomization test in MATLAB (R2013b), were employed for checking whether each
genus was significantly different between baseline and week 52 samples.
3.1.4 Results and Discussions
Below tables showed the genera whose abundances were identified as different between
baseline and week 52 by Wilcoxon signed rank test, Wilcoxon rank sum test, sign test, paired ttest, unpaired t-test, paired randomization test, and unpaired randomization test.
A paired t-test requires that the difference between the two samples to be compared must
be normally distributed. The unpaired t-test requires that both variables be normally distributed.
The data were therefore first checked for normality by using Kolmogorov-Smirnov, Lilliefors or
Jarque-Bera test. For the t-tests, several genera that showed the significant difference after the
power 1/5 transformation were still not normally distributed based on a Kolmogorov-Smirnov test
after data transformation. However, the transformed data were judged to be normal based on either
a Lilliefors test or a Jarque-Bera test. In these cases, the conservative approach was to look for
differences using non-parametric tests, which showed that the differences were significant.
Randomized test circumvents the normality issue and allows one to do parametric tests in
cases where it would not be allowed otherwise. The randomization tests were done in two ways.
For the paired randomization test, the baseline and week 52 results were scrambled randomly but
for each patient separately. The program just calculated the number of times in the original data
that baseline exceeded week 52 and that week 52 exceeded baseline. Baseline got +1 if it exceeded
week 52, and week 52 got +1 if it exceeded baseline. If there were ties, both baseline and week 52
got 0.5. Whichever got the highest score, baseline or week 52, that score became the criterion.
Then the baseline and week 52 numbers for each patient were randomly scrambled, and the statistic
was calculated. If the statistic equaled or exceeded the criterion 10% of the time or less, the original
result was considered significant.
For the unpaired randomization test, the baseline and week 52 data for all the patients
combined were scrambled. The criterion was the greater of the number of counts in the baseline
or week 52 data. Take Arsenicicoccus as an example. It showed up a total of 7 times in the baseline
patients and zero times in the week 52 patients. So, the criterion would be 7. Then the assignments
of baseline and week 52 were randomly scrambled for each of the patients. Each time the larger of
the total counts in the baseline and week 52 patients was determined, and that number was
compared to 7. If the number equaled or exceeded 7 10% of the time or less, the result with the
original data was significant. In this case, there is no way the number could have exceeded 7, but
it could have equaled 7 some of the time.

Table 3.2 Wilcoxon signed rank test detected 16 genera, the abundance of which was shown to be
significantly different between baseline and week 52 samples (p < 0.1). The genera were ordered
from the smallest to the largest p-value.
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Genus
Ruminococcus
Sporobacter
Anaerosporobacter
Arsenicicoccus
Desulfovibrio
Parasutterella
Lactonifactor
Anaerofustis
Bifidobacterium
Anaerotruncus
Oscillibacter
Subdoligranulum
Eubacterium
Clostridium IV
Parabacteroides
Bilophila

Wilcoxon signed rank (p)
0.051
0.051
0.0513
0.0654
0.066
0.073
0.073
0.074
0.0742
0.082
0.083
0.083
0.0858
0.0862
0.098
0.0985

Table 3.3 Wilcoxon rank sum test detected 18 genera, the abundance of which was found to be
significantly different between baseline and week 52 samples (p < 0.1). The genera were ordered
from the smallest p-value to the largest one.
Genus
Pseudomonas
Clostridium XII
Anaerofustis
Desulfovibrio
Arsenicicoccus
Acinetobacter
Rudaea
Alloscardovia
Anaerosporobacter
Robinsoniella
Lactonifactor
Sporobacter
Ruminococcus
Akkermansia
Acetanaerobacterium
Anaerotruncus
Eubacterium
Bilophila

Wilcoxon rank sum (p)
0.001
0.001
0.002
0.0029
0.003
0.0117
0.0293
0.034
0.0388
0.0483
0.057
0.0654
0.0658
0.0674
0.0674
0.073
0.073
0.098

36

Table 3.4 Sign test detected 11 genera, the abundance of which was shown to be significantly
different between baseline and week 52 samples (p < 0.1). The genera were ordered from the
smallest p-value to the largest one.

Genus
Bilophila
Desulfovibrio
Anaerosporobacter
Subdoligranulum
Lactonifactor
Sporobacter
Akkermansia
Eubacterium
Ruminococcus
Anaerotruncus
Arsenicicoccus

Sign (p)
0.0039
0.0039
0.005
0.026
0.0295
0.0382
0.0702
0.076
0.085
0.085
0.099

Table 3.5 The paired t test detected 15 genera, the abundance of which was shown to be
significantly different between baseline and week 52 samples (p < 0.1). The data were raised to
the power 1/5 to produce numbers that passed the normality test. The genera were ordered from
the smallest p-value to the largest one.
Genus
Paired t (p)
Hydrogenoanaerobacterium
0.0152
Rudaea
0.016
Anaerofustis
0.033
Bifidobacterium
0.046
Eubacterium
0.047
Arsenicicoccus
0.0625
Alloscardovia
0.0625
Anaerosporobacter
0.0781
Oscillibacter
0.0784
Lactonifactor
0.084
Sporobacter
0.091
Subdoligranulum
0.098
Clostridium IV
0.0989
Desulfovibrio
0.0999
Anaerovorax
0.1

Table 3.6 The unpaired t test detected 16 genera, the abundance of which was shown to be
significantly different between baseline and week 52 samples. The data were raised to the power
1/5 to produce numbers that passed the normality test. The genera were ordered from the smallest
p-value to the largest one.
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Genus
Unpaired t (p)
Anaerovorax
0.0107
Anaerosporobacter
0.0117
Clostridium IV
0.0195
Desulfovibrio
0.021
Alloscardovia
0.0323
Eubacterium
0.0348
Arsenicicoccus
0.037
Rudaea
0.037
Acinetobacter
0.0414
Oscillibacter
0.0438
Anaerofustis
0.046
Lactonifactor
0.047
Subdoligranulum
0.048
Caulobacter
0.0592
Sporobacter
0.0654
Bifidobacterium
0.1

Table 3.7 Paired randomization test detected 17 genera, the abundance of which was shown to be
significantly altered in week 52 samples when compared to the baseline samples (p < 0.1). The
genera were ordered from the smallest p-value to the largest one.
Genus
Parabacteroides
Anaerostipes
Anaerotruncus
Parasutterella
Oscillibacter
Subdoligranulum
Bifidobacterium
Clostridium IV
Clostridium sensu stricto
Desulfovibrio
Lactonifactor
Sporobacter
Anaerosporobacter
Methanobrevibacter
Eubacterium
Arsenicicoccus
Bilophila

Paired randomization (p)
0.017
0.0251
0.0268
0.031
0.0348
0.0379
0.041
0.041
0.062
0.0671
0.0774
0.0816
0.0816
0.084
0.084
0.084
0.09

Table 3.8 Unpaired randomization test detected 16 genera, the abundance of which was
significantly different between baseline and week 52 samples (p < 0.1). The genera were ordered
from the smallest p-value to the largest one.
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Genus
Caulobacter
Bifidobacterium
Clostridium sensu stricto
Clostridium IV
Lactonifactor
Acinetobacter
Anaerosporobacter
Arsenicicoccus
Rhizobium
Paracoccus
Alloscardovia
Oscillibacter
Eubacterium
Desulfovibrio
Sporobacter
Subdoligranulum
Anaerofustis
Azoarcus

Unpaired randomization (p)
0.028
0.0313
0.0313
0.0317
0.033
0.0377
0.039
0.042
0.0552
0.067
0.0736
0.079
0.079
0.08
0.083
0.0885
0.0938
0.0964

All these analyses were looking at the data in different ways. The genera that were found
to be significantly different based on one metric might not be screened out based on another. Only
5 genera (Sporobacter, Eubacterium, Lactonifactor, Desulfovibrio, and Anaerosporobacter) were
judged to be significantly different based all these tests, while each specific test detected several
cases that the other tests missed.
We found that the paired tests tended to identify fewer significant differences than the
unpaired tests in this study. Also, the genera identified in the paired tests were not always just a
subset of the genera identified in the unpaired tests. The Wilcoxon signed rank test, for example,
identified several genera that were not flagged by the Wilcoxon rank sum test, Parasutterella,
Bifidobacterium, Oscillibacter, Subdoligranulum, Clostridium IV and Parabacteroides. However,
the Wilcoxon rank sum test identified the abundance of Clostridium XII, Pseudomonas,
Acinetobacter, Rudaea, Alloscardovia, Robinsoniella, Acetanaerobacterium and Akkermansia as
being different between baseline and week 52. The reason was that a few large differences counted
heavily in an unpaired test, but their magnitude was ignored, for example, in a simple sign test;
however, if one dataset was consistently higher or lower than another but by a small amount each
time, that counted heavily in the case of a paired test but tended to get lost in the noise of an
unpaired test. In this study, the chance of the existence of a few large differences might be a little
higher than the chance of the existence of consistently higher or lower differences, the result being
that the unpaired tests detected more differences. The trend that unpaired tests detected more
differences was not fixed, and it could become opposite in other studies.
To determine whether a paired or unpaired test was reasonable, other possible factors
that could impact the results should be considered. For instance, if 11 individuals were employed
as replicates in the study because the variance among them had negligible effects on the research
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target (gut microbiota in our case), then both unpaired and paired tests would be reasonable to use.
Otherwise, paired tests would be more reasonable than unpaired tests.

Table 3.9 The number of genera the abundance of which was found to be significantly different
between baseline and week 52 samples by different types of analysis of variance tests.

Paired
Unpaired

Non-parametric
Wilcoxon signed rank Sign
16
11
Wilcoxon rank sum
18

Paired t
15
Unpaired t
16

Parametric
Paired randomization
17
Unpaired
randomization
18

If we just counted the number of genera found to be significantly different, I would get
the same results (18) with the unpaired Wilcoxon rank sum and unpaired randomization tests.
However, the genera found to be different were not entirely the same. If we look at the actual data,
we can see why some genera were found to be different by some tests and not by others.
For example, there were more Akkermansia at week 52 than at baseline for 9 of the 11
patients. The probability of 9 or more patients having more Akkermansia at week 52 than at
baseline was only 0.0325. If there was no difference between baseline and week 52, that result was
significant at p = 0.065 by a two-sided test. Thus, the non-parametric test, e.g. Wilcoxon rank sum
and sign tests, detected the difference. However, the two unusual cases had a lot more Akkermansia
at baseline than week 52, so if the test was based on the actual data, the difference was not
significant, as concluded by the parametric Student’s t and randomization tests.
The results of different types of non-parametric tests could also be different, and some
genera that were found to be significantly different by one test but not by another test. For example,
the genus Akkermansia was more abundant at week 52 in 9 of the 11 patients. That was significant
at p = 0.0654 by a simple two-sided sign test. The reason the Wilcoxon signed test did not pick it
up was that the two exceptions were very different—they were the second and third largest
differences in magnitude. Thus, although the Wilcoxon signed rank test was nominally a nonparametric test, it was looking at ranks, whereas the sign test just looked at pluses and minuses and
paid no attention to the magnitude of the numbers.
Another example is the genus bifidobacterium, which was identified as having changed
only by the Wilcoxon signed rank test, but not the Wilcoxon rank sum and sign tests. It actually
decreased in 7 of the 11 patients between baseline and week 52. In 3 other cases, there was either
no change or a change of only 1. There was only one case of it increasing by more than 1 (1225).
The sign test did not detect a difference because the sign test ignored the magnitude of the decrease
in those 7 patients. The Wilcoxon rank sum test did not detect a difference because it tests counted
the number of times the first value in one group was greater than any measurements in the other
group and counted 0.5 for any ties. Considering that before treatment the levels of this genus were
variable and this test neglected the initial variance among these 11 patients and that the data in
these two groups were not completely independent, this test is not the most reasonable and
powerful test in this scenario.
The results of different types of parametric tests could also be different, and some genera
that were found to be significantly different by one test might not be detected by another test. The
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traditional parametric test such as Student’s t-test could be greatly influenced by outliers when
compared to the randomization tests, although both tests are based on actual data. For example,
the genus Parabacteroides was only detected by paired randomization test among all abovementioned parametric tests. Actually, its abundance in 8 patients increased, but its levels in three
other patients were reduced by some small amounts. A small outlier could have a great influence
on the significance of the traditional parametric tests.
For the ANOVA analyses in microbial studies, the researchers should first take enough
carefulness in choosing which ANOVA test is more reasonable or appropriate to use. Then, when
explaining their test results, more details of the statistical test results relating to the corresponding
tests should be researched, described, and explained by. In this way, more detailed, reasonable and
trustable information or discoveries could be disclosed, and the understandings of their conclusions
made based on these tests could be more accurate and thorough.
3.2 Analysis of Covariance
3.2.1 Abstract
Because data on human subjects in the field of medical research are limited by ethical
and practical considerations, data from every human subject are valuable, and the inclusion of any
valid human subject in a medical study enhances the probability of making important discoveries.
Hence there is an incentive to make the best use of available information by combining data from
different groups of human subjects if possible. Analysis of covariance (ANCOVA) has been
widely used as a statistical tool to determine whether data from two or more groups of subjects
can be combined. However, typical ANCOVA software programs test only the null hypothesis
that the regression slopes of different groups are homogeneous. However, if the slopes appear to
be homogeneous, it is appropriate to ask whether there is a difference among the groups in the
elevations of the relationships. Typical ANCOVA software programs do not address this question.
Failure to do so could result in an inappropriate combining of datasets. Here we report the use of
an improved ANCOVA program that tests for the homogeneity of regression elevations if the
slopes of regression lines are judged to be homogeneous. Use of this program allows decisions
about combining datasets to be made in a more informed way and in particular, lowers the
probability that different datasets may be inappropriately combined.
3.2.2 Introduction
Analysis of covariance (ANCOVA) is a general linear model that integrates analysis of
variance and regression. It has been used to assess whether mean of a population of a dependent
variable is equal across all levels of a categorical independent variable (e.g., a treatment) while
statistically controlling for the effects of other continuous variables (covariates) that are not of
primary interest. It can be employed to increase statistical power and to adjust for preexisting
differences between unequal groups. But its application in the latter case requires that the
regression slopes be homogeneous. This application aims at correcting for initial differences (prior
to group assignments) that exist among several groups of the dependent variable. Categorical
variables are used to adjust scores to make them more similar than was the case without taking
account of the categorical variable.
Some research groups have used only before-treatment baseline data to perform
correlation tests to check whether there are significant correlations between the relative abundance
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of specific microbial component such as the genus Akkermansia and physiological variables such
as the fasting glucose level (Ding et al., 2010, Collado et al., 2010, Marlene et al., 2013, Everard
et al., 2013, Everard et al., 2014, Damms-Machado and Mitra, 2015, Zhang et al., 2015,
Schneeberger et al., 2015, Dao et al., 2016, Louis et al., 2016). This method is rather conservative
and does not make good use of all the available information, such as post-treatment datasets. Some
other groups have done the correlations by combining all of the before-and-after treatment data
points without even bothering to test if the before-and-after treatment datasets are statistically
different from one another (In other words, the linear relationships within the groups have slopes
and elevations that are not significantly different) by using the analysis of covariance test (Marlene
et al., 2013). The same concern applies to regression tests.
Most software, for example, SAS, performs analysis of covariance by only checking to
determine if there is a significant difference between or among the slopes of different lines fit to
each data set. These tests do not determine if the intercepts or elevations are significantly different
or not. Thus, by using this software, when the ANCOVA test finds no significant difference for
the slopes among different groups, then the researchers may combine the two different datasets
because they suppose that the ANCOVA results showed that these different datasets are from the
same population and can be combined. However, that is not always the case. When the intercepts
or the elevations of the different linear relationships (lines) are different, even though they have
the same slope, the implication is that these different datasets are not from the same population, so
it is not reasonable to combine these different datasets and carry out statistical analyses such as
correlation and regression tests.
We created a MATLAB program for the ANCOVA test that includes the steps of testing
both the slopes and elevations of the linear relations belonging to different datasets. This program
added an additional step that was designed for checking the difference of the elevations of the lines,
on the basis of the original ANCOVA test, which only checks for significant differences in the
slopes of the lines for different datasets. In short, to check if the two different datasets are from the
same dataset, this new program checks 1) whether the slopes of the two datasets are parallel.
(Hypothesis 1: whether they are separate or parallel lines). 2) if the slopes are parallel, then whether
their elevations are the same (Hypothesis 2: whether there is only one line).
3.2.3 Materials and Methods
The abundances of genera (a taxonomic level in microbiology) detected by Illumina
sequencing (Illumina Miseq platform) from the genomic DNA samples extracted from fecal
samples obtained at baseline before bariatric surgeries (procedures used to alter the anatomy of the
human digestive system, to limit the food amount that can be taken in and digested for obesity
reduction) and fecal samples obtained at week 52 post bariatric surgeries were used. There were
11 bariatric surgery participants included, and 11 pairs of relative abundance data for each genus.
In total, 247 genera were detected. All statistical analyses and programming were carried out using
MATLAB R2016a software.
3.2.4 Results and Discussions
To illustrate how to perform the analysis step by step, we used the before-treatment
baseline and week 52 post bariatric surgery data for the relative abundance of the genus
Akkermansia and the corresponding host’s body weight as an example. For instance, the issue we
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are trying to investigate is whether there is a significant correlation between the relative abundance
of the genus Akkermansia in the gut and body weight. Instead of using only baseline data or
combining all the baseline and week 52 datasets, I used the following program to determine
whether the two datasets seemed to come from the same population. If the answer is yes, then I
can go ahead and combine all the baseline and week 52 data to determine the significance of the
correlation. This method can help make the best use of all the data I have (i.e., not waste any data).

Table 3.2.4.1 The relative abundance of the genus Akkermansia in the gut microbiota and the
weights of 11 participants before and after bariatric surgeries.

BRS participants
P1
P2
P3
P4
P5
P6
P7
P8
P9
P10
P11

Baseline
Akkermansia Weight (kg)
(X1)
(Y1)
0
124.2
1.07E-02
110.5
0
126.1
1.35E-02
126.6
0
123
0
151
1.09E-03
159.1
7.26E-05
152.9
0
140.4
4.33E-02
102.4
6.48E-02
140.7

Week 52
Akkermansia
Weight (kg)
(X2)
(Y2)
1.59E-02
99.8
4.85E-02
60.3
2.18E-04
88.2
5.30E-02
89.1
4.14E-03
80.3
3.03E-02
111
3.16E-02
90.1
2.83E-03
103.4
6.50E-02
94.8
7.26E-05
81.1
8.56E-03
82.2

The analysis can be divided into three steps. 1) The first step is to determine the equation
of a best-fit line using linear regression for each dataset (i.e., a separate regression line for each
dataset). Specifically, the slope and intercept for each dataset is calculated to determine the
equation (Y = A + BX) for each dataset. The equation for calculating the slope of the regression
line is

B

(x x)(y y)
(x x) 2

where x and y are the averages of the x and y values, respectively. Using the data in Table 3.2.4.1,
I found that B1 = (–1.0487)/0.0048 = –220.8, and B2 = (–0.2238)/0.0055 = –40.6, where the
subscripts 1 and 2 refer to the baseline data and week 52 data, respectively. The equation for
calculating the corresponding intercept is A = y - Bx . Using the data in Table 3.2.4.1, I found that
A1 = 135.1, and A2 = 90.1. Thus, the equations of these two lines are Y1 = 135.1 – 220.8X1, and Y2
= 90.1 – 40.6X2. 2) The second step is to determine whether the null hypothesis that the slopes of
the two straight lines for the two datasets (e.g., the baseline and week 52 groups) are the same
should be accepted or rejected based on an F-test. The alternative hypothesis states that the slopes
of the two straight lines for the two datasets are not the same. To carry out the analysis, two parallel
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lines are fit to the two datasets. Their common slope was calculated using the equation B = (–
1.0487 – 0.2238) / (0.0048 + 0.0055) = –123.5. Then the intercept for each straight line was
calculated using the equation A = y - Bx , so

A1  y1  (123.5)x1 = 132.4 + (123.5) × (0.0121) =

133.9, and A2  y2  (123.5)x 2 = 89.1 + (123.5) × (0.0236) = 92. Thus, the equations for these
two lines are Yp1 = 133.9 – 123.5X1 and Yp2 = 92 – 123.5X2. To test if the difference of the slopes
of the two lines is significant, an F test was used, and for this step I first calculated the normalized
difference of the sums of squares between the baseline and week 52 groups when the two lines
were parallel and the sums of squares between the two groups when the two lines were separate,
(SSp – SSsep) / (dfp – dfsep). This normalized difference is then compared with the normalized sum
of squares of the two groups when the two lines are separate (SSsep/dfs). The F-value is calculated
using the equation

F=

(SSp - SSsep ) / (dfp - dfsep )
SSsep / dfsep

= Fdf -df
p

(3.2.1)

sep ,dfsep

In equation 4.1,
SSp

(y1

yˆ p1 )2

(y1 yˆ s1 )2

SSsep

(y2

yˆ p2 )2 = 3034 + 1880 = 4914

(y2 yˆ s2 )2 = 2989 + 1842 = 4831

(3.2.2)
(3.2.3)

In equations 4.1, 4.2 and 4.3, y is the measured value of y given a value of x (y1 indicates
the baseline dataset and y2 the week 52 dataset), ŷ p is the calculated or predicted value of y given
a value of x using the equations obtained from forcing the two lines to be parallel in the second
step (yp1 indicates the baseline dataset and yp2 the week 52 data), and ŷ s represents the predicted
value of y calculated by using the equations obtained from the separate lines obtained in the 1st
step ( ŷ s1 indicates the baseline dataset and ŷ s2 the week 52 dataset). SS stands for the sum of the
squares of the deviations: SSsep stands for the SS value when the two lines are separate, and SSp is
the SS value when the two lines are parallel. The degrees of freedom are equal to the number of
data points minus the number of coefficients in the linear model. For example, there is a total of
22 data points, and 2 intercepts and 2 slopes for the separate lines, so dfsep = 22 – 2 – 2 = 18. There
are 2 intercepts and 1 slope for the parallel lines, so dfp = 22 – 2 – 1 = 19. Therefore,

F

SS

p

 SSsep   df p  dfsep 
SSsep dfsep



(4914  4831) / (19  18)
 0.309
4831 / 18

This F-value is to be compared with the threshold value of F(1,18) = 4.41 for α = 0.05. If
the F-value is greater than the threshold F-values for the relevant degrees of freedoms in the
reference table, then the null hypothesis is rejected. In that case, the implication would be that the
slopes of the two regression lines were different, and it would be illogical to go forward to the next
step (i.e., it would be illogical to ask if the two lines were one line because they clearly would not).
If the F-value is less than the threshold F-value, then the null hypothesis is accepted. The
implication is that the slopes of the two regression lines are not significantly different. In this case,
the next step would be needed, so it is necessary to go ahead to test the second hypothesis. 3) The
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third step is to determine if the two parallel lines are the same line. In other words, the test is to
determine if the intercepts (or elevations) of the two parallel lines are the same. To test if the
difference between the elevations of the two lines is significant, an F test is used, and for this step
one calculates the normalized difference of the sums of squared deviations of the baseline and
week 52 groups when the two lines are one line, and the sums of squared deviations of the baseline
and week 52 when the two lines are parallel (SS1 – SSp) / (df1 – dfp). This difference is then
compared with the normalized sums of squares when the two lines are parallel (SSp/dfp). In the
equation, SS1 represents the SS value calculated when fitting one line to all the data. The value of
F is calculated with the equation

F=

(SS1 - SSp) (df 1 - dfp )
(SSp dfp )

SS1
(y1 yˆ 11 )2
(y2 yˆ 12 )2 . To get the equation to calculate the values of y11 and y12,
which are the predicted y values given the x values on the assumption that the two lines are one
line (y11 is for the baseline dataset, and y12 is for the week 52 dataset.), the slope and the intercept
of the regression line for the dataset obtained by combining the data in both the baseline and week
52 groups need to be calculated first. B = 365.6, A = y - Bx = 117.3, so the equation for the
combined dataset is Y = 117.3 – 365.6X; SS1
(y1 yˆ 11 )2
(y2 yˆ 12 )2 = 13,929. When
there is only one line, there are only two coefficients (one slope and one intercept), so the
corresponding degrees of freedom, represented as df1, is 22 – 1 – 1 = 20. F = ((13929 – 4914)/(20
–19))/(4914/19) = 34.9, which is greater than the threshold value for F(9-8,19) = F(1,19) = 4.38 for α
= 0.05. The implication is that the null hypothesis should be rejected because the intercepts of the
two parallel lines are different. It is, therefore, unreasonable to combine these two datasets for
further statistical analyses. If the F-value were smaller than the threshold value, then the null
hypothesis would be accepted because the intercepts of the two lines would not appear to be
different. Thus, it would be reasonable to combine the two datasets for further analyses. Further
analysis using each dataset separately would be unnecessary. For our datasets, the results of the
analysis of covariance showed that the baseline and week 52 data should not be combined for
further statistical analysis because it is very likely that the data came from different populations.
Below is a plot produced by an analysis of covariance program written in Matlab (Figure 3.2.4.1).
For the 1st null hypothesis, the F-value is 0.3096, and the p-value is 0.5848. For the 2nd null
hypothesis, the F-value is 34.854, and the p-value is 1.1  10–5. The relevant computer programs
are attached in the supplemental data.
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Figure 3.2.4.1 The parallel regression lines for the relative abundance of the genus Akkermansia
vs weight at baseline (black) and week 52 (red).

The equation
E(Σ(y – ŷ)2) = V(y|x)df + Σ(E(y – ŷ))2

(3.2.4)

follows from the definition of the variance of the variable y. In Eq. (4.4), df is the degrees of
freedom, ŷ is the value of y estimated using an analytical equation that contains parameters that
were chosen to give the best fit to the data, and V(y|x) is the variance of y given x. Because the
parameters in the model were deliberately chosen to minimize Σ(y – ŷ)2, the expectation value of
that sum is less than would be the case if the true parameter values (which are never known) were
used to calculate ŷ. The result is that V(y|x) in Eq. (4.4) must be multiplied by the df, which is
equal to N, the number of data, minus the number of parameters in the model.
Equation (4.4) follows from the formal definition of the variance of a variable y:

V(y)

E(y E(y))2

E(y2 ) (E(y))2

(3.2.5)

which can be rearranged to give

E(y2 ) V(y) + (E(y))2

(3.2.6)

When applying this expression to a dataset that contains finite data points (xk, yk), this equation
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NV y | x

E(( y k

yˆ k

E(( y k

yˆ k ) 2 ) (E( y k

E(( y k

E( y k



yˆ k )) 2 )
yˆ k )) 2

 x k ) 2 ) (E( y k 

 x k )) 2

(3.2.7)

biased estimate because A and B were chosen to minimize the sum of the squared differences ŷ k
– A – BxK. Alpha and beta are the expectation values of A and B if A and B are unbiased estimates
of  and . A and B must be used because we do not know the values of  and . The problem
with A and B is that they were calculated to minimize the sum of the squared deviations every
time we do the experiment, so we are getting a smaller expression for the sum of the squared
deviations than we would if we used the values of  and . The correction for this bias is to
multiply V(y|x) by df rather than N in Eq. 4.7, where df represents the degrees of freedom. In other
words, an unbiased estimate of V(y|x) is the right-hand side of Eq. 4.7 divided by df. After
modification, the above expression becomes the following one:
dfV y | x E(( y k yˆ k E( y k yˆ k )) 2 )

E(( y k
E(( y k

yˆ k ) 2 ) (E( y k

yˆ k )) 2

A Bx k ) 2 ) (E( y k

A Bx k ))2

(3.2.8)

Rearranging Eq. 4.8 gives

dfV(y | x)

E(( yk

A Bx k )2 ) (E( yk

A Bx k ))2

(3.2.9)

In ANCOVA, an important question is whether

E(yk yˆ k ) 0
For
E(

the
(y

(3.2.10)

condition
ˆ s )2 )
y

of

two

V(y | x)dfs

separate
(E(y

lines,

Eq.

4.10

can

be

expressed

yˆ s )) 2

For the condition of two parallel lines, the equation can be expressed as

E( (y yˆ p )2 )

V(y | x)dfp

(E(y yˆ p )) 2

For the condition of one single line, the equation can be expressed as
E(

(y

ˆ 1 )2 )
y

V(y | x)df1

(E(y

yˆ 1 )) 2

For testing if the two lines are parallel or not
E SSp

SSS

V y | x df p dfs

(E ( y

and
F=

(SSp - SSs ) / (df p - dfs )
SSs / dfs

If the lines are parallel, then
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ˆ p ))2
y

( E( y

ˆ s ))2 (3.2.11)
y

as

both

(E(y yˆ p ))2
and
(E(y

yˆ s ))2

are zero.
In that case, both the numerator and denominator of the quotient used to calculate F are unbiased
estimates of V(y|x), and the calculated F-value would be expected to be less than or equal to the
critical F-value 95% of the time and greater than the critical F-value 5% of the time.
If the lines are separate (i.e., not parallel), then

(E(y yˆ p ))2
would be greater than 0, but
(E(y

yˆ s ))2

2

2

(E(y yˆ s )) would be greater than 0. In that case, the
would still be 0, so (E(y yˆ p ))
numerator of the quotient used to calculate the F ratio would be an overestimate of V(y|x), and the
calculated F-value would be expected to be greater than the critical F-value more than 5% of the
time. That is the reason why the null hypothesis would be rejected when the calculated F-value is
greater than the critical F if the type I error rate is 5%.
For testing whether the two lines are one single line or not,
E(SS1 SSp ) V(y | x)(df1 df p )
(E( y yˆ 1 ))2
(E( y yˆ p )) 2
and

F

(SS1 SSp ) / (df1 df p )
SSp / df p

If the two parallel lines are in fact one single line, then both
(E(y

yˆ 1 ))2

and

(E(y yˆ p ))2
are 0. In that case, both the numerator and denominator of the quotient used to calculate F are
unbiased estimates of V(y|x), and the calculated F-value would be expected to be less than or equal
to the critical F-value 95% of the time and greater than the critical F-value 5% of the time.
If the lines are not the same line, then
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(E(y

yˆ 1 ))2

would be greater than 0, but

(E(y yˆ p ))2

2

2

(E(y yˆ 1 ))
(E(y yˆ p )) would be greater than zero, and the
would still be zero, so
numerator of the quotient used to calculate the F ratio would be an overestimate of V(y|x). The
calculated F-value would, therefore, be expected to be greater than the critical F-value more than
5% of the time. That is the reason why the null hypothesis would be rejected when the calculated
F-value is greater than the critical F if the type I error rate is 5%.
In this case, if we use the current ANCOVA program would lead to the conclusion that
it is valid to combine the data from the data from baseline and week 52 post treatment to do other
intended tests (e.g. correlation tests). However, based on the test results of our program, it is not
reasonable to combine these two data sets. Therefore, it is meaningful to employ this ANCOVA
program for examining homogeneity of the regression intercepts for the validity of data
combination and we suggest that it could be used in other related research for reducing the chances
of making error conclusions and/or increasing the chances of making more discoveries.
3.3 Principal Component Analysis
3.3.1 Abstract
It is important to investigate the differences between the ecological communities in
different experimental samples (e.g., samples before and after specific treatments) because those
differences provide information about the relationships between environment factors and
community ecology. This information can be used to guide manipulations of environmental factors
to maintain or control ecological communities in a desirable way. Principal component analysis
(PCA) analysis is one of the commonly used methods for analyzing and visualizing ecology
distance. However, no programs have been created to test whether the ecological distance between
samples or groups represented in a PCA plot is statistically significant or not. To address this issue,
a program to determine the statistical significance of the ecological distances between groups
represented in a PCA plot was developed. Another issue in applying PCA to the field of microbial
ecology is that PCA cannot include all variables (e.g., all species) in the analyses when the variable
size (the number of variables) is greater than the sample size (the number of samples) because in
that case for n data points there can only be (n-1) principal components (no remaining variation
can be assigned to the extra principal components). This issue can be addressed by employing
dissimilarity tests, which can be used to compare the ecological distances between different sample
groups, including all microbial components. Use of the program to examine whether two microbial
community structures were significantly different showed that both the program and the
dissimilarity test detected statistically significant differences between microbial community
structure of samples before and after treatment. We conclude that both the dissimilarity tests and
PCA analyses with a significance test for ecological distances are useful for determining the
significance of the ecological distance between two communities.
3.3.2 Introduction
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Principal component analysis (PCA) is one of the oldest ordination methods used as a
tool in exploratory data analysis and for making predictive models. It has been used, for example,
to calculate so-called ecological distances in the context of microbial composition and abundance.
Ecology can be defined as the study of all processes that influence the distributions, abundances,
and interactions of organisms with one another and with their environment (Begon, 2006).
Differences in microbial composition and abundance are reflected in the ecological distance
between samples. PCA analysis is one way to calculate ecological distances, and a scatter diagram
of the PCA scores on the first two principal components is one way to visualize ecological
distances. The scores are basically the representation of the centered, normalized matrix of
observations (rows) and variables (columns) in principal component space. The distance between
a pair of points on this graph is a measure of the ecological distance between the pair of
observations. If the variables are patients and the observations are the numbers of specific kinds
of flora in their guts, then patients that are close together on the graph are interpreted as having gut
flora that are similar in composition, whereas patients that are far apart on the graph are interpreted
as having gut flora that is different in composition. However, currently no published tests to
determine whether the ecological distances are significantly different from zero in a statistical
sense.
3.3.3 Materials and Methods
The abundance of genera detected by Illumina sequencing (Illumina Miseq platform) of
the genomic DNA samples extracted from human feces at baseline before bariatric surgery and at
week 52 post bariatric surgery was used. Eleven bariatric surgery patients participated in the study,
and 11 pairs of relative abundance data for each of 247 genera were analyzed.
PCA analyses and the tests for significance of the ecological distances were performed
using MATLAB (R2013b). Three complementary non-parametric dissimilarity tests, including
MRPP (multiresponse permutation procedure) (Sickle, 1997), ANOSIM (analysis of similarity)
(Clarke, 1993) and Adonis (permutational multivariate analysis of variance) (Anderson, 2001)
were performed using the Vegan package in R 3.1.2 (http://www.r-project.org/) based on the BrayCurtis or Jaccard similarity distance matrices.
3.3.4 Results and Discussions
A PCA analysis can be carried out only when the number of columns (e.g., genera) is
less than or equal to the number of rows (e.g., patients). Otherwise, the matrix that must be inverted
to carry out the PCA is singular (i.e., has a determinant of zero) and cannot be inverted. Therefore,
microbial study researchers usually include only the microbial components that are found to be
significantly different among patients. Since 247 genera were detected in all baseline and week 52
samples obtained from the 11 participants, these genera could not all be included in the PCA
analysis. Thus, we chose to include only the 16 genera for which the abundances were judged to
be significantly different between baseline and week 52 samples by a Wilcoxon signed rank test.
The relevant matrix, therefore, contained 16 columns and 22 rows (11 baseline patients and 11
week 52 patients). The PCA plot below showed that the baseline samples were more clustered
together than the week 52 samples, the indication being that the relative abundances of these 16
genera were more similar among the baseline samples than among the week 52 samples, in other
50

words, the difference between the baseline and week 52 groups was greater than the difference
between the baseline or within the week 52 group, the indication being that the relative abundances
of the 16 genera in the baseline and week 52 groups were different.

Figure 3.3.4.1 PCA plot of the 16 genera that were determined to be significantly different (p <
0.1) between the baseline and week 52 groups based on Wilcoxon signed rank test. Principal
component 1 explained 38.8% of the total variance and principal component 2 explained 16.3% of
the total variance.
3.3.5 The Significance of the PCA Result
The observation that the distance between the baseline and week 52 groups was larger than
the distance within the baseline group and within the week 52 group indicated that the relative
abundances of the genera in the baseline and week 52 samples were different, but whether the
difference between the relative abundance of the genera in the baseline and week 52 samples is
statistically significant was not investigated or reported by researchers.
To solve this problem, we coded a Matlab program (supplemental data) that scrambled the
genera data randomly between baseline and week 52 and determined in what percentage of the
cases the distance between baseline and week 52 was as large as or larger than the observed
distance in the score analysis. The 16 genera that were judged to be significantly different by a
Wilcoxon signed rank test were chosen for this analysis. Because there were only 11 patients,
when the data were scrambled between baseline and week 52, there were only 211 = 2048
possibilities. Systematic consideration of these possibilities revealed that only two of the possible
permutations produced a distance equal to or greater than the observed distance. One was the
observed assignment of weeks, and the other corresponded to reversing the baseline and week 52
assignments for all the genera. The type I error rate was therefore 2/2048 = 0.00098. It’s
unnecessary to write a program that went through all those possibilities in a systematic way.
Instead, the baseline and week 52 data for each patient were scrambled 4000 times. This
undoubtedly produced many repeat scenarios. However, it was enough to get good convergence
on the type I error rate, which was about 7.5E−04. We need to know what the type I error rate
would have to be if we did 18 independent tests and came up with an overall type I error rate of
1%. To be correct 99% of the time after making 18 tests, we would need (1-p)^18 = 0.99, where p
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is the type I error rate for an individual test. Then p = 0.00056. The p-value of 7.5E−04 we obtained
was smaller than 0.00056, so it indicated that the result of the test was statistically significant. In
other words, it meant that for the community of the genera whose abundance was significantly
altered between the baseline and week 52 groups, their difference was statistically significant. The
null hypothesis that the relative abundance of the 16 bacterial genera was the same for the baseline
and week 52 samples can, therefore, be rejected with a high degree of confidence.
In detail, to test whether the difference between the two treatment groups (baseline and
week 52) was significantly different, we first calculated the distance between these two groups by
using the mean value on axis PC1 and the mean value on axis PC2 (DISTANCE = sqrt((xbx7)^2+(yb-y7)^2)).
Then we permuted the two sets of data (baseline and week 52 groups in this case) in
each column in matrix X randomly to make a new matrix and obtained the corresponding PC
scores and calculated the distance between these two groups again, by using the code ‘distance =
sqrt((xb-x7)^2+(yb-y7)^2)’ and ran this procedure for 4000 times. The ratio of the probability of
times to get the distance which is greater or equal to the distance that we obtained from our PCA
solution to the total times we permutated will be calculated and displayed.
The above PCA analysis answered the question of whether there was a significant
difference in the relative abundances of the 16 genera between baseline and week 52. However,
the gut flora consisted of 247 genera, not just 16 genera. It was obviously of interest to determine
whether the entire microbial community was significantly different between baseline and week 52
samples.
3.3.6 Limitation of PCA Analysis
PCA analysis usually cannot give much meaningful information for the analysis of the
OTU table because usually, the number of variables (microbes) is greater than the number of
samples (patients). To overcome this problem, the microbes can be clustered at specific taxonomic
levels (e.g., using HCluster in R) and then one chosen from each cluster and the PCA performed
on the representatives from the different clusters. Also, as in the example above, an ANOVA can
be used to identify OTUs that are different between baseline and week 52. The PCA can then be
carried out using the samples and the variables identified from the ANOVA. A PCA plot can then
be made, but the plot cannot reveal whether the baseline and week 52 groups are different or not.
Eventually, the p values from a statistical analysis will be needed to reach a conclusion.
3.3.7 Dissimilarity Tests
To determine whether there was a significant difference between the entire microbial
community at baseline and week 52, a distance matrix was produced based on either the BrayCurtis dissimilarity index or the Jaccard similarity index, followed by application of three nonparametric dissimilarity tests, including analysis of variance (Adonis), analysis of similarity
(ANOSIM), and a multiresponse permutation procedure (MRPP). The Jaccard index includes only
presence or absence information, while Bray-Curtis index includes both presence/absence and
abundance information. The results showed that there was a significant difference between
baseline and week 52 based on all three dissimilarity tests using the matrix based on the Jaccard
similarity index (Table 3.3.7.1).
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Table 3.3.7.1 The results of the dissimilarity tests to determine whether the ecological distance
associated with the gut bacterial genera at baseline and week 52 were significantly different.

BRS_BL vs W52
Genus
Jaccard
Bray-Curtis

MRPP
Delta
p
0.602 0.079
0.551 0.164

ANOSIM
R
p
0.073 0.064
0.059 0.159

Adonis
F
p
1.344 0.055
1.572 0.154

Two different programs, Jaccard and Bray-Curtis, were used to make the distance matrix,
and three different programs, MRPP, Anosim, and Adonis, were used to test the statistical
significance of the distance.
The Jaccard index, which can also be called the Jaccard similarity coefficient, measures
the similarity between sample groups, and it can be used to compare the similarity of data sets
(Jaccard, 1901). It is calculated by calculating the size of the intersection divided by the size of the
union of the sample sets. The letters A and B stand for two datasets. J stands for the Jaccard index.

AB
AB

AB A  B  AB
The Jaccard distance measures the dissimilarity between sample groups. It is obtained
by subtracting the Jaccard coefficient from 1, that is, the difference of the sizes of the union and
the intersection of the two datasets divided by the size of their union. dJ stands for the Jaccard
distance.
AB  AB
d J (A,B)  1  J(A,B)=
AB
The Bray-Curtis dissimilarity index is a statistic used to quantify the compositional
dissimilarity between two different sites, based on the counts at each site.
2Cij
BCij  1 
Si +S j
J(A,B)=

Cij is the sum of the lesser values for the units of interest, which is a genus in this case, in common
between the baseline and week 52 groups. Si and Sj are the number of genera in these two datasets,
respectively (Bray and Curtis 1957).
3.3.8 Conclusion
PCA is a useful way to determine whether groups have different microbial components,
when the number of the microbial components is less than the number of samples or, alternatively,
when using only the significantly different microbial components. It can provide a way to visualize
the difference directly. Dissimilarity tests must be used to investigate the differences when the
number of microbial components exceeds the number of samples and if all microbial components
are to be taken into consideration.
3.4 Measurement of Biodiversity
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3.4.1 Abstract
There are many types of diversity indices used to describe the diversity in the ecology
studies, and usually, researchers choose the most popular ones, for example, Shannon diversity or
Simpson diversity to use. However, these different diversity indices were all developed from true
diversity index with different selected. Choosing the different value of the parameters in the true
diversity equation could make the produced diversity index have specific stresses on a specific
group of the interested entities. Thus, by using this methodology the true diversity index can be
customized by the users to meet their specific emphasis and make more discoveries. This paper
reviewed the true diversity and the group that it emphasizes when the different parameter is chosen.
We conclude that researchers can tailor the true diversity index by applying different parameters
to make more discoveries on the diversity with the emphasis on some specific group of the entities
that they are interested in.
3.4.2 Introduction
In the field of ecology, three different types of diversity, alpha diversity (α diversity),
beta diversity (β diversity) and gamma diversity (γ diversity) were developed for describing
species diversity. Gamma diversity was defined as the total species diversity in a geological area,
and it is determined by alpha diversity and beta diversity. Alpha diversity was referred as the
diversity in a particular local ecosystem or habitat, or the mean of the diversity in particular local
sites and beta diversity is the distinction or diversity among those different habitats.
When diversity indices are used in ecology, the types of interest are usually species, but they can
also be other categories, such as other taxonomic levels including classes, orders, families, and
genera. The interested entities are usually individual plants, animals, and microbes, and the
measure of abundance can be, for example, the number of individuals.
Researchers often use diversity indices to measure alpha diversity. A diversity index is
a quantitative measure that considers both species richness (the number of different types) and
their evenness. For example, the Shannon index or the Simpson index are most commonly used.
However, it might be more reasonable to use true diversity, which is the effective number species,
as the measurement of species diversity because this method can weight abundant and rare species
in differential means (weight more on abundant species, weight more on rare species or weight
abundant and rare species equally), and its implication can be understood intuitively easier. The
Shannon index and the Simpson index, are simple transformations of true diversity, which is the
effective number of types, but different diversity indices can explain the diversity from different
angles. True diversity is the effective number of species, which is the number of equally distributed
types required to obtain the equal average relative abundance of types as that observed in the
investigated dataset in which the abundance of all types may not be equally abundant.
Suppose species diversity is the effective number of species. Alpha diversity is the mean species
diversity per subunit and can be calculated by first taking the weighted generalized mean Mq-1 of
the proportional abundances within subunits, and then taking its inverse. The equation is
R
1
1
q
D
( piq )1/(1 q) (Tuomisto, 2010). In the equation, the denominator
R
Mq 1 q 1
i 1
p pq 1
i 1

i i

Mq-1 equals the average proportional abundance of the types in the dataset as calculated with the
weighted generalized mean with exponent q-1. R is richness, the total number of types that were
54

contained in the dataset of interest, and pi is the proportional abundance of the ith type. The
nominal weights are the proportional abundances.
R
q
The form D

piq )1/(1

(

q)

is usually written as the general expression of true diversity

i 1

(Hill, 1973, Jost, 2006). The term q is usually referred to as the order of the diversity. By changing
its value the measurement of the true diversity can adjust the weight put on abundant or rare types,
to customize its sensitivity to abundant or rare species. In general, a higher q value leads to the
higher effective weight given to the most abundant types, and thus result in a greater Mq-1 value
and a smaller true diversity value. When q = 1, the weighted geometric mean of the pi values is
used, and each type is exactly weighted by its proportional abundance. When q > 1, more weight
was given to abundant types, and when q < 1, more weight was given to rare types. Some prevalent
diversity indices such as Shannon index and Simpson index are transformations of the true
diversity with different q values (Jost, 2006).
As q equals 1, the weighted geometric mean of the pi values is used, and each type is
exactly weighted by its proportional abundance. Although the equation of true diversity is
undefined when q = 1, it can be defined as q approaches to 1 infinitely. Below is its equation.
R

H'

R

ln pipi

pi ln pi
i 1

i 1

p1
1

(ln p

ln p 2

p2

ln p3p3

ln p R pR )

ln p 1 p1 p 2 p2 p 3 p3 ...p R pR
ln(
ln(

p1

p1 p 2

p2

1
)
p 3 p3 ...p R pR

1
R
i 1

pipi

)

Shannon index quantifies the uncertainty in predicting the identity of an entity that is
taken at random from the dataset (Shannon 1948). In the field of ecology, pi in the equation stands
for the proportion abundance of the ith type in the dataset of interest. The sum of the pi values
equals unit by definition, so the denominator equals the weighted geometric mean of the pi values,
with the pi values themselves being used as the weights. The term inside of the parentheses is true
diversity 1D, so H’ = ln(1D) (Hill, 1973, Tuomisto, 2010).
When the proportional abundance of each type in the dataset is equal, all pi equals to
1/R, the Shannon index equals ln(R). The more different types there are, the more equal their
proportional abundances in the dataset of interest. As the proportional abundance becomes more
even, the smaller the weighted geometric mean of the pi value is, and the greater the Shannon
index is. Conversely, the more uneven proportional abundance becomes, the greater the weighted
geometric mean of the pi value is, and the smaller the Shannon index is. As the degree of the
extent for the proportional abundance becomes uneven increases, the intensity becomes more
focused on one type, and the Shannon index approaches to 0. When there is only one type, the
Shannon index equal to 0, suggesting that there should be no indeterminacy in predicting the
identity of the following type taken from the dataset at random.
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Moreover, the Renyi entropy is a generalization of the Shannon index to other q values.
R
1
1
q
ln( piq ) ln(
) ln( q D) (Beck and Schlögl, 1993),
Its expression is H
R
q
1
1 q i1
q 1
pp
i 1

i i

and it is the logarithm of true diversity with any values of q.
On the contrary to the the Shannon index, which measures the probability to get a
different type of the next draw when taking the individuals randomly from the dataset with
replacement, the Simpson index (λ) measures the probability that two entities chosen from the
interested dataset randomly belong to the same type instead (Simpson 1049). Its equation is

=

R

pi2 . It equals the weighted arithmetic mean of the proportional abundances of the types in
i 1

the dataset of the interest, with the proportional abundances themselves as the weights.
However, the above formula needs to do some modification when the size of the dataset
is small. This is because when the size of the dataset is large enough, the calculated result using
the above equation could be the same. However, for small size dataset, the result of calculation
using the above equation could be very different. In this case, the formula was modified to
R

l

i 1

n i (n i

1)

N(N 1)

. In the equation, ni is the number of entities for the ith type and N is the total

number of entities in the dataset. In the field of microbiology, the Hunter–Gaston index is another
name for this form of Simpson index.
Based on the measurement of Simpson index (λ), the diversity index increases when the diversity
reduces. It counteracts with the human intuitive, leading to inversed Simpson index (1/λ) or GiniSimpson index (1- λ), whose value increases with increasing diversity, was used more popularly
(Hill 1973; Jost 2006). The inversed Simpson index is 1/ 

1
R
i

2

p
1

2
i

D , which is equated

with the true diversity with q = 2. For example, the effective number of types that is obtained when
the weighted arithmetic mean is used to quantify the average proportional abundance of types in
the dataset of interest. Gini–Simpson index, which was written as 1 – λ, measures the probability
that the two entities are taken from a dataset represent different types. Its equation is

1 

R

pi2

1

1 1/ 2 D and it can be expressed as a transformation of true diversity with q

i 1

= 2.
3.4.3 Materials and Methods
The abundances of genera (a taxonomic level in microbiology) detected by Illumina
sequencing (Illumina Miseq platform) from the genomic DNA samples extracted from fecal
samples obtained at baseline before bariatric surgeries and fecal samples obtained at week 52 post
bariatric surgeries were used. There were 11 bariatric surgery participants included, and 11 pairs
of relative abundance data for each genus. In total, 247 genera were detected.
3.4.4 Results and Discussions
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To illustrate the values and differences of these different diversity indices, we used the
genus data for the baseline and week 52 post bariatric surgery treatment as an example to calculate
them and make comparisons among them. The true diversity is calculated by the formula
R
q

D

piq )1/(1

(

q)

. If choosing q = 1 to not give more weight to either abundant or rare type, and

i 1
R

then the true diversity equals to the Shannon index, that is, D   pi ln pi . If choosing a q value
1

i 1

greater than 1, then the true diversity becomes more sensitive to abundant types and more weight
will be given to abundant types. For example, when choosing q = 2, the true diversity is the
1
2
inversed Simpson index in this case and equals to D
. If choosing a q value less than 1,
R
2
( pi )
i 1

and then the true diversity becomes more sensitive to rare types, and more weight will be given to
R
0.5

rare types. For instance, when choosing q = 0.5, the true diversity will be equal to D

pi ) 2 .

(
i 1

Below are the results of the calculations for the diversity indices in the above-mentioned conditions.

Table 3.4.4.1 The richness of genus for each baseline and week 52 post bariatric surgery sample.
The means sand standard deviations for the genus richness of these two groups were listed at the
bottom.
BRS
Participant ID
Band0186
Bypass0610
Bypass9968
Sleeve1517
Sleeve2069
Sleeve2104
Sleeve3036
Sleeve3289
Sleeve5155
Sleeve7603
Sleeve8684
Mean
Std

Genus richness
BL
W52
61
83
54
63
67
90
82
79
65
80
56
69
66
81
83
85
58
47
32
61
59
75
62.09 73.91
13.85 12.70

Table 3.4.4.2 The result of tests for comparing whether the difference between the genus richness
in baseline and week 52 post bariatric surgery samples are statistically significant.
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Genus richness_BL vs W52
Paired t test
Paired u test

p
0.008
0.018

The result showed that the mean genus richness of the week 52 samples was higher than
the mean genus richness of the baseline samples (Table 3.4.4.1), and both paired t-test and paired
u test results showed that the increase was statistically significant (Table 3.4.4.2). In other words,
the genus richness at baseline was significantly lower when compared to the week 52 samples, and
the genus richness at week 52 post-treatment was significantly higher when compared to the
baseline samples.

Table 3.4.4.3 The values of the true diversities of the genus community in baseline and
week 52 post bariatric surgery samples, when calculated with different q values, were listed. The
means and standard deviations of the true diversities for the genus community in the baseline and
week 52 groups were listed at the bottom of the table.

BRS
Participant ID
Band0186
Bypass0610
Bypass9968
Sleeve1517
Sleeve2069
Sleeve2104
Sleeve3036
Sleeve3289
Sleeve5155
Sleeve7603
Sleeve8684
Mean
Std

Genus diversity at BL
q=1
q = 2 q = 0.5
1.728 3.297 12.286
2.150 6.250 13.729
2.183 4.749 17.655
2.626 8.417 26.184
2.418 5.762 20.633
2.129 4.295 16.511
1.801 3.924 12.999
2.178 4.738 19.729
2.609 9.858 20.501
1.368 2.385
7.640
1.765 3.366 13.429
2.087 5.186 16.482
0.391 2.263
5.141

Genus diversity at W52
q=1
q=2
q = 0.5
2.602
8.474
25.526
2.720 10.742 24.089
2.548
7.247
25.479
2.957 12.224 30.432
2.212
4.381
21.413
2.738
9.710
24.699
1.957
3.964
17.471
2.270
5.084
21.835
2.093
5.757
12.764
1.522
2.529
11.350
1.960
3.718
17.599
2.325
6.712
21.151
0.428
3.194
5.817

Table 3.4.4.4 The test results for comparing whether there is a statistically significant difference
between the true diversities for the genus community in the baseline and week 52 post bariatric
surgery samples when calculated with different q values, were listed.
BRS_BL vs W52
True diversity of genus
Paried t test
Paired u test
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q=1
0.067
0.083

p
q=2
0.123
0.083

q = 0.5
0.019
0.019

The results showed that the average of the true diversity was increased at week 52 when
compared to the baseline level (Table 3.4.4.3). In addition, both paired t-test and paired u test
results showed that when choosing smaller q values, the difference of the true diversity between
baseline and week 52 samples become more statistically significant. For example, when q was set
as 0.5 to emphasize the rarer genera, the baseline diversity was significantly lower than the week
52 diversity (p = 0.019), while when q was set as 2 to emphasize the abundant genera, the p-value,
which is equal to 0.083, was not as significant as the p-value calculated when q was set as 0.5
(Table 3.4.4.4). It indicates that the difference for the rare genera between before and after
treatment was more significant when compared to the difference for the abundant genera. In other
words, it indicates that the changes in the gut flora have been mainly in the comparatively rare
genera.
Therefore, we conclude that it would be meaningful for researchers to employ different
types of diversity indices or the true diversity with different q values when comparing the
diversities between different groups. This methodology can help the researchers to dig out more
detailed information, for example, whether the difference in diversities is more concentrated on
abundant types or rare types in the dataset we are interested in.
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CHAPTER FOUR: OBESITY IMPROVEMENT WAS EFFICIENT AND
PERSISTENT AFTER BRS AND IT WAS LESS EFFICIENT AND
PERSISTENT AFTER LCD
4.1 Obesity Improvement after BRS Was Efficient and Persistent
We observed that almost all physiological variables were significantly improved at week
7 and week 52 after BRS. Weight, fat mass, lean mass, fat%, BMI, 24HourEE, SubcutMeanSize,
GLU, INS, GHRA, ADP, ADPHMW, and hsCRP were all significantly improved at week 7 and
week 52 post BRS, and CHOL and GHR were significantly improved at week 7 post BRS,
GDR1/Weight, GDR2/Weight, TRIG, HDL, were significantly improved at week 52 post BRS.
More specifically, weight was significantly reduced from mean of 128.36 kg (std = 4.94
kg) at baseline to mean of 111.99 kg (std = 4.14 kg) at week 7 to mean of 85.62 kg (std =3.34 kg)
at week 52 post BRS (p =3.05E−05 for baseline and week 7; p =1.22E−04 for baseline and week
52; p = 0.0001 for week 7 and week 52). Similarly, IDXA weight was significantly reduced from
baseline mean of 129.6 kg (std =20.6 kg) to week 7 mean of 115.0 kg (std =17.19 kg) to week 52
mean of 86.92 kg (std =13.72 kg) (p = 4.37E−04 for baseline & week 7, p = 4.38E−04 for baseline
& week 52 and week 7 & week 52). Fat mass was significantly reduced from mean of 69.56 kg
(std = 11.86 kg) at baseline to mean of 60.48 kg (std = 10.70 kg) at week 7 (p = 1.22E−04), and
from mean of 67.48 kg (std = 14.30 kg) at baseline to mean of 37.02 kg (std = 9.44 kg) at week 52
(p = 0.0156), and from mean of 59.69 kg (std = 13.78 kg) at week 7 to mean of 37.02 kg (std =
9.44 kg) at week 52 (p = 0.0156). IDXA fat mass was significantly reduced from baseline mean
of 67.36 kg (std = 13.17 kg) to week 7 mean of 58.15 kg (std = 11.43 kg) (p = 6.10E−05), from
baseline mean of 67.36 kg (std = 13.17 kg) to week 52 mean of 33.93 kg (std = 10.42 kg) (p =
6.10E−05), and from week 7 mean of 57.28 kg (std = 11.57 kg) to week 52 mean of 33.22 kg (std
= 10.46 kg) (p = 4.38E−04). Lean mass was also significantly reduced from mean of 54.13 kg (std
= 13.02 kg) at baseline to mean of 48.65 kg (std = 10.25 kg) at week 7 (p = 1.22E−04), from
baseline mean of 50.72 kg (std = 16.46 kg) to week 52 mean of 44.52 kg (std = 11.63 kg) (p =
0.0156). IDXA lean mass was significantly reduced from baseline mean of 57.49 kg (std = 8.53
kg) to week 7 mean of 52.86 kg (std = 7.45 kg) (p = 6.10E−05), from baseline mean of 57.66 kg
(std = 8.82 kg) to week 52 mean of 50.32 kg (std = 6.08 kg) (p = 2.44E−04), and from week 7
mean of 54.67 kg (std = 9.87 kg) to week 52 mean of 52.07 kg (std = 8.96 kg) (p =0.0054). Fat%
was significantly reduced from baseline mean of 53.81 (std = 4.67) to week 7 mean of 52.21 (std
= 4.90) (p = 0.0054), from baseline mean of 53.81 (std = 4.67) to week 52 mean of 39.80 (std =
7.59) (p = 6.10E−05), and from week 7 mean of 51.02 (std = 6.71) to week 52 mean of 38.61 (std
= 8.73) (p = 4.38E−04). 24HourEE was significantly reduced from baseline mean of 2453.56
kcal/day (std = 418.48 kcal/day) to week 7 mean of 2085.5 kcal/day (std = 261.66 kcal/day) (p =
4.38E−04), from baseline mean of 2451.4 kcal/day (std = 433.08 kcal/day) to week 52 mean of
1918.13 kcal/day (std = 304.80 kcal/day) (p = 6.10E−05), and from week 7 mean of 2087 kcal/day
(std = 270.78 kcal/day) to week 52 mean of 1918.13 kcal/day (std = 304.80 kcal/day) (p = 0.0014).
BMI was significantly reduced from baseline mean of 45.83 kg/m2 (std = 6.56 kg/m2) to week 7
mean of 40.02 kg/m2 (std = 5.77 kg/m2) to week 52 mean of 30.57 kg/m2 (std = 4.44 kg/m2) (p =
4.38E−04) for baseline & week 7, baseline & week 52, and week 7 & week 52). Subcutaneous fat
size was significantly reduced from baseline mean of 1.52 µl (std = 0.657 µl) to week 7 mean of
1.203 µl (std = 0.23 µl) (p = 0.064), from week 7 mean of 1.251 µl (std = 0.222 µl) to week 52
mean of 0.829 µl (std = 0.230 µl) (p = 0.0098), from baseline mean of 1.543 µl (std = 0.718 µl) to
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week 52 mean of 0.829 µl (std = 0.230 µl) (p = 0.0039). It indicated that after BRS, obesity was
significantly improved.
Fasting glucose was significantly reduced from baseline mean of 100.59 mg/dl (std = 11.40
mg/dl) to week 7 mean of 91.19 mg/dl (std = 13.48 mg/dl) to week 52 mean of 86.09 mg/dl (std =
8.38 mg/dl) (p = 0.0034 for baseline & week 7; p = 6.10E−05 for baseline & week 52). INS was
significantly reduced from baseline mean of 13.24 uU/dl (std = 8.57 uU/dl) to week 7 mean of
5.77 uU/dl (std = 3.03 uU/dl) to week 52 mean of 5.34 uU/dl (std = 6.80 uU/dl) (p = 9.35E−04 for
baseline & week 7; p = 7.76E−04 for baseline & week 52; p = 0.0494 for week 7 & week 52).
GDR1/Weight was not significantly altered during baseline and week 7, but was significantly
increased from week 7 mean of 2.49 mg/kg/min (std = 0.83 mg/kg/min) to week 52 mean of 4.91
mg/kg/min (std = 1.13 mg/kg/min) (p = 4.37E−04) and from baseline mean of 2.57 mg/kg/min
(std = 0.84 mg/kg/min) to week 52 mean of 4.91 mg/kg/min (std = 1.13 mg/kg/min) (p =
4.38E−04). Similarly, GDR2/Weight was not significantly altered during baseline and week 7, but
was significantly increased from week 7 mean of 7.11 mg/kg/min (std = 1.88 mg/kg/min) to week
52 mean of 12.93 mg/kg/min (std = 1.58 mg/kg/min) (p = 4.38E−04) and from baseline mean of
7.29 mg/kg/min (std = 2.27 mg/kg/min) to week 52 mean of 12.93 mg/kg/min (std = 1.58
mg/kg/min) (p = 4.38E−04). It indicated that after BRS, the insulin resistance was significantly
improved.
Triglycerides were significantly reduced from baseline mean of 143.47 mg/dl (std = 86.11
mg/dl), to week 7 mean of 96.67 mg/dl (std = 37.04 mg/dl) (p = 0.0291), from baseline mean of
140.06 mg/dl (std = 84.29 mg/dl), to week 52 mean of 75.63 mg/dl (std = 35.62 mg/dl) (p = 0.0023),
and from week 7 mean of 96.67 mg/dl (std = 37.04 mg/dl) to week 52 mean of 78 mg/dl (std =
35.53 mg/dl) (p = 0.0946). HDL was significantly reduced from baseline mean of 51.43 mg/dl (std
= 10.32 mg/dl) to week 7 mean of 44.58 mg/dl (std = 10.66 mg/dl) (p = 0.174), but was
significantly increased from baseline mean of 51.43 mg/dl (std = 10.32 mg/dl) to week 52 mean
of 61.89 mg/dl (std = 10.90 mg/dl) (p = 0.0025), and from week 7 mean of 44.58 mg/dl (std =
10.66 mg/dl) to week 52 mean of 61.89 mg/dl (std = 10.90 mg/dl) (p = 4.38E−04). Cholesterol
was significantly reduced from baseline mean of 173.88 mg/dl (std = 47.19 mg/dl) to week 7 mean
of 148.56 mg/dl (std = 37.36 mg/dl) (p = 0.014), but was significantly increased from week 7 mean
of 148.56 mg/dl (std = 37.36 mg/dl) to week 52 mean of 170.69 mg/dl (std = 32.54 mg/dl) (p =
0.0057), but it was still less than the baseline mean and there was no statistically significant
difference between baseline and week 52 levels. No significant alteration of LDL was observed
during the three periods. It indicated that after BRS, the lipid profile became significantly
improved.
Hormone adiponectin (ADP) was significantly increased from baseline mean of 8.19 mg/dl
(std = 5.09 mg/dl) to week 52 mean of 16.45 mg/dl (std = 11.60 mg/dl) (p = 0.037), and from week
7 mean of 10.13 mg/dl (std = 5.69 mg/dl) to week 52 mean of 16.76 mg/dl (std = 11.27 mg/dl) (p
= 6.42E−04). The normal range of adiponectin for individuals with BMI > 30 kg/m2 is 2-20 mg/dl
for males and 4-22 for females (Mayo medical laboratories 2017). The patients who had over 10
years of diabetic mellitus type 2 showed abnormally higher level of ADP, and after excluding it
from the analysis, ADP showed significant increased at week 7 (mean = 9.7 mg/dl, std = 5.62
mg/dl), when comparing to baseline (mean = 8.19 mg/dl, std = 5.09 mg/dl) (p = 0.037). Meanwhile,
this patient also showed least lean mass (but not IDXA lean mass), biggest SubcutMeanSize,
highest GLU, lowest INS, highest ADPHMW, and lowest LEP. Similarly, the active form of ADP,
high-molecular-weight adiponectin (ADPHMW) was significantly increased from mean week 7
mean of 5435.73 mg/dl (std = 3343.05 mg/dl) to week 52 mean of 9780 mg/dl (std = 6893.75
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mg/dl) (p = 0.0072), and from baseline mean of 5795.56 mg/dl (std =7138.77 mg/dl) to week 52
mean of 10029 mg/dl (std = 6734.06 mg/dl) (p = 4.38E−04), and after excluding the patient with
greater than 10-year diabetics, ADPHMW was significantly increased from at week 7 (mean =
5435.73 mg/dl, std = 3343.05 mg/dl), when comparing with baseline (mean = 4162.07 mg/dl, std
= 2976.53 mg/dl) (p = 0.0012). GHR was significantly reduced from baseline mean of 550.44
mg/dl (std = 129.68 mg/dl) to week 7 mean of 407.81 mg/dl (std = 182.06) to week 52 mean of
479.88 mg/dl (std = 240.29 mg/dl) (p = 0.0027 for baseline & week 7; p = 0.098 for baseline &
week 52). GHRA was significantly reduced from baseline mean of 119.67 mg/dl (std = 60.11
mg/dl) to week 7 mean of 61.6 mg/dl (std = 16.78 mg/dl) (p = 9.16E−04), but was significantly
increased from week 7 mean of 59.03 mg/dl (std = 19.19 mg/dl) to week 52 mean of 85.88 mg/dl
(std = 41.54 mg/dl) (p = 0.0067); However, the week 52 level was still lower than the baseline
level. There were many GLP-1 values were below 2 mg/dl, making the comparison between
baseline, week 7 and week 52 inaccurate, so it was not reported. No significant alteration of PYY
levels were observed among the three periods. Leptin was significantly reduced from baseline
mean of 53.76 mg/dl (std = 20.76 mg/dl) to week 7 mean of 32.88 mg/dl (std = 13.34 mg/dl) to
week 52 mean of 21.56 mg/dl (std = 13.33 mg/dl) (p = 9.35E−04 for baseline & week 7; p =
5.30E−04 for baseline & week 52; p = 0.0032 for week 7 & week 52). It indicated the significant
improvement of obesity-related hormones after BRS.
HsCRP was significantly reduced from baseline mean of 10.01 mg/l (std = 8.86 mg/l) to
week 7 mean of 7.31 mg/l (std = 5.59 mg/l) (p = 0.098), from baseline mean of 10.46 mg/l (std =
8.97 mg/l) to week 52 mean of 2.97 mg/l (std = 3.17 mg/l) (p = 6.10E−05), and from week 7 mean
of 7.27 mg/l (std = 5.79 mg/l) to week 52 mean of 3.14 mg/l (std = 3.21 mg/l) (p = 6.10E−05).
HsCRP measures general inflammation levels, and the normal range of hsCRP in healthy human
beings is below 10 mg/l. At week 52 post BRS, all patients showed hsCRP levels less than 10 mg/l,
except one patient showed hsCRP level equaling to 10 mg/l. Considering that obesity is usually
linked with increased inflammation levels and the significant reduction of hsCRP further supported
the signinificant improvement of obesity condition.
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Figure 4.1.1 Changing patterns of obesity-related physiological variables in the BRS group.
Different letters (a, b, and c) stand for statistical significance.

4.2 Obesity Improvement after LCD Was Less Efficient and Persistent
For the LCD group, we also observed significant improvement of obesity-related
physiological variables, but the number of significantly improved variables and the degree of their
improvements were much less than the BRS group. Weight, fat mass, lean mass, and ADP were
all significantly improved at week 7 and week 52 post LCD treatment, and BMI, 24HourEE, GLU,
INS, and CHOL were significantly reduced at week 7 post LCD, and SubcutMeanSize and hsCRP
were significantly reduced at week 52 post LCD.
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More specifically, weight was significantly reduced from baseline mean of 130.01 kg (std
= 30.59 kg) (p = 0.0078). IDXA weight was significantly reduced from baseline mean of 129.91
kg (std = 30.19 kg) to week 7 mean of 122.94 kg (std = 31.92 kg) to week 52 mean of 125.05 kg
(std = 30.13 kg) (p = 0.0078 for baseline & week 7 and p = 0.0781 for baseline & week 52). Fat
mass was significantly reduced from baseline mean of 70.17 kg (std = 19.98 kg) to week 7 mean
of 65.32 kg (std = 20.56 kg) (p = 0.0078), and from baseline mean of 74.35 kg (std = 21.78 kg) to
week 52 mean of 68.9 kg (std = 21.33 kg) (p =0.0625). IDXA fat mass was significantly reduced
from baseline mean of 57.51 kg (std = 8.97 kg) to week 7 mean of 53.70 kg (std = 7.71 kg) (p =
0.0625), but was significantly increased from week 7 mean of 56.32 kg (std = 9.43 kg) to week 52
mean of 59.37 kg (std = 10.02 kg) (p = 0.0313). Lean mass was significantly reduced from baseline
mean of 52.61 kg (std = 11.87 kg) to week 7 mean of 49.97 kg (std = 10.84 kg) (p = 0.0078), and
from baseline mean of 54.98 kg (std = 12.78 kg) to week 52 mean of 51.53 kg (std = 12.79 kg) (p
= 0.0313). IDXA lean mass was significantly reduced from baseline mean of 51.22 kg (std = 3.06
kg) to week 7 mean of 47.38 kg (std = 3.77 kg) (p = 0.0625). No significant alteration of fat% or
SubcutMeanSize was observed after LCD. 24HourEE was significantly reduced from baseline
mean of 2365.13 kcal/day (std = 363.84 kcal/day) to week 7 mean of 2160.25 kg (std = 351.60 kg)
(p = 0.0156). BMI was significantly reduced from baseline mean of 47.19 kg/m2 (std = 8.76 kg/m2)
to week 7 mean of 44.11 kg/m2 (std = 9.41 kg/m2) (p = 0.0078). It indicated that obesity was
significantly improved after LCD treatment.
GLU was significantly reduced from baseline mean of 98 mg/dl (std = 9.25 mg/dl) to week
7 mean of 92.69 mg/dl (std = 9.12 mg/dl) (p = 0.0234). INS was significantly reduced from
baseline mean of 14.18 uU/dl (std = 9.06 uU/dl) to week 7 mean of 9.35 uU/dl (std = 6.83 uU/dl)
(p = 0.0391). No significant alteration of GDR1/weight or GDR2/Weight was observed after LCD.
It indicated during LCD treatment, the insulin resistance was significantly improved, but the
improvement disappeared after the cease of the LCD treatment.
No significant alteration of TRIG or LDL was observed. HDL was significantly reduced
from baseline mean of 51.28 mg/dl (std = 5.80 mg/dl) to week 7 mean of 45.6 mg/dl (std = 5.67
mg/dl) (p = 0.0781), but was significantly increased from week 7 mean of 45.6 mg/dl (std = 5.67
mg/dl) to week 52 mean of 50.48 mg/dl (std = 8.53 mg/dl) (p = 0.0547); no significant difference
between baseline and week 52 levels. CHOL was significantly increased from week 7 mean of
165.13 mg/dl (std = 26.14 mg/dl) to week 52 mean of 189.63 mg/dl (std = 42.48 mg/dl) (p =
0.0858), but no significant difference between baseline and week 52 levels. It indicated that lipid
profile was not significantly altered after LCD.
ADP was significantly increased from baseline mean of 9.06 mg/dl (std = 4.61 mg/dl) to
week 7 mean of 11.2 mg/dl (std = 6.08 mg/dl) (p = 0.0313). LEP was significantly reduced from
baseline mean of 67.16 mg/dl (std = 27.27 mg/dl) to week 7 mean of 49.21 mg/dl (std = 8.58 mg/dl)
(p = 0.0391), but was significantly increased from week 7 mean of 49.21 mg/dl (std = 8.58 mg/dl)
to week 52 mean of 68.01 mg/dl (std = 19.25 mg/dl) (p = 0.0156); no significant difference of
LEP between baseline and week 52 post LCD. No significant alteration of ADPHMW, GHR,
GHRA, GLP-1, or PYY was observed. It indicated the significant improvement of obesity-related
hormone during LCD treatment, but the significant improvement was short-term, considering that
it was disappeared after the cease of LCD treatment.
No significant alteration of the hsCRP level was observed after LCD.
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Figure 4.2.1 Changing patterns of obesity-related physiological variables in the LCD group.
Different letters (a, b, and c) stand for statistical significance.
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CHAPTER FIVE: MICROBIAL COMMUNITY STRUCTURE WAS
SIGNIFICANTLY ALTERED AFTER TREATMENTS
5.1 Gut Microbial Richness and Diversity Was Significantly Increased
Richness measures how many different types of categories existing in the sample, and it
increases as the number of different category type increases. The genus richness was significantly
from around 60 to 80, and OTU richness was significantly increased from around 800 to 100.
Diversity considers both richness and evenness, and it increases as richness and evenness increase.
Alpha-diversity measures local diversity, and here it was measured by Shannon index and inversed
Simpson index, both of which showed significantly increase at genus and OTU level. Combining
them together, it indicated that microbial richness and diversity were significantly increased at
genus and OTU levels.

Figure 5.1.1 Genus richness was significantly increased at week 52 after BRS treatment.

Figure 5.1.2 Genus alpha diversity was significantly increased at week 52 after BRS treatment.
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Figure 5.1.3 OTU richness was significantly increased at week 52 after BRS treatment.

Figure 5.1.4 OTU diversity was significantly increased at week 52 after BRS treatment.
Similarly, we observed that the significant increase of genus diversity at week 52 post LCD
treatment, although no significant increase of genus richness was observed. At OTU level, we did
not observe a statistically significant increase of richness and diversity, but all the 4 LCD
participants whose microbial data were available showed increased OTU richness and diversity.

Figure 5.1.5 Genus diversity was significantly increased at week 52 post LCD treatment.
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Figure 5.1.6 OTU richness was not statistically significantly increased, but they were all increased
in all 4 LCD participants whose microbial data was available.

Figure 5.1.7 OTU diversity was not statistically significantly increased, but they were all increased
in all 4 LCD participants whose microbial data was available.

Taken together, it indicated that the richness and alpha diversity of the entire microbial
community structure were significantly increased after both BRS and LCD treatments, and degree
of their increase was higher in the BRS group than the LCD group.
Like all healthy ecosystems, the richness of gut microbiota characterizes the healthy status,
and a loss of diversity is linked to several disease statuses (Ott and Schreiber, 2006). Here, our
results supported that the increased microbial richness and diversity was linked to the improved
obesity condition, and greater increased microbial richness and diversity was linked to greater
improved obesity condition in the severely obese subjects. It was reported that fasting treatment
increased gut microbial diversity (Remely et al., 2015), and considering that bariatric surgeries
induced different degrees of calorie restriction (the direct effect of BRS), so our result confirmed
this link and indicated that the calorie restriction induced by BRS could be one of the mechanisms
that contributed to the increased microbial diversity. Besides, considering that the main
physiological alteration of the patients after BRS was weight loss and better healthiness status
(indirect effects of BRS), so the increased microbial diversity could be induced by weight loss or
improved health condition. In addition, there could be some other alteration of physiological
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alterations initiated by BRS, such as hormone levels, alteration of pH levels, temperature etc, etc
that could be contributed to the increased microbial diversity.
5.2 Gut Microbial Distribution and Composition Was Altered at Different Taxonomic Levels
The overall microbial taxonomy represented by the fecal microcosm in vitro was
distributed amongst defined phyla, classes, orders, families, genera, and some undefined taxa.
Around 99.86% of sequences belong to bacteria and 0.14% sequences belong to Archaea. The
phylum was dominated by Firmicutes (70.37%), Bacteroidetes (14.40%), Actinobacteria (7.67%),
Proteobacteria (5.51%), Verrucomicrobia (1.49%) and others (0.56%, including Euryarchaeota,
Fusobacteria,
Acidobacteria,
CyanobacteriaChloroplast,
Spirochaetes,
Synergistetes,
Gemmatimonadetes, Nitrospira, Planctomycetes, TM7, Deinococcus-Thermus, Chloroflexi,
Thermotogae, Chlorobi, Deferribacteres, Armatimonadetes and unclassified).
The phylum Actinobacteria was significantly reduced, while the phylum Verrucomicrobia
was significantly increased at week 52 after BRS treatment (Figure 5.2.3).

Figure 5.2.1 Phylum distribution at baseline post-BRS treatment.

Figure 5.2.2 Phylum distribution at week 52 post-BRS treatment.
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Figure 5.2.3 Phyla Actinobacteria and Verrucomicrobia were significantly altered at week 52 after
BRS treatment.

It has been reported that the phylum Actinobacteria increased its relative abundance in the
gut of mice fed a high-fat diet (Clarke et al., 2012). Also, it has been reported that it was higher in
the gut microbiota belonging to the obese ones in the twins than the lean ones (Turnbaugh et al.,
2009). Additionally, it has been reported that it was reduced after RYGB treatment (Graessler et
al., 2013).
It has been reported that the obese individuals had a lower relative abundance of
Verrucomicrobia (Clarke et al., 2012), and it was increased after RYGB (Liou et al., 2013). It was
also reported that it was more abundant in normal-weight and post-gastric bypass individuals than
the obese individuals (Zhang et al., 2009).
In addition, we observed that Proteobacteria was significantly increased from baseline
mean of 6.3% (std = 14.5%) to week 7 mean of 13.1% (std = 21.5%) post BRS treatment (p =
0.0029) and this observation was consistent with the finding reported by other groups which found
that Proteobacteria was enriched after RYGB in the individual’s distal gut (Sweeney and Morton,
2014, Tremaroli et al., 2015).
We did not observe significant alteration of the relative abundance of any phyla at week 7
post LCD treatment. However, at week 52 post LCD treatment, we observed that phylum
Firmicutes were significantly reduced, while phylum Bacteroidetes was significantly increased
(Figure 5.2.6).
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Figure 5.2.4 Phylum distribution at baseline post LCD treatment.

Figure 5.2.5 Phylum distribution at week 52 post LCD treatment.

Figure 5.2.6 Phylum Firmicutes and Bacteroidetes were significantly altered at week 52 post LCD
treatment.

At class level, Clostridia (60.67%) dominated, followed by Bacteroidia (14.3%),
Actinobacteria (7.67%), Bacilli (5.53%), Gammaproteobacteria (4%), Erysipelotrichia (3.17%),
Verrucomicrobiae (1.48%), Alphaproteobacteria (1.19%), and others (1.98%, including
Negativicutes, Betaproteobacteria, Methanobacteria, Deltaproteobacteria, Fusobacteria,
Flavobacteria, Sphingobacteria, Chloroplast, Spirochaetes, Synergistia, Acidobacteria Gp4,
Acidobacteria Gp6, Acidobacteria Gp1, Gemmatimonadetes, Nitrospira, Planctomycetacia,
Spartobacteria, Acidobacteria Gp7, Deinococci, Acidobacteria Gp3, Bacteroidetes incertae sedis,
Subdivision3, Anaerolineae, Epsilonproteobacteria, Thermotogae, Acidobacteria Gp18,
Acidobacteria Gp16, Deferribacteres, Holophagae, Ignavibacteria, Cyanobacteria, Acidobacteria
Gp10, Acidobacteria Gp17, Methanococci, Zetaproteobacteria and unclassified).
We observed that the class Gammaproteobacteria was significantly increased at week 7
after BRS treatment, and it was consistent with the finding reported by the other group and they
also found after RYGB, Gammaproteobacteria was significantly increased (Zhang et al., 2009).
Also, the class Actinobacteria was significantly reduced, and Verrucomicrobiae was significantly
increased at week 52 after BRS treatment.
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Table 5.2.1 Class Gammaproteobacteria was significantly increased at week 7 post-BRS treatment.
BRS
Class
BL
W7
Wilcoxon signed rank (p)

Gammaproteobacteria
Mean
Std
6.5%
1.51%
1.14%
2.32%
0.0273

Table 5.2.2 Class Actinobacteria was significantly reduced, while Verrucomicrobiae was
significantly increased at week 52 after BRS treatment.
BRS
Class
BL
W52
Wilcoxon signed rank (p)

Actinobacteria
Mean
Std
12.97% 13.54%
5.21% 6.12%
0.0537

Verrucomicrobiae
Mean
Std
1.21%
2.18%
2.36%
2.35%
9.77E-04

We did not a significant alteration of the relative abundance of any classes at week 7 post
LCD treatment, but it was detected that at week 52, class Clostridia was significantly reduced and
Deltaproteobacteria was significantly increased when comparing with the baseline level.
Reduction of clostridia was reported to be correlated with weight loss.
Table 5.2.3 Classes which were significantly altered at week 52 post LCD treatment.
Class
LCD
Mean
Std
Wilcoxon signed rank (p)

Clostridia
Deltaproteobacteria
BL
W52
BL
W52
76.37% 68.07% 0.06%
0.16%
14.34% 18.15% 0.10%
0.30%
0.091
0.0629

At genus level, Blautia dominated (26.20%), followed by Bacteroides (11.82%),
Lachnospiracea incertae sedis (8.89%), Bifidobacterium (4.68%), Dorea (3.82%), Roseburia
(3.28%), EscherichiaShigella (2.84%), Streptococcus (2.51%), Anaerostipes (2.47%), Collinsella
(2.25%), Faecalibacterium (2.20%), Clostridium IV (1.89%), Akkermansia (1.48%), Alistipes
(1.14%), Granulicatella (1.13%), Gemmiger (1.12%), Clostridium XVIII (1.03%), and others
(12.59%, including Erysipelotrichaceae incertae sedis, Clostridium XlVa, Ruminococcus,
Lactobacillus, Clostridium sensu stricto, Coprococcus, Clostridium XI, Parabacteroides,
Prevotella, Megasphaera, Enterococcus, Lactococcus, Catenibacterium, Eggerthella, Pantoea,
Haemophilus, Oscillibacter, Sporobacter, Dialister, Anaerotruncus, Turicibacter, Eubacterium,
Mogibacterium, Subdoligranulum, Methanobrevibacter, Butyricicoccus, Dysgonomonas,
Paraprevotella, Veillonella, Actinomyces, Slackia, Fusobacterium, Peptococcus, Flavonifractor,
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Clostridium XlVb, Barnesiella, Phascolarctobacterium, Pediococcus, Acetanaerobacterium,
Coprobacillus, Lachnobacterium, Burkholderia, Gordonibacter, Sutterella, Acidaminococcus,
Odoribacter, Parasutterella, Lactonifactor, Morganella, Chryseobacterium, Bilophila,
Stenotrophomonas,
Rothia,
Succiniclasticum,
Desulfovibrio,
Rhodanobacter,
Pseudoflavonifractor, Hespellia, Butyricimonas, Acinetobacter, Pseudoflavonifractor, Hespellia,
Acinetobacter, Butyricimonas, Olsenella, Leuconostoc, Gemella, Allisonella, Thiobacillus,
Clostridium III, Citrobacter, Streptophyta, Bulleidia, Enterorhabdus, Anaerosporobacter, Dyella,
Tannerella, Comamonas, Howardella, Nakamurella, Tepidimonas, Holdemania, Anaerofustis,
Anaerovorax, Anaerofilum, Peptostreptococcus, Pseudobutyrivibrio, Variovorax, Zoogloea,
Acetitomaculum, Papillibacter, Robinsoniella, Bradyrhizobium, Atopobium, Peptoniphilus,
Pseudomonas, Treponema, Lysobacter, Brevundimonas, Methyloversatilis, Delftia,
Rummeliibacillus, Staphylococcus, Rhizobium, Cloacibacillus, Solobacterium, Corynebacterium,
Ethanoligenens, Sphingomonas, Paracoccus, Weissella, Arsenicicoccus, Bosea, Megamonas,
Methanosphaera, Acidovorax, Caulobacter, Alcaligenes, Gp6, Gp4, Caulobacter, Alcaligenes,
Gp4, Gp6, Azoarcus, Clostridium XII, Anaerococcus, Finegoldia, Gemmatimonas,
Methylobacterium, Lactovum, Parvimonas, Alloscardovia, Gp1, Herbaspirillum, Nitrospira,
Ralstonia, Aquamicrobium, Mitsuokella, Pseudorhodoferax, Spartobacteria genera incertae sedis,
Tsukamurella, Vampirovibrio, Varibaculum, Hydrogenoanaerobacterium, Solirubrobacter,
Thauera, Anaerorhabdus, Xanthobacter, Limnobacter, Rudaea, Terrimonas, Gp7, Mycobacterium,
Naxibacter, Paludibacter, Porphyromonas, Sphingobacterium, Sphingopyxis, TM7 genera
incertae sedis, Vagococcus, Williamsia, Dechloromonas, Ensifer, Ferruginibacter,
Flavisolibacter, Moryella, Pseudoxanthomonas, Singulisphaera, Syntrophococcus, Dyadobacter,
Gp3, Rhodobacter, Sphingosinicella, Acetivibrio, Aeromonas, Arthrobacter, Cellulosilyticum,
Mucilaginibacter, Inquilinus, Arthrobacter, Cellulosilyticum, Inquilinus, Mucilaginibacter,
Ohtaekwangia, Pandoraea, Pedomicrobium, Salmonella, Subdivision3 genera incertae sedis,
Auritidibacter, Cryptobacterium, Mesorhizobium, Pasteuria, Phenylobacterium, Roseomonas,
Sarcina, Skermanella, Sporichthya, Thermus, Acidisoma, Anaeroglobus, Anaeromyxobacter,
Aquabacterium, Bacillariophyta, Conexibacter, Devosia, Duganella, Flavobacterium, Janibacter,
Labrys, Nocardioides, Petrimonas, Thermotoga, Alkaliphilus, Bacillus, Bellilinea, Blastococcus,
Caldithrix, Chelatococcus, Chondromyces, Cupriavidus, Edaphobacter, Ferribacterium, Geothrix,
Gp16, Gp18, Hallella, Ignavibacterium, Kaistia, Kofleria, Luteimonas, Micrococcus,
Oribacterium, Oxobacter, Pedobacter, Roseateles, Steroidobacter, Thiohalophilus,
Achromobacter, Abiotrophia, Steroidobacter, Thiohalophilus, Abiotrophia, Achromobacter,
Actinobaculum, Aminobacter, Asticcacaulis, Brucella, Cellulomonas, Deinococcus,
Denitratisoma, Desulfobulbus, Fusibacter, Gallicola, Geobacillus, GpIX, Gracilibacter,
Hydrocarboniphaga, Luteibacter, Marvinbryantia, Pseudolabrys, Pseudoramibacter,
Rhizomicrobium, Rhodococcus, Rhodoplanes, Rhodovulum, Rikenella, Schlegelella, Spirosoma,
Streptomyces, Thiohalobacter, Actinomadura, Alicyclobacillus, Amycolatopsis, Ancylobacter,
Armatimonadetes gp5, Azonexus, Azospirillum, Beijerinckia, Blastochloris, Brevibacterium,
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Catenulispora, Chitinophaga, Cloacibacterium, Curvibacter, Cystobacter, Desulfocapsa,
Desulfuromonas, Dokdonella, Dongia, Enhydrobacter, Gardnerella, Gemmata, Geobacter,
Globicatella, Gp10, Gp17, Haliangium, Kocuria, Hydrogenophaga, Gp17, Haliangium,
Hydrogenophaga,
Kocuria,
Luteolibacter,
Mariprofundus,
Methanococcus,
Methanothermobacter,
Methylococcus,
Methylomonas,
Methylosarcina,
Neisseria,
Novosphingobium, Nubsella, Oxalicibacterium, Parascardovia, Parasporobacterium,
Phaeobacter, Piscicoccus, Planctomyces, Porphyrobacter, Propionivibrio, Prosthecobacter,
Pseudonocardia, Rhodoblastus, Rhodopseudomonas, Saxeibacter, Scardovia, Sediminibacter,
Sharpea, Stella, Syntrophus, Terribacillus, Terriglobus, Truepera, Virgisporangium, and
Zavarzinella).
Beta-diversity measuring the dissimilarity for every pair of samples were calculated based
on the incidence-based Jaccard dissimilarity index and abundance-based Bray-Curtis dissimilarity
index. Then the permutational multivariate analysis of variance test (Adonis) detected the
significant dissimilarity between the baseline and week 52 genus community after both BRS and
LCD treatments. As shown in the two PCA plots, the distance between the baseline and week 52
groups were further than the distances within the baseline and week 52 groups. Also, it showed
that most of the significantly altered genera were increased and were the ones associating with
better obesity or health condition, such as Oscillibacter (Tims et al., 2013, Hu et al., 2015),
Desulfovibrio (Karlsson et al., 2012), Subdoligranulum (Louis et al., 2016) and Akkermansia
(Everard et al., 2013, Schneeberger et al., 2015), and were increased significantly. The number of
the significantly reduced genera was much less and most of them were the ones associating with
worse obesity or health conditions, such as Arsenicicoccus (rho = 0.4636, p = 0.0298 with GLU;
rho = 0.4382, p = 0.0414 with INS; rho = 0.362, p = 0.0978 with TRIG), Parasutterella (Zhang
et al., 2012, Yeom et al., 2016, Dao et al., 2016) and Rudaea. There were a few exceptions, for
example, Bifidobacterium was significantly reduced; its reduction after gastric bypass surgery was
also reported by the other group (Furet et al., 2010) and it was also reported the decreased
Bifidobacterium species after calorie restriction treatment (Santacruz et al., 2009, Queipo-Ortuno
et al., 2013).

Table 5.2.4 Dissimilarity test between the baseline and week 52 genus community in the BRS
group.
BRS_genus
BL vs W52
Jaccard
Bray-Curtis
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Adonis
F
p
1.346 0.042
0.929 0.448

Figure 5.2.7 PCA plots for the genus community at baseline and week 52 in the BRS group.

The similar pattern was shown in the LCD group. The genus community structure at week
52 was significantly different from the genus community structure at week 52 post LCD treatment
based on the dissimilarity test. Also, most of the significantly increased genera belong to
commensal microbes. For example, the significantly increased genera include Streptococcus, wich
produce lactate (Pessione, 2012), Faecalibacterium (Sokol et al., 2008, Machiels et al., 2014),
which produces butyric acid, and Coprococcus which produce both butyrate and acetate, and
commensal genera Subdoligranulum (cor = −0.3667, p = 0.0932 with TRIG; cor = −0.3958, p =
0.0683 with CHOL) and Bilophila (rho = −0.4592, p = 0.0316 with LDL), both of which showed
significant negative correlations with obesity based on correlation tests.

Table 5.2.5 Dissimilarity test between the genus community at baseline and week 52 post LCD.
LCD_genus
Adonis
BL vs W52
F
p
Jaccard
0.742 0.945
Bray-Curtis 1.735 0.095
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Figure 5.2.8 PCA plots for the genus community at baseline and week 52 in the LCD group.

Taken Together, it indicated that the microbial community structure at different taxonomic
levels was significantly altered after both BRS and LCD treatments, and appeared to switch toward
a healthier community with a higher relative abundance of beneficial microbial groups and lower
relative abundance of harmful microbial groups.
5.3 Gut Microbial Community at Different Taxonomic Levels Were Significantly Correlated
with Obesity-related Physiological Variables
We examined the correlation between the entire microbial community structure at different
taxonomic levels and obesity-related physiological variables, using the baseline data from the
combined BRS and LCD groups, with mantel test based on the Euclidean distance matrix. The
result showed that the microbial community at different taxonomic levels was significantly
correlated with the obesity-related variables, including subcutaneous fat size, fat mass, glucose,
and hormones GLP-1, ADP, and ADPHMW (Table 5.3.1).
In addition, the partial mantel test detected that ADPHMW and subcutaneous fat size were
the two main factors that were significantly correlated with the entire microbial community at
OTU level (Table5.3.2).

Table 5.3.1 The correlation between the genus community at different taxonomic levels and
obesity-related variables in the combined BRS and LCD groups at baseline, based on mantel test.
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Table 5.3.2 The correlation between the OTU community and obesity-related variables in the
combined BRS and LCD groups at baseline, based on mantel test.

Table 5.2.10 The partial mantel test detected that the correlation between the entire microbial
community at OTU level and ADPHMW and SubcutMeanSize were still significant when
partialling out ADP, GLU, and GLP-1 respectively.

Next, to examine the correlation between microbial connectivity and obesity, we
constructed the ecology association network through the random matrix theory-based methods
(Deng et al., 2012) using the baseline data in the combined BRS and LCD groups at the genus
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level, and it is visualized by the software Cytoscape (Figure 5.3.1). Then the mantel test was used
to examine the correlation between the genus connectivity and obesity-related physiological
variables, and it detected that the genus connectivity was significantly correlated with fat% and
insulin (Table 5.3.3); it further confirmed the significant correlation between the entire microbial
community and obesity.

Table 5.3.3 Genus connectivity was significantly correlated with fat% and INS at baseline in the
combined BRS and LCD groups.
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Figure 5.3.1 Ecology association network at genus level visualized by the Cytoscape software.

Taken together, it supported that the entire gut microbial community at different taxonomic
levels and microbial connectivity were significantly correlated with obesity, and the hormone
ADPHMW might be one of the important players that were involved in their correlation.
5.4 Microbial Functional Gene Community Structure Was Significantly Altered at Week 7
after BRS and LCD Treatments
To test the hypothesis on gene community structure, beta-diversity of the gene community
structure before and after treatments were calculated for pairs of samples using Jaccard and BrayCurtis dissimilarity indices to make the dissimilarity matrix and was then compared by the Adonis
test. It showed that, at week 7 post treatments, the gene community structure was significantly
altered in both treatment groups, indicating that the two treatments did have a significant effect on
the gut microbial gene community structure. Also, the gene community structure of two treatment
groups at week 7 also became significantly different, considering that there was no detected
significance between these two groups at baseline, indicating that the effect of the alteration of the
gut microbial gene community by the BRS and LCD treatments was significantly different. For
example, these two treatments may have two totally different effects on the gene community, or
two same effects, but the degree of the same effect was significantly different. It suggested that
the underlying mechanisms for the change of gut microbial gene community after the two
treatments might be significantly different.

Table 5.4.1 Gene community structure was significantly altered at week 7 after BRS and LCD
treatments, and at week 7 post treatments, the BRS gene community was significantly different
from the LCD group.
Gene community
BRS_BL vs W7
Jaccard
Bray-Curtis

Adonis
F
p
1
0.08
1.6 0.07

Gene community
LCD_BL vs W7
Jaccard
Bray-Curtis

Gene community
BRS vs LCD_W7
Jaccard
Bray-Curtis

Adonis
F
p
3.8
0.04
2.35 0.07

Adonis
F
p
2.66 0.06
1.53 0.18

To examine how the gene community was altered at week 7 after both BRS and LCD
treatments, we compared the gene richness and diversity but did not find they were significantly
altered in both groups. Then we examined the relative abundance of the gene communities under
different gene categories and found that many of them were significantly altered at week 7, and
this may explain the significantly altered gene community structure.

81

Next, we examined how the week 7 BRS group was significantly different from the week
7 LCD group, by comparing the richness and alpha diversity of the gene community. As shown in
the figure, at week 7 post treatments, the gene richness in the BRS group was significantly higher,
with about 2000 more genes on average, compared to the LCD group. The alpha diversity was also
significantly higher in the BRS group than in the LCD group as measured by Shannon index and
inversed Simpson index. It indicated that no matter what kind of mechanisms contributed to the
significant alteration of the gene community structure involved in the BRS and LCD treatments,
the BRS treatment had a better effect on gene community structure than the LCD group.

Figure 5.4.1 Gene richness was significantly higher at week 7 in the BRS group than the LCD
group.

Figure 5.4.2 Gene diversity was significantly higher at week 7 in the BRS group than the LCD
group.

The above results indicated that accompanying with significant obesity improvement at
week 7 after both BRS and LCD treatments, the microbial functional gene community structure
became significantly different from the baseline. Moreover, the functional gene community
structure at week 7 was significantly different between the BRS and LCD groups, with
significantly higher gene richness and gene diversity in the BRS group.
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5.5 Functional Microbial Gene Community Was Significantly Correlated with Obesityrelated Physiological Variables
Considering that at week 7 post treatments, the BRS group showed significantly lower
levels of GHR and GHRA (Figure 5.5.1). It indicated that the significantly lower GHR and GHRA
in the BRS group than the LCD group might be linked to the significantly higher microbial gene
richness and diversity in the BRS group than the LCD group). Thus, we examined the correlation
between gene richness and diversity, and obesity-related physiological variables by using the
baseline data from the combined BRS and LCD groups, with the non-parametric spearman rank
correlation test. The result showed that both gene richness and diversity were significantly
negatively correlated with hunger hormone ghrelin (GHR) and its active form GHRA (Table 5.5.1
and Table 5.5.2).

Figure 5.5.1 At week 7 post treatment, GHR and GHRA was significantly lower in the BRS group
than the LCD group.

Table 5.5.1 Gene richness was significantly negatively correlated with GHRA and GHR.
Gene richness
BRS+LCD_BL
GHRA
GHR

Spearman
rho
p
−0.53 0.04
−0.41 0.09

Table 5.5.2 Alpha diversity of the functional microbial gene community measured by Shannon
index was significantly negatively correlated with GHRA and GHR.
Shannon
BRS+LCD_BL
GHRA
GHR

Spearman
rho
p
−0.53 0.04
−0.41 0.09

Next, the correlation between the entire functional microbial gene community and
physiological variables was examined by mantel test, and it showed that the entire functional
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microbial gene community was significantly correlated with obesity-related hormones, including
ADP, ADPHMW, and GHRA (Table 5.5.3).

Table 5.5.3 The entire microbial gene community was significantly correlated with ADP,
ADPHMW, and GHRA.
Gene community
BRS+LCD_BL
ADP
ADPHMW
GHRA

Mantel test
r
p
0.31 0.06
0.22 0.07
0.27 0.09

Next, mantel test was also applied to check the correlations between each gene community
under different gene categories and obesity-related physiological variables, and the result showed
that over half of them were shown significant correlations with obesity-related physiological
variables. These gene categories showing significant correlations with obesity-related
physiological variables include the gene categories involved in the metabolism of amino acid, lipid,
energy, carbohydrate, glycan, cofactors and vitamins, and antibiotic resistance. We also noticed
that the gene communities involved in metabolisms of short-chain fatty acids, such as acetate
kinase, propionate kinase, butyrate kinase, L-lactate dehydrogenase, and acetyl-CoA
acyltransferase were also significantly correlated with obesity-related variables. These results
supported that functional microbial gene communities under over half of the gene categories
involved in gut microbial metabolisms were significantly correlated with obesity.
5.6 Conclusions
In summary, accompanying with significant obesity improvement after the BRS and LCD
treatments, microbial community structure was significantly altered. First, microbial richness and
diversity were significantly increased after both treatments, with the BRS group showing a higher
degree of increase of the microbial richness and diversity than the LCD group. Second, microbial
distribution and compositions at different taxonomic levels were switched toward a healthier
profile with increased beneficial microbial groups and reduced harmful groups. Third, the
functional microbial gene community was significantly altered at week 7 after both BRS and LCD
treatments, with significantly higher gene richness and gene diversity at week 7 post treatment in
the BRS group than the LCD group.
In addition, the entire microbial community structure at different taxonomic levels was
significantly correlated with obesity-related variables, and ADPHMW might be an important
contributing factor that linked their correlation. Also, over half of the gene categories involved in
gut microbial metabolisms were significantly correlated with obesity-related physiological
variables, and the entire functional microbial gene community was significantly correlated with
obesity-related hormones, including ADP, ADPHMW, and GHRA, with gene richness and gene
diversity significantly negatively correlated with GHR and GHRA.
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CHAPTER SIX: GENUS AKKERMANSIA WAS SIGNIFICANTLY
INCREASED AFTER BARIATRIC SURGERIES AND CORRELATED
WITH OBESITY
6.1 Abstract
Mechanisms underlying the weight loss effect of bariatric surgery are not fully understood.
Recently, several studies suggested that Akkermansia may play a role in obesity in mammalian
models; however, limited relevant research has been conducted in human subjects. This study aims
to investigate the correlation between genus Akkermansia and obesity and how Akkermansia was
involved in obesity improvement after BRS and LCD treatments. We hypothesize that the relative
abundance of gut Akkermansia is increased after BRS treatment and associated with obesity
improvement.
In the bariatric surgery participants, obesity improvement was significantly improved, and
the relative abundance of gut Akkermansia was significantly increased at week 52 post-BRS.
Significant negative correlations were observed between the relative abundance of gut
Akkermansia and ADPHMW, PYY and fat%. Similar correlations were also seen between changes
in the relative abundance of gut Akkermansia and changes in several obesity-related physiological
variables after BRS. Significant negative correlations were shown between the change of the
relative abundance of Akkermansia and change of weight, IDXA weight, IDXA fat mass, IDXA
lean mass, BMI, 24HourEE, GLU, INS, and GHRA. Significant positive correlations were shown
between the change of the relative abundance of gut Akkermansia and change of high-dose glucose
rate (GDR2/Weight). Change in the relative abundance of Akkermansia was also positively
correlated with percentage excess weight loss (% EWL), ADP, ADPHMW, GLP-1, and PYY.
The well-known effect of bariatric surgery to reduce body weight was paralleled by an
increase in the relative abundance of gut Akkermansia. The significant inverse correlation between
the relative abundance of gut Akkermansia and human obesity indicates that a decrease in weight
loss caused by bariatric surgery may increase gut Akkermansia’s relative abundance, which may,
in turn, further foster weight loss and forms a positive loop contributing to the maintenance of
weight loss.
6.2 Introduction
In 2004, the Akkermansia muciniphila MucT strain was isolated from a human intestinal
tract and its physical and genetical information was characterized (Derrien et al., 2004). It was
reported that Akkermansia muciniphila MucT strain is non-motile, Gram-negative, strictly
anaerobic, chemo-organotrophic, and mucolytic, and the cells can use mucin as a carbon, nitrogen,
and energy source, and release sulfate in a free form from fermenting mucin (Derrien et al., 2004).
In 2011, based on 37 human GI tract metagenome libraries, Mark’s group found that the
relative abundance of Akkermansia (abundance of Akkermansia’s 16S rDNA divided by the total
abundance of 16S rDNA) varied from less than 0.01% to 4%, and 30% of the 37 libraries contained
Akkermansia species shared greater than 95% similarity of the 16S rRNA gene sequence with A.
muciniphila, and eight distinct species of the genus Akkermansia were discovered. They also found
that A. muciniphila’s genome contains many mucinase-encoding gene candidates, supporting the
proposed mucin-degrading capability of Akkermansia (van Passel et al., 2011).
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Next, increasing number of studies indicate that Akkermansia residing in human GI tract
may participate in obesity regulation. In 2013, Patrice’s group reported that A. muciniphila
abundance decreased in both genetically leptin-deficient obese mice and high-fat-fed (HF-fed)
mice (Everard et al., 2013), and administration of viable A. muciniphila improved metabolic profile
of HF-fed mice, including ameliorated diet-induced fasting hyperglycemia by a mechanism related
to glucose-6-phosphatase expression shrink in liver, the indication being that there had been a
reduction of gluconeogenesis, and reduced the insulin resistance index, increased the levels of
adipocyte differentiation and lipid oxidation marker (but not lipogenesis markers), and offset the
diminution of the mucus layer (Everard et al., 2013). The involved mechanism might include that
A. muciniphila administration raised intestinal levels of acylglycerols, including 2-oleoylglylcerol
(2-OG), 2-arachidonoylglycerol (2-AG), and 2-palmitoylglycerol (2-PG), which are involved in
intestinal and glucose homeostasis, such as inflammation, gut barrier, and gut peptide secretion
(Everard et al., 2013).
In 2014, the Bae’s group reported that after HFD-fed mice were treated with metformin,
the abundance of the mucin-degrading genus Akkermansia and the number of mucin-producing
goblet cells was significantly increased (Shin et al., 2014). Also, administration of Akkermansia to
HFD-fed mice without metformin treatment significantly increased glucose tolerance and
attenuated adipose tissue inflammation by inducing adipose tissue-resistant CD4 Foxp3 regulatory
T cells (Shin et al., 2014).
In 2014, the Roeselers’s group reported that A. muciniphila and its metabolites propionate,
modulate the levels of expression of important regulators of lipolysis, satiety, transcription factor,
and cell cycle control, including Fasting-induced adipose factor (Fiaf), G protein-coupled receptor
43 (Gpr43), histone deacetylases (HDACs), and peroxisome proliferator-activated receptor
gamma (Pparγ) in the intestinal epithelial organoids of mice (Lukovac et al., 2014). Dao et al.
(2016) have also reported that A. muciniphila was related to a healthier metabolic status and better
clinical outcomes after calorie restriction in overweight or obese adults (Dao et al., 2016).
Based on the above findings, we hypothesize that genus Akkermansia might have increased
after bariatric surgeries and associated with the substantial and persistent obesity improvement
after bariatric surgeries.
6.3 Genus Akkermansia Was Associated with Better Health Status
To examine the correlation between Akkermansia and obesity-related variables at baseline,
we first median split the participants into the group with lower Akkermansia abundance and the
group with higher Akkermansia abundance, and then the non-parametric Wilcoxon rank sum test
was used to detect whether the physiological variables in these two group were significantly
different, and the result showed that a number of physiological variables (weight, IDXA weight,
fat mass, IDXA fat mass, lean mass, 24HourEE and HDL) showed significantly better conditions
in the higher Akkermansia group than the lower Akkermansia group (Figure 6.3.1). The similar
pattern was observed when the diabetic participants were not included in the analysis (Figure 6.3.2).
These results indicated that the individuals whose GI tract harbored a higher relative abundance of
genus Akkermansia had lighter obesity conditions, indicated that Akkermansia was associated
better health condition.
In addition, the non-parametric Spearman and parametric Pearson correlation tests detected
that Akkermansia was significantly correlated with better conditions of hormones PYY, GLP-1
and ADPHMW (Table 6.3.1). When applying the partial correlation test for checking the
correlations between each hormone and Akkermansia when partialling out the other two factors,
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these three factors still show significant correlations with Akkermansia, indicating that their
correlations with Akkermansia were independent (Table 6.3.2). The similar pattern was observed
when the diabetic participants were not included, but fat% replaced ADPHMW (Table 6.3.3).
These results further confirmed the significant negative correlation between Akkermansia and
obesity conditions.

Figure 6.3.1 The higher Akkermansia group showed better obesity conditions. Diabetic
participants were included in the analysis.
Table 6.3.1 Akkermansia at baseline in the combined BRS and LCD group showed significant
correlation with obesity-related hormones. Diabetic participants were included in the analysis.
BL_BRS+LCD
Akk
PYY
GLP-1
ADPHMW

Spearman
rho
p
0.29
0.278
0.191 0.395
0.29
0.236

Pearson
cor
p
0.558 0.007
0.527 0.012
0.395 0.069

Table 6.3.2 Partial correlation test showed that Akkermansia at baseline in the combined BRS and
LCD group were significantly correlation with each hormone when controlling the other two
hormones. Diabetic participants were included in the analysis.
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Partial correlation
rho
Spearman
p
cor
Pearson
p

ADPHMW
0.3692
0.1091
0.5489
0.0122

PYY
0.3797
0.0987
0.7077
0.0005

GLP-1
−0.1237
0.6032
0.4117
0.0713

Figure 6.3.2 The higher Akkermansia group showed better obesity conditions. Diabetic
participants were not included in the analysis.
Table 6.3.3 Akkermansia at baseline in the combined BRS and LCD group showed significant
correlation with obesity-related hormones. Diabetic participants were not included in the analysis.
BRS+LCD_BL (No DM)
Akk
Fat%
PYY
GLP-1

Spearman
rho
p
-0.485 0.048
0.29
0.202
0.031
0.893

Pearson
cor
p
-0.421 0.092
0.661
0.001
0.47
0.032

6.4 Genus Akkermansia Was Increased after BRS and Associated with Obesity Improvement
6.4.1 Genus Akkermansia Was Significantly Increased after BRS
Considering that the relative abundance of Akkermansia was not shown as normally
distributed, non-parametric sign test was performed to check whether there was a significant
alteration of the relative abundance of Akkermansia after BRS treatment. The result showed that
the relative abundance of gut Akkermansia was significantly enhanced (p = 0.0654) from the
baseline level of 1.21% (std = 2.18%) to 2.36% (std = 2.35%) at week 52 after bariatric surgeries.
Meantime, we observed that weight was significantly reduced (p = 0.001) from the baseline of
132.45 kg (std = 17.95 kg) to week 52 of 89.12 kg (std = 13.61 kg).

88

Figure 6.4.1.1 The relative abundance of Akkermansia (column plot) was significantly increased,
accompanying with the significant weight reduction (line plot) at week 52 post-BRS. The error
bars were made based on the standard errors. The sign test was used to calculate the p values.
6.4.2 Increase of Akkermansia after BRS Was Significantly Associated with Obesity
Improvement
That the coincidence of significant weight loss after BRS and significantly increased
relative abundance of Akkermansia suggested that there could be correlations between the relative
abundance of Akkermansia and obesity status. Then, correlation tests were performed to check
the correlations between the change of Akkermansia (Akk) after BRS and change of obesity-related
physiological variables. The results showed that change of Akk at week 7 post-BRS was
significantly positively correlated with obesity-related hormones including ADP, ADPHMW, and
PYY, while significantly negatively correlated with hormone GHRA (Table 6.4.2.1), indicating
the change of Akk at week 7 was associated with improvement of obesity-related hormones. Also,
it showed that change of week 52 post-BRS was significantly negatively correlated with change
in fasting glucose and insulin levels (Table 6.4.2.2), indicating the increase of Akk at week 52 after
BRS was associated with improvement of insulin resistance.

Table 6.4.2.1 Change of Akkermansia during baseline and week 7 post-BRS showed significant
correlations with the improvement of obesity-related hormones.
BRS_W7−BL
∆ Akk
∆ ADP
∆ ADPHMW
∆ GHRA
∆ PYY

Spearman
rho
p
0.38
0.31
0.21
0.59
−0.68 0.06
0.61
0.08

Pearson
cor
p
0.76
0.02
0.7
0.04
−0.51 0.19
0.36
0.35

Table 6.4.2.2 Change of Akkermansia during baseline and week 52 post-BRS showed significant
correlations with the improvement of GLU and INS.
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BRS_W52−BL
∆ Akk
∆ GLU
∆ INS

Spearman
rho
p
−0.57 0.07
−0.55 0.09

After combining all the changes of Akkermansia during baseline and week 7, during
baseline and week 52, and during week 7 and week 52 post BRS, and then check their correlation
with the corresponding change of obesity-related physiological variables, the result showed that
the change of the relative abundance of genus Akkermansia was significantly negatively correlated
with change in the fasting glucose level (Table 6.4.2.3) (the combination was also validated by
ANCOVA tests). As shown in the regression plot (Figure 6.4.2.1), the change of Akkermansia
after BRS was significantly negatively correlated with the change of fasting glucose level; greater
increase of the relative abundance of genus Akkermansia after BRS, greater reduction of the fasting
glucose level. It further confirmed that increase in the relative abundance of Akkermansia after
BRS was associated with obesity improvement, and it also indicated that obesity-related hormones
(ADP, ADPHMW, GHRA, and PYY) might be important factors that linked their association.

Table 6.4.2.3 The correlation between change of Akkermansia and change of GLU after BRS
treatment.
BRS_W7−BL, W52−BL, W52−W7

Δ Akk

Δ GLU

Spearman

rho
p
cor
p

−0.41
0.03
−0.45
0.02

Pearson
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Figure 6.4.2.1 The regression plot showed that a greater increase of Akkermansia was associated
with a greater reduction of GLU.
6.4.3 Change of Akkermansia Was Significantly Negatively Correlated with Change of
Obesity Condition
We did not observe significant alteration of the relative abundance of genus Akkermansia
after the LCD treatment. However, after combining the BRS and LCD groups, the change of
Akkermansia at week 7 and week 52 still showed significant negative correlation with a change in
obesity.
After median splitting the participants based on the change of the relative abundance of
genus Akkermansia, the group with higher change of the relative abundance of genus Akkermansia
at week 7 after BRS and LCD treatments showed significantly greater improvement of GLP-1 and
PYY levels, than the group with lower change of the relative abundance of Akkermansia (Table
6.4.3.1). Also, the change of the relative abundance of genus Akkermansia at week 7 after BRS
and LCD treatments showed significant positive correlations with a change of GLP-1 and PYY
(Table 6.4.3.2), indicating a significant correlation between change of Akkermansia and
improvement of obesity-related hormones at week 7 after BRS and LCD treatments.
Moreover, the group with a higher change of the relative abundance of genus Akkermansia
at week 52 after BRS and LCD treatments showed significantly greater improvement of obesityrelated physiological variables, including weight, IDXA weight, EWL, BMI, GLU, INS,
GDR1/Weight, GDR2/Weight, and TRIG (Table 6.4.3.3). Also, the change of the relative
abundance of genus Akkermansia at week 52 after BRS and LCD treatments showed significant
negative correlations with change of weight, GLU, and INS, and significant positive correlation
with change of GDR2/Weight (Table 6.4.3.4), indicating the significant negative correlation
between change of Akkermansia and change of obesity condition at week 52 post BRS and LCD
treatments.

Table 6.4.3.1 The group with a higher change of the relative abundance of genus Akkermansia at
week 7 after BRS and LCD treatments showed significantly greater improvement of GLP-1 and
PYY levels.
BRS & LCD
W7−BL
∆ GLP-1
∆ PYY

Low ∆ Akk
Mean Std
−0.35 0.64
−21
24

High ∆ Akk
Mean
Std
0.37
0.94
17
31.14

Wilcoxon rank sum
p
0.067
0.032

Table 6.4.3.2 Change of Akkermansia during baseline and week 7 in the combined BRS and LCD
groups showed significant correlation with a change of GLP-1 and PYY.
BRS & LCD_W7−BL
Δ Akk
Δ GLP-1
Δ PYY
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Spearman
rho
p
0.55 0.05
0.59 0.03

Table 6.4.3.3 The group with a higher change of Akkermansia during baseline and week 52 in
the combined BRS and LCD groups showed significantly better obesity conditions.
BRS & LCD
W52−BL
∆Weight
∆ IDXA weight
EWL
∆ BMI
∆ GLU
∆ INS
∆ GDR1/Weight
∆ GDR2/Weight
∆ TRIG

Low Δ Akk
Mean Std
−15
20
−16
20
32
43
−6
7
−4
6
−1
5
1
2
2
3
−11
40

High Δ Akk
Mean Std
−45
13
−40
19
69
24
−16
5
−18
11
−8
8
2
1
6
3
−61
67

Wilcoxon rank sum
p
0.004
0.017
0.055
0.012
0.004
0.079
0.059
0.009
0.079

Table 6.4.3.4 Change of Akkermansia at week 52 after BRS and LCD treatments showed
significant correlation with a change of obesity condition.
BRS & LCD_W52−BL
Δ Akk
Δ Weight
Δ GLU
Δ INS
Δ GDR2/Weight

Spearman
rho
p
−0.49
−0.66
−0.52
0.45

0.039
0.002
0.023
0.061

Additionally, after combination of the change of the relative abundance of Akkermansia
during baseline and week 7, during baseline and week 52, and during week 7 and week 52 post
BRS and LCD treatments, change of the relative abundance of Akkermansia after BRS and LCD
treatments showed significant correlations with improvements of obesity-related physiological
variables, including weight, BMI, and GLU (the combination was also validated by the ANOVA
test). As shown in the regression plot (Figure 6.4.3.1), change of Akkermansia after BRS and LCD
treatments was significantly negatively correlated with the change of GLU; the greater increase of
the relative abundance of genus Akkermansia, the greater reduction of GLU after BRS and LCD
treatments. It further confirmed the negative correlation between change of Akkermansia and
change of obesity condition after BRS and LCD treatments.
Table 6.4.3.5 Change of Akkermansia after BRS and LCD treatments showed significant
correlations with improvements obesity-related physiological variables.
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BRS & LCD_W7−BL, W52−W7, W52−BL

Δ Akk
rho
p
cor
p

Spearman
Pearson

Δ Weight
−0.2934
0.0562
−0.2524
0.1024

Δ BMI
−0.3044
0.0472
−0.2577
0.0953

Δ GLU
−0.3912
0.0087
−0.4027
0.0067

Figure 6.4.3.1 The regression plot showed the significant negative correlation between change in
the relative abundance of Akkermansia and change of GLU after BRS and LCD treatments.
In addition, no significant difference of the obesity-related physiological variables was
observed between the BRS and LCD groups at baseline, but the BRS group showed significantly
more improvement of the obesity-related physiological variables, when comparing with the LCD
group, including significantly more reduction of weight (p = 8.16E−06), IDXA weight (p =
2.71E−06), fat mass (p = 0.0012), IDXA fat mass (p = 0.0001), IDXA lean mass (p = 0.0194),
fat% (p = 0.0001), 24HourEE (p = 0.0011), BMI (p = 8.16E−06), IDXA BMI (p = 2.72E−06),
GLU (p = 0.0141), INS (p = 0.0143), TRIG (p = 0.0017), LEP (p = 0.0064) and hsCRP (p =
0.061), and significant more increase of GDR1/Weight (p = 0.0024), GDR2/Weight (p = 0.0011),
HDL (p = 0.0087), ADP (p = 0.0926), and ADPHMW (p = 0.0007). Meanwhile, there was no
significant difference of the relative abundance of the genus Akkermansia between the BRS and
LCD group at baseline; however, at week 52 post treatment, the BRS group showed a significantly
higher relative abundance of Akkermansia than the LCD group (p = 0.0059). Also, the increase of
the relative abundance of the genus Akkermansia during baseline to week 52 in the BRS group
was significantly higher than the LCD group (p = 0.0317). In short, there was no significant obesity
difference between BRS and LCD group at baseline, but after treatments, the improvement of
obesity and increase of relative abundance of Akkermansia after BRS were both significantly
higher than the LCD group. It supports that significant increase of the relative abundance of genus
Akkermansia may be involved in the substantial and persistent weight loss process induced by
bariatric surgeries.
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6.4.4 Other than Akkermansia muciniphila, There Might be Other Akkermansia Species
Contributing to the Significant Increase of Genus Akkermansia after BRS
The Illumina sequencing result detected 42 different OTUs belonging to the genus
Akkermansia using 97% nucleotide sequence similarity as the clustering threshold. It was further
confirmed by using the online software nucleotide baselineAST (Basic Local Alignment Search
Tool) (baselineASTN 2.5.0+) (Zhang et al., 2000) to search these 42 OTU sequences
(http://blast.ncbi.nlm.nih.gov/Blast.cgi)
against
the
database
rRNA_typestrains/prokaryotic_16S_ribosomal_RNA (16S ribosomal RNA (Bacteria and
Archaea)) (16S ribosomal RNA sequences from bacteria and archaea; update date: 2016/08/02;
number of sequence: 18928)) for identifying them and found that the resulted top hit for all of
them are Akkermansia muciniphila strain ATCC BAA-835 16S ribosomal RNA gene (Accession
NR_074436.1) or Akkermansia muciniphila strain Muc 16S ribosomal RNA gene
(Accession NR_042817.1), but many of their nucleotide sequence similarity were lower than 97%.
That we detected 42 Akkermansia OTUs in total, and most of them were altered to the same
direction after BRS, indicating that the increase of genus Akkermansia may be also owing to the
other Akkermansia species, besides the known species Akkermansia muciniphila.
6.4.5 Quantitative PCR Results Showed the Similar Patterns as the Above-mentioned
Illumina Sequencing Results
The quantitative PCR result showed the similar pattern as Illumina sequencing results. At
baseline, the group with a higher abundance of Akkermansia had significantly smaller
subcutaneous fat size than the group with lower Akkermansia abundance (Table 6.4.5.1), and the
baseline relative abundance of Akkermansia was significantly positively correlated with hormones
ADP and ADPHMW (Table 6.4.5.2).

Table 6.4.5.1 The group with a higher abundance of genus Akkermansia showed significant
smaller subcutaneous fat size than the group with lower Akkermansia abundance.

BRS+LCD_BL
Low Akk
High Akk

SubcutMeanSize
1.37
0.32
1.11
0.31

Wilcoxon rank sum (p)
0.09

Table 6.4.5.2 At baseline, the relative abundance of genus Akkermansia showed significant
positive correlations with ADP and ADPHMW.
BRS+LCD_BL

Akkermansia

ADP

ADPHMW

Pearson

cor
p

0.5
0.04

0.53
0.03

In addition, the qPCR result showed that the relative abundance of genus Akkermansia was
significantly increased at both week 7 and week 52 post BRS treatment (Figure 6.4.5.1 and Figure
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6.4.5.2), and the change of Akkermansia after BRS showed significant correlations with the
improvement of several obesity-related physiological variables, including weight, IDXA weight,
IDXA fat mass, IDXA lean mass, BMI, 24HourEE, GLU, INS and GHRA (Figure 6.4.5.3). These
results further confirmed the negative correlation between Akkermansia and obesity.

Figure 6.4.5.1 The relative abundance of Akkermansia was significantly increased at week 7 after
BRS.

Figure 6.4.5.2 The relative abundance of Akkermansia was significantly increased at week 52 after
BRS.
Table 6.4.5.3 Change of Akkermansia after BRS showed significant negative correlations of
change of obesity conditions, including weight, IDXA weight, IDXA fat mass, IDXA lean mass,
BMI, 24HourEE, GLU, INS, and GHRA.
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BRS
∆ Akk
∆ Weight
∆ IDXA weight
∆ IDXA fat
∆ IDXA lean
∆ BMI
∆ 24HourEE
∆ GLU
∆ INS
∆ GHRA

Spearman
rho
p
−0.29
0.226
−0.24
0.329
−0.13
0.613
−0.67
0.003
−0.27
0.26
−0.38
0.119
−0.23
0.336
−0.72 5.26E−04
−0.73 8.70E−04

Pearson
cor
p
−0.46
0.047
−0.42
0.077
−0.42
0.094
−0.58
0.015
−0.47
0.042
−0.41
0.093
−0.43
0.069
−0.65
0.003
−0.78 2.16E−04

6.5 Conclusions
In conclusion, the relative abundance of genus Akkermansia was significantly correlated
with better health status, and it was significantly increased after the BRS, accompanying with the
substantial and long-lasting effect of obesity improvement. Also, alteration of the relative
abundance of Akkermansia was significantly negatively correlated with alterations of obesity
condition, and the obesity-related hormones might be important factors that contribute to their
correlation.
It indicates that bariatric surgeries may directly or indirectly cause the increase of the
relative abundance of genus Akkermansia, which may, in turn, further boost the obesity-improving
effect of BRS, forming a positive loop contributing to their persistent effects in alleviating obesity
conditions. In addition, the obesity-related hormones might be involved in the correlation between
Akkermansia and obesity. For example, Akkermansia might contribute to the improvement of
obesity and insulin resistance after BRS treatment through improving the levels of obesity-related
hormones such as ADP, ADPHMW, PYY, and GHRA.
Moreover, based on our observation of several different OTUs in the genus Akkermansia,
we conclude that except for Akkermansia muciniphila, there may exist other Akkermansia species
contributing to the increase in the relative abundance of genus Akkermansia after BRS.
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CHAPTER SEVEN: THE AMOUNT AND CONSTITUTION OF SHORTCHAIN FATTY ACIDS (SCFAS) WERE SIGNIFICANTLY ALTERED
AFTER TREATMENTS
7.1 Abstract
Bariatric surgeries have been shown to be efficient in reducing obesity, but the underlying
mechanisms have not been completely disclosed. Meanwhile, increasing evidence has shown that
human gut microbiota is involved in obesity, and their metabolites, i.e., short-chain fatty acids
(SCFAs), might be one of the factors that link their correlation. We hypothesize that the
concentration and composition of SCFAs are altered after BRS, and may contribute to its
substantial and persistent obesity alleviation effect. Here we used a microFAST™ gas
chromatography (GC) to quantitate the concentrations of SCFAs and compare their levels in
participants before and after BRS and LCD treatments. The result showed that the total SCFAs
was significantly decreased at week 52 after both treatments, and the acetate concentration was
significantly reduced at week 7 and week 52 after both BRS and LCD treatments. In addition, after
BRS treatment, the percentage of acetate (the ratio of acetate concentration to total SCFAs
concentration) was significantly reduced during baseline and week 7, baseline and week 52, and
week 7 and week 52, respectively, while the percentage of propionate was significantly increased
during week 7 and week 52 and the percentage of butyrate was significantly increased during
baseline and week 52. We also identified some butyrate-producing genera and propionateproducing genera which were significantly increased after BRS and LCD treatments. These
bacteria may have potential to be developed as probiotics for sustaining weight loss.
7.2 Introduction
SCFAs are saturated aliphatic organic fatty acids with fewer than 6 carbon atoms and they
are mainly formed by gut microbial fermentation of carbohydrates, proteins, peptides and amino
acids (Gibson et al., 1996). About 95% of SCFAs are composed of acetate (C2), propionate (C3),
and butyrate (C4) with a ratio of 3:1:1 (Puddu et al., 2014). They are absorbed by the colonic
mucosa and metabolized by the host to provide up to 5-10% of total energy intake in healthy
individuals (Du et al., 2010); they contribute to 60-80% of the colon’s energy requirement, with
butyrate as the primary energy source for colonocytes. The ones that escape metabolism in the
colon may enter the hepatic portal blood or be excreted with feces. It was reported that the amount
of total SCFAs was significantly higher in obese human subjects than the lean counterparts. The
reduced luminal pH by SCFAs may help counteract against pathogenic microbes (Alicia and
Mercedes 2013), stimulate mineral absorption through increased mineral solubility (Younes et al.,
1996, Coudray et al., 1997), and reduce secondary bile acid formation (Macdonald et al., 1978),
which may accumulate as a result of enterohepatic circulation, leading to GI problems, such as the
formation of gallstone and colonic cancer (Jason et al. 2006). Also, different SCFAs can have
different physiological effects. Acetate is less metabolized in the colon and is easy to be absorbed
and transported to the liver (Cook and Sellin, 1998); it is a substrate for lipogenesis and cholesterol
synthesis (Wong et al., 2006). Propionate can prevent GI inflammation, lower fatty acid production
in liver (Nishina and Freedland, 1990, Demigne et al., 1995) and plasma (Chen et al., 1984,
DiCostanzo et al., 1999), and improve insulin resistance (Al-Lahham et al., 2010). Butyrate
contributes to about 70% total energy demand of colon and can stimulate the growth of colonic
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mucosa. It also showed a preventive and remedial effect in colonic diseases such as colonic
ulcerative colitis and colon cancer (Canani et al., 2011), and diet-induced insulin resistance (Gao
et al., 2009). In addition, propionate and butyrate can function as signaling molecules to interact
with their intestinal receptors in intestinal epithelial cells, inducing the release of gut hormones
GLP-1 and PYY, both of which can signal brain the feeling of satiety (Lin et al., 2012, Kuwahara,
2014). Therefore, we hypothesize that the amount and constitution of SCFAs are altered after BRS
treatment, with reduced acetate and increased propionate and butyrate, and their alteration may
contribute to the efficient obesity alleviation effect by bariatric surgeries.
7.3 Retention Time and Calibration Curve for Each SCFA
The retention time (RT: the time from injection to elution) for each SCFA (acetate,
propionate, and butyrate) was obtained from the respective gas chromatogram after injection of
the standard solution containing only one type of SCFA into the GC instrument, and the RTs are
shown in table 7.3.1. Usually, the compound with a smaller molecular weight elutes out earlier
than the compound with a larger molecular weight and thus has a shorter RT. The standard curve
for each SCFA was produced based on 6 data sets of known concentrations and their corresponding
GC peak areas of the standard solutions for each SCFA, which distributes evenly in the range that
covers the measurements of the real samples. GC has different detection specificities for each
SCFA, so the selected 6 sets of standard concentrations for each SCFA may not always be the
same.
Table 7.3.1 Retention time for each SCFA.
SCFAs
Retention time (seconds)
Acetate
8.6
Propionate
17.5
Butyrate
22.0
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Figure 7.3.1 The calibration curve for each SCFA.
7.4 Concentrations of Total SCFAs and Acetate Were Significantly Reduced after both BRS
and LCD Treatments
The total SCFAs amount in the BRS group was significantly reduced at week 52 post
treatment (mean = 515.59 ppm, std = 170.21 ppm) when compared with the baseline level (mean
= 737.79 ppm, std = 382.98 ppm) (p = 0.1094 by Wilcoxon signed rank test, and p = 0.0724 by
paired t-test) (Figure 7.4.1). In addition, the total SCFAs amount was significantly reduced (p =
0.0781 by Wilcoxon signed rank test, and p = 0.0612 by paired t-test) at week 52 in the combined
RYGB and SGx group, and it also showed the tendency to decrease at week 7 based on the
observation that 6 out of 7 individuals in the combined RYGB and SGx group showed reduced
total SCFA at week 7. This observation was similar to the pattern reported previously that total
SCFAs tended to decrease 9 years after bariatric surgeries (Tremaroli et al., 2015). Considering
that BRS treatment reduced the amount of total food intake, as well as its absorption, and the food
is the main source of the gut microbial production of total SCFAs, it is reasonable that after BRS
treatment the amount of total SCFAs was significantly reduced. The SCFAs extract extra energy
from the indigestible and non-digested food and provide more energy to the host, and thus increase
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the harvesting efficiency of the host. It has been reported that the amount of total SCFAs was
positively correlated with obesity and was reduced after gastric bypass and gastric band surgeries
(Tremaroli et al., 2015).

Figure 7.4.1 Total SCFAs concentration was significantly reduced at week 52 post-BRS treatment.

Similarly, there was a significant reduction of total SCFAs at week 52 post LCD treatment
(mean = 474.49 ppm, std = 215.42 ppm), when compared with the baseline level (mean = 646.44
ppm, std = 286.82 ppm) (p = 0.0391 by Wilcoxon signed rank test) (Figure 7.4.2). In addition,
total SCFAs in the four individuals, whose baseline and week 7 data of total SCFAs were available,
were all reduced although the p values calculated by Wilcoxon signed rank and sign test were both
0.125. That the increase cannot be determined as statistically significant could be caused by the
small sample size of 4. These results indicated that the LCD treatment might be associated with
the reduction of the amount of total SCFAs. Since the LCD treatment reduced the total food intake
of the participants and food is the main source of gut microbial production of SCFAs, it is
reasonable that the amount of total SCFAs was significantly reduced after the LCD treatment.

Figure 7.4.2 Total SCFAs concentration was significantly reduced at week 52 post-LCD treatment.
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Given that SCFAs can supply more energy to individuals and that obese individuals have
a higher total SCFAs amount than the lean group, the significantly reduced total SCFAs after both
BRS and LCD treatments might have also contributed to the obesity alleviation.
Moreover, the acetate concentration of the BRS group was significantly reduced at week 7
(mean = 330.12 ppm, std = 235.16 ppm) when compared with the baseline level (mean = 452.56
ppm, std = 305.25 ppm) (p = 0.0703 by sign test) (Figure 7.4.3). The significant reduction was
also observed at week 52 (mean = 191.59 ppm, std = 15.36 ppm), when compared with the week
7 level (mean = 248.28 ppm, std = 54.50 ppm) (p = 0.0469 by Wilcoxon signed rank test) (Figure
7.4.3). Significant reduction was observed at week 52 as well (mean = 195.93 ppm, std = 28.52
ppm), when compared with the baseline level (mean = 384.90 ppm, std = 283.94 ppm) (p = 0.0039
by Wilcoxon signed rank test). In summary, the results showed that acetate concentration was
significantly reduced from the baseline to week 7, week 7 to week 52, and baseline to week 52
after BRS treatment. The pattern of change of acetate concentration after BRS treatment was
similar to the pattern of change of obesity condition, which was significantly reduced during the
three periods after BRS treatment. The results indicated that the reduced obesity after BRS might
be linked to the reduced acetate concentration.

Figure 7.4.3 Acetate concentration was significantly reduced during baseline and week 7, and
week 7 and week 52, and baseline and week 52 in the BRS group.

Similar to BRS, LCD significantly reduced the acetate concentration at week 7 (mean =
238.81 ppm, std = 82.87 ppm), in comparison to the baseline level (mean = 312.97 ppm, std =
89.59 ppm) (p = 0.125 by Wilcoxon signed rank test and p = 0.0713 by paired t test), as well as at
week 52 (mean = 215.94 ppm, std = 62.40 ppm), when compared with the baseline level (mean =
299.42 ppm, std = 76.17 ppm) (p = 0.0078 by Wilcoxon rank sum test) (Figure 7.4.4). However,
we did not observe a significant reduction of acetate concentration during week 7 and week 52
after LCD treatment. The pattern of change of acetate concentration after LCD treatment
corresponded to the pattern of change of obesity condition, which was significantly reduced at
week 7 and week 52 after LCD treatment, but not during week 7 and week 52, supporting that
obesity improvement after LCD treatment might be linked to the reduction of acetate concentration.
Also, the pattern that there was a significant reduction of acetate concentration during week
7 and week 52 in the BRS group, but not in the LCD group, was similar to the pattern that there
was a significant reduction of obesity during week 7 and week 52 in the BRS group, but not in the
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LCD group, further supporting that the significant improvement of obesity was associated with the
significant reduction of acetate concentration after BRS and LCD treatments.

Figure 7.4.4 Acetate concentration was significantly reduced at week 7 and week 52 in the LCD
group.
We did not observe a significant alteration of propionate and butyrate concentrations after
BRS and LCD treatment. Considering that acetate is the main component of SCFAs and it was
significantly reduced while the other two SCFAs were not significantly altered, the observed
significant reduction of the total SCFAs after BRS and LCD treatments should be mainly owing
to the significant reduction of acetate.
Similarly, considering that both BRS and LCD reduced the amount of the participants’
food intake (and their absorption), which is the main source for gut microbial production of acetate,
it is reasonable that after both treatments, acetate concentration was significantly reduced; also
considering the amount the food intake during week 7 and week 52 post BRS treatment was still
limited in comparison to the LCD group, it is reasonable that the concentration of acetate during
week 7 and week 52 post BRS was significantly reduced, but not in the LCD group. Compared to
other SCFAs, acetate is less metabolized in colon since it can be easily absorbed and transported
to liver (Cook and Sellin, 1998), and once it enters the systemic circulation, it can be converted to
acetyl-CoA, which is the starting material for fatty acid synthesis (Wong et al., 2006). Besides its
involvement in lipogenesis, acetate is also the principal substrate for cholesterol synthesis, so its
significant reduction might further contribute to the decreased adiposity post-treatment because of
the decreased acetate repertory for lipogenesis. The results suggested one possible pathway that
the BRS treatment induced a significant reduction of acetate concentration, which further
supported the weight loss and formed a positive loop for persistent weight loss after the treatment.
Propionate and butyrate are more metabolized in the GI tract and provide energy and
nutrition to the intestinal cells, and thus maintain their healthiness. If they are significantly
increased, they may provide more energy to the patient, and if they are significantly reduced, the
healthiness of the GI tract might be compromised. In our study, these two SCFAs were not
significantly altered, so they might have helped the maintenance of the healthiness of the GI tract.
7.5 Percentage of Acetate Was Significantly Reduced after BRS treatment
The percentage of acetate was significantly reduced at week 52 post BRS treatment (mean
= 53.45%, std = 14.31%), when compared with the baseline level (mean = 40.17%, std = 8.46%)
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(p = 0.0547 by Wilcoxon signed rank test) (Figure 7.5.1), and it was also significantly reduced
from week 7 (mean = 50.91%, std = 8.96%) to week 52 (mean = 37.54%, std = 12.50%) after BRS
treatment (p = 0.0781 by Wilcoxon signed rank test) (Figure 7.5.2).

Figure 7.5.1 The percentage of acetate was significantly reduced at week 52 post-BRS treatment.

Figure 7.5.2 The percentage of acetate was significantly reduced during week 7 and week 52 postBRS treatment.

As the above discussion on the reduction of acetate concentration, considering that acetate
might not be as good as propionate and butyrate for improving obesity, the significant reduction
of the percentage of acetate after BRS treatment might help further weight loss. In addition, the
coincidence of the significant reduction of the relative abundance of Bifidobacteria, the main
fermentation products of which are acetate and lactate, and the significant reduction of the relative
proportion of acetate in total SCFAs indicated that one possible underlying mechanism for the
weight loss effect of BRS might be that the significant decrease of the relative abundance of
acetate-producing bacteria (e.g. Bifidobacteria) after BRS results in the significant decrease of the
relative proportion of acetate in total SCFAs, which further helps weight loss.
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7.6 Percentage of Propionate Was Significantly Increased during Week 7 and Week 52 after
BRS treatment
We did not observe significant alteration of propionate concentration after BRS or LCD
treatment. However, the percentage of propionate was significantly increased during week 7 (mean
= 17.58%, std = 5.58%) and week 52 (mean = 30.25%, std = 13.35%) after BRS treatment (p =
0.0313 by Wilcoxon signed rank test) (Figure 7.6.1). That the coincidence of the significantly
increased percentage of propionate and significantly reduced obesity during week 7 and week 52
post-BRS treatment indicated that the efficient and persistent obesity improvement during week 7
and week 52 after BRS treatment might be linked to the significant increase in the percentage of
propionate among the total SCFAs.

Figure 7.6.1 Propionate percentage was significantly increased during week 7 and week 52 postBRS treatment.
Propionate has been reported to show protection against diet-induced obesity via inducing
the secretion of gastrointestinal hormones that regulate satiety and inhibition of food intake in mice
(Lin et al., 2012). It can also inhibit the lipogenesis from acetate in the liver and adipose tissue,
which facilitates the weight loss effect of bariatric surgeries (Wolever et al., 1991). In addition,
propionate is a substrate for hepatic gluconeogenesis and can inhibit cholesterol synthesis in the
liver (Venter et al., 1990, Cheng and Lai, 2000). Therefore, the increased relative proportion of
propionate during week 7 and week 52 post-BRS might further help weight loss during this period.
Since genus Akkermansia produces propionate and the significant increase in the relative
abundance of genus Akkermansia at week 52 post-BRS treatment might have contributed to the
significant increase in the relative proportion of propionate during week 7 and week 52 after BRS
treatment. Thus, the possible mechanism underlying the significant weight loss after BRS might
include that the BRS treatment induced significantly increased relative abundance of propionateproducing bacteria (e.g. Akkermansia) during week 7 and week 52, resulting in significantly
increased the relative proportion of propionate, which might further help weight loss during week
7 and week 52 post BRS treatment.
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7.7 Percentage of Butyrate and Relative Abundance of Butyrate-producing Genera Were
Significantly Increased after BRS treatment
We did not observe significant alteration of butyrate concentration after BRS or LCD
treatment. However, although there was no significant difference of the butyrate concentration
between the BRS and LCD group at baseline, the butyrate concentration in the BRS group (mean
= 166.74 ppm, std = 63.33 ppm) was significantly higher than the LCD group (mean = 95.80 ppm,
std = 45.13 ppm) (p = 0.0582 by Wilcoxon rank sum test) at week 7 post treatments (Figure 7.7.1).

Figure 7.7.1 Butyrate concentration at week 7 post-BRS treatment was significantly higher than
that in the LCD group.
Moreover, we observed that the percentage of butyrate was significantly increased at week
52 (mean = 35.79%, std = 5.74%) post BRS treatment when comparing with the baseline level
(mean = 28.92%, std = 11.03%) (p = 0.0703 by Wilcoxon signed rank test) (Figure 7.7.2). That
the coincidence of significantly increased of butyrate percentage among total SCFAs and
significantly reduced obesity at week 52 post-BRS treatment indicated that the significant obesity
improvement after BRS might be linked with the significant increase in the percentage of butyrate
among the total SCFAs.
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Figure 7.7.2 The percentage of butyrate was significantly increased at week 52 post-BRS treatment.
It was reported that butyrate and propionate, but not acetate, induce gastrointestinal
hormones which can signal brain feeling of satiety to reduce food intake (Lin et al. 2012). Butyrate
has been reported to improve insulin sensitivity and increase energy expenditure in mice (Gao et
al. 2009). In addition, both propionic acid and butyric acid showed protection against diet-induced
obesity via induction of gut hormones and inhibition of food intake independent of free fatty acid
receptor3 (FFAR3) in mice (Lin et al., 2012).
Moreover, we found that most butyrate-producing genera were significantly increased at
week 52 after BRS treatment (Figure 7.7.3), and were significantly negatively correlated with
obesity based on non-parametric Spearman correlation test and/or parametric Pearson correlation
test using the baseline data from the combined BRS and LCD groups. For example, Eubacterium
was significantly negatively correlated with GLU (cor = −0.3611, p = 0.0987), LDL (rho =
−0.4076, p = 0.0597) and CHOL (rho = −0.5283, p = 0.0115). Anaerotruncus was significantly
positively correlated with GDR1/Weight (cor = 0.4136, p = 0.0557) and GDR2/Weight (cor =
0.3923, p = 0.071), Anaerostipes was significantly correlated with GLU (rho = −0.5123, p =
0.0148) and LEP (rho = 0.4213, p = 0.0508), and subdoligranulum was significantly correlated
with TRIG (cor = −0.3667, p = 0.0932) and CHOL (cor = −0.3958, p = 0.0683). It indicated that
the significant increase in the percentage of butyrate among total SCFAs might result from the
significant increase in the relative abundance of these butyrate-producing genera.

Figure 7.7.3 The relative abundance of butyrate-producing genera were significantly increased
after BRS.
7.8 Functional Microbial Gene Communities Involved in Metabolism of SCFAs Were
Significantly Correlated with Obesity-related Hormones
Mantel test was used to check the correlations between the gene categories involved in the
metabolism of SCFAs, including acetate kinase, acetyl-CoA acyltransferase, propionate kinase,
and butyrate kinase, and obesity-related physiological variables, by using the baseline data in the
combined BRS and LCD group. The result showed that the SCFA-related gene communities were
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significantly correlated with obesity-related hormones, including ADP, ADPHMW, PYY and
GHRA (Figure 7.8.1), indicating that obesity-related hormones might be important factors that
linked obesity and gut microbiota. The possible underlying mechanism could be like the loop of
SCFA-producing microbes----metabolism of SCFAs----obesity-related hormones----obesity. That
is, 1) SCFA-producing microbes produce SCFAs; 2) the produced SCFAs induce the alteration of
obesity-related hormones; 3) the altered obesity-related hormones alter the obesity condition. In
the case of BRS treatment, it is possible that BRS treatment induced the significant alteration of
the SCFA profile, including the significant reduction of total SCFAs and acetate concentration,
and significant reduction of the percentage of acetate, and significant increase in the percentage of
propionate and butyrate, which induced the significant improvement of obesity-related hormones,
(especially ADP and ADPHMW, both were significantly increased after BRS treatment), and then
the significantly improved hormones (e.g. increased ADP and ADPHMW) contributed to the
significant obesity improvement after BRS treatment.
Table 7.8.1 Gene communities under the gene categories involved in the metabolisms of shortchain fatty acids were significantly correlated with obesity-related hormones including ADP,
ADPHMW, PYY and GHRA.
BRS & LCD_BL

Acetate kinase
r
p

Mantel test
BRS & LCD_BL
Mantel test

ADP ADPHMW
0.26
0.23
0.08
0.08

Acetyl-CoA acyltransferase
r
p

BRS & LCD_BL
Mantel test

Propionate kinase PYY ADPHMW
r
0.1
0.1
p
0.05
0.08

BRS & LCD_BL
Mantel test

ADP ADPHMW
0.65
0.57
0.05
0.05

Butyrate kinase PYY GHRA
r
0.25
0.2
p
0.06
0.06

7.9 Conclusions
In summary, accompanied with significant obesity improvement by BRS and LCD
treatments, the concentrations of total SCFAs was significantly reduced at week 52 post both BRS
and LCD treatments. Acetate concentration was significantly reduced at week 7 and week 52 after
BRS and LCD treatments, and it was also significantly reduced during week 7 and week 52 after
BRS treatment.
After BRS treatment, the relative proportion of acetate in total SCFAs was significantly
decreased during baseline and week 52, and during week 7 and week 52, while that of propionate
was significantly increased during week 7 and week 52 and that of butyrate was significantly
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increased during baseline and week 52. This phenomenon was not observed in the LCD group. In
addition, after BRS treatment, the relative abundance of butyrate-producing genera was
significantly enhanced.
Moreover, the gene communities involved in the metabolism of SCFAs were significantly
correlated with obesity-related hormones, including ADP, ADPHMW, PYY and GHRA.
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CHAPTER EIGHT: DISCUSSIONS
Microbial richness and diversity were significantly increased after both treatments. Like
all healthy ecosystems, a higher diversity of gut microbiota structure characterizes the healthy
status, and a loss of diversity is linked to disease status. The microbial increased richness and
diversity may indicate that the microbial community structure and the host’s health status become
healthier after the treatments. It was reported that fasting induces an increase of microbial diversity
(Remely et al., 2015). It is likely that the reduction of calorie intake after both BRS and LCD
treatments lowered the food sources of the originally dominating microbial groups, making the
abundance of each microbial component became evener. Also, the significant improvement of
obesity after these two weight-loss treatments might have improved the patients’ entire
physiological conditions, especially the gastrointestinal physiological conditions, and the
improved physiological variables may allow the growth of more different types of microbes. A
healthy ecosystem usually has mild conditions that allow various types of organisms to live in the
system, while the extreme environmental conditions (e.g. pH, temperature, etc.) usually only allow
the growth of specific microbial groups. As we have observed, more types of genera were
significantly increased, and only a few genera were significantly reduced. This indicates that the
total richness of the genera was increased, which was in agreement with the statistical tests. In
addition, the significantly improved physiological conditions after bariatric surgeries may support
the growth of the beneficial microbes more than the growth of the harmful microbes. As we
observed, most of the significantly increased genera were commensal microbes. The degree of the
increase of the microbial richness and diversity was greater in the BRS group than in the LCD
group, and this pattern was consistent with the greater obesity improvement occurred in the BRS
group, further confirming that higher microbial richness and diversity was correlated with better
health conditions.
The distribution and composition of the microbial community at different taxonomic levels
were switched toward a healthier profile with more beneficial microbes and less harmful microbes.
For example, it has been reported that the phylum Actinobacteria was increased in the high-fat-fed
mice and it was higher in the obese ones in the twins than the lean ones (Turnbaugh et al., 2009),
and it was reduced after RYGB. The relative abundance of Actinobacteria was also significantly
reduced after BRS in our research. Also, it has been reported that obese individuals had lower
relative abundance of phylum Verrucomicrobia (Clarke et al., 2012) and it was increased after
RYGB (Liou et al., 2013), and it was also more abundant in normal-weight and post-RYGB
individuals than the obese individuals (Zhang et al., 2009). The phylum Verrucomicrobia was
significantly increased at week 52 after BRS treatment in our study. We did not observe significant
alterations of other phyla at week 52 after BRS, indicating that, when compared with the baseline
level, the week 52 microbial community was switched to a healthier profile with significantly
increased beneficial phylum Verrucomicrobia and significantly reduced harmful phylum
Actinobacteria after BRS. Phylum Firmicutes dominates the gut microbiota in most human
populations and has been found to associate with obesity. After each meal, its abundance increases
more than the abundance of other phyla. The increased availability of incoming food may increase
the abundance of this phylum and lead to more energy intake and adipose formation in the host.
High-calorie food is also related to the increased Firmicutes abundance, and it was reported that
Firmicutes was significantly reduced in individuals after RYGB (Zhang et al., 2009). The
Firmicutes/Bacteroidetes ratio is greater in obese than normal people (Abdallah Ismail et al., 2011).
In addition, the significantly reduced phylum Firmicutes and significantly increased Bacteroidetes
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at week 52 post LCD treatment indicated that at the phylum level the microbial community became
healthier after the LCD treatment. The gut microbiota structure became healthier after both
treatments, but the pattern was not totally the same, indicating that the involved mechanism in the
BRS and LCD groups might be different. Their changing pattern was not totally the same at other
taxonomic levels, either. For example, at the genus level, the community structure at week 52 post
both treatments became significantly different than the baseline level; however, the only a few
genera were significantly altered in both treatments. Additionally, it seems that the degree of the
change of the gut microbiota toward a healthier profile was higher in the BRS group than the LCD
group. For example, nearly all the known butyrate-producing genera were significantly increased
and showed significantly negative correlation with obesity, and the propionate-producing genus,
Akkermansia, was also significantly increased.
Microbial functional gene community was significantly altered at week 7 after both
treatments, but not at week 52 post treatments, while the change of the host’s physiological
conditions (especially the GI tract’s physiological condition) was more substantial at week 7 for
both BRS and LCD groups and the obesity improvement was more significant at week 52 post
both treatments. These observations suggest that the microbial functional gene community might
be mostly correlated with the change of the GI tract’s physiological condition. The entire microbial
functional gene community contains the gene categories (143 in total in this research) involved in
all kinds of metabolic processes, and not all of the 143 gene categories are significantly involved
in obesity condition. Thus, the significant alteration of the GI tract’s environmental conditions at
week 7 and week 52 after BRS was associated with the significantly altered entire gene community.
The relative abundance of some gene categories and gene communities under different gene
categories were significantly altered at week 7 and week 52 post treatments and they may have
correlated with the significant alteration of obesity conditions after the treatments. After week 52,
the physiological condition was not as extreme as at week 7 and this may explain why the
significant alteration of the entire gene community structure was observed. Having no significant
alteration of the entire gene community might also display the resilience of human microbiota.
Total SCFAs and acetate were significantly reduced after both treatments. It has been
reported that total SCFAs were positively correlated with obesity possibly because they can
provide more energy. The significantly reduced SCFAs after the two weight-loss treatments might
have reduced the amount of the total energy that the host can obtain and thus help their weight loss.
As mentioned previously, the acetate was the main component of the total SCFAs and it was
harmful to obesity, so its significant reduction might have contributed to the significant reduction
of total SCFAs and benefited the weight loss process, considering that no significant alteration of
the concentrations of the propionate and butyrate was observed.
The significantly reduced proportion of acetate and significantly increased proportion of
propionate and butyrate after bariatric surgeries indicate that the SCFA profile after bariatric
surgeries becomes healthier for obesity, considering that in general acetate is harmful to obesity,
while propionate and butyrate are beneficial to health status. This shifted profile of the SCFAs was
not observed in the LCD group, and it may have contributed to the more substantial obesity
improvement after BRS treatment compared to the LCD group.
That the relative abundance of most butyrate-producing genera was significantly increased
after BRS may explain the source of the significantly increased proportion of the butyrate.
Akkermansia is one of the propionate-producing genera and the significant increase of its relative
abundance may explain the source of the significantly increased proportion of the propionate. Also,
the significant reduction of the relative abundance of the genus Bifidobacteria, the main
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fermentation products of which are acetate and lactate, may explain the significant reduction in the
proportion of the acetate after the bariatric surgeries.
The gene communities relevant to the metabolisms of short-chain fatty acids were
significantly correlated with obesity-related hormones (ADP, ADPHW, PYY and GHRA),
indicating the possible pathway that links SCFAs and obesity. That is, the SCFAs might induce
the alteration of obesity-related hormones, which further exert their functions in regulating
adiposity. For example, it has been reported that butyrate can stimulate the gene expression of
adiponectin, which is associated with AMPK (Adiponectin-induced AMP-activated protein kinase
or Adenosine monophosphate-activated protein) that monitors the energy status of the cell and
stimulates fatty acid oxidation.
The degree of the change in gut microbiota community was higher in the BRS group than
in the LCD group, including the greater degree of the increase of microbial richness and diversity
and beneficial microbes, such as genus Akkermansia and butyrate-producing genera, and the
greater gene richness and diversity, and the healthier profile of their metabolites SCFAs that
include greater degree of acetate reduction and better SCFA composition (significantly reduced
proportion of acetate and increased proportions of propionate and butyrate). Considering that the
degree of the obesity improvement effect of BRS was also greater than the LCD group, the
difference in the degree of the change of the gut microbial community structure and the profile of
their metabolites, SCFAs, may either be caused by the different mechanisms that drive the change
of the gut microbial community, or by use of the same/similar mechanism with different degrees
of change, or by a mix of the two.
In addition, the microbial community structure at different taxonomic levels and the
microbial connectivity showed significant correlations with obesity, and it seemed that ADPHMW
was an important factor involved in their correlation. Moreover, over half of the gene communities
under different types of gene categories showed significant correlations with obesity-related
variables and the entire gene community was significantly correlated with obesity-related
hormones (ADP, ADPHMW, and GHRA), with gene richness and diversity significantly
negatively correlated with GHR and GHRA. The gene communities relating to the metabolism of
SCFAs also showed significant correlations with obesity-related hormones, including ADP,
ADPHMW, PYY and GHRA). These findings together suggest that the obesity-related hormones
may be the factors involved in the link between gut microbiota and obesity. Studies have reported
the involvement of GLP-1, PYY, and GHR, but very few have evidenced the link between gut
microbiota and obesity via ADP or ADPHMW.
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CHAPTER NINE: CONCLUSIONS
After bariatric surgeries and low-calorie diet treatment, the gut microbial community
structure and function were significantly altered. The changes included significantly increased
microbial diversity, altered microbial distribution and composition toward a healthier profile with
significantly increased commensal microbes (for example, the genus Akkermansia and the
butyrate-producing genera) and reduced harmful microbes, altered microbial functional gene
community, and the altered amount and composition of the gut microbial metabolites SCFAs, with
significantly reduced concentrations of total short-chain fatty acids and acetate.
The degree of the change in the gut microbiota community after BRS was higher compared
with the LCD group, including the greater degree of the increase of microbial richness and
diversity, greater degree of the increase of the relative abundance of beneficial microbes, such as
genus Akkermansia and butyrate-producing genera, greater gene richness and diversity, and
healthier profiles of their metabolites SCFAs, including greater degree of acetate reduction, better
SCFA composition (significantly reduced proportion of acetate and significantly increased
proportions of propionate and butyrate). Also, the reduction of the acetate concentration after BRS
was more efficient and persistent compared with the LCD treatment, and the significant reduction
of the proportion of acetate was observed during baseline to week 7, week 7 to week 52 and
baseline to week 52 after BRS treatment, but not in the LCD group. The significant increase of the
proportion of propionate was only observed during week 7 to week 52 after BRS treatment, and
not in the LCD group, and the significant increase of the proportion of butyrate was only observed
at week 52 after BRS treatment, and not in the LCD group. These results indicated that the BRS
treatment had better effects in improving the gut microbial community’s healthiness, including the
microbial richness and diversity, microbial functional gene richness and diversity, and the amount
and composition of the microbial metabolites than the LCD group. This corresponded to the more
significant obesity and health improvement effects of the BRS treatment when compared to the
LCD treatment. The difference in the degree of the change of the gut microbial community
structure and the profile of their metabolites, SCFAs, may either be caused by the different
mechanisms that drive the change of the gut microbial community, or by the same/similar
mechanism with different degrees of change, or by a mix of the two.
Our results supported that the increased microbial richness and diversity was linked to the
improved obesity condition, and the greater increased microbial richness and diversity was linked
to the greater improved obesity condition in the severely obese subjects. The distribution and
composition of microbial community were switched toward a healthier profile with a significantly
lower relative abundance of phylum Actinobacteria, and significantly higher relative abundance
of phylum Verrucomicrobia at week 52 post-BRS treatment, and significantly lower relative
abundance of the phylum Firmicutes, and a significant increase of phylum Bacteroidetes after lowcalorie diet treatment. Microbial functional gene community structure was significantly altered at
week 7, accompanying with the more significant alteration of the GI tract’s physiological
conditions.
In addition, based on the baseline data combined from the both BRS and LCD groups, we
found that the entire microbial communities at different taxonomical levels were significantly
correlated with obesity-related physiological variables, and the hormone ADPHMW and might be
an important factor that links the significant correlation between the entire microbial community
and obesity, at OTU level. Also, the microbial connectivity also showed significant correlations
with obesity, suggesting that microbes with higher connectivity were significantly correlated with
112

obesity, supporting the significant correlation between the topology of the microbial association
network and obesity and further confirming the significant correlation between the microbial
community structure and obesity. The relative abundance of many genera (or other taxonomic
microbial groups) also showed significant correlations with obesity-related physiological variables,
further supporting the involvement of gut microbes in the obesity condition. Moreover, over half
of the gene communities under different gene categories showed significant correlations with
obesity-related physiological variables, further confirming the significant correlation between
microbial community and obesity, and supporting the involvement of microbial genes in the host’s
obesity conditions. In addition, the entire gene community was significantly correlated with
obesity-related hormones, ADP, ADPHMW, and GHRA, and the richness and diversity of the
entire gene community were significantly negatively correlated with GHR and GHRA, suggesting
these obesity-related hormones might be the factors that linked the significant correlation between
gut microbiota and obesity.
Additionally, this research discovered that the Akkermansia’s relative abundance was
significantly increased after bariatric surgeries, and there was a significant reverse nexus between
human gut Akkermansia’s relative abundance and obesity condition. It indicates that bariatric
surgeries may directly or indirectly increase gut Akkermansia’s relative abundance, which may, in
turn, further boost the obesity-alleviating effect of bariatric surgeries, forming a positive loop that
contributes to their persistent effects in improving obesity conditions. Akkermansia may have the
potential to serve as a physiological indicator of obesity status and be developed as a supplement
for the prevention and/or treatment of obesity and obesity-related complexities.
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